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Abstract
The microbiota, a community of micro-organisms in a particular environment, have
been intensely researched in the past decade and interest appears to continue to
increase. The human body is richly populated with bacterial cells (3.8x10'^) and
alterations in these communities are associated with disease. The work presented in
this thesis explores aspects of microbiota research methodologies with regard to
optimisation and concerns over a lack of reproducibility. Additionally, we
investigated the effects of medication, in particular Proton Pump Inhibitors, on the
human gut microbiota, along with comparisons between the microbiota of patients
with active and inactive Inflammatory Bowel Disease.
Microbiota research lacks standardised approaches to experimental design and
data analysis due to rapidly evolving techniques and software. We conducted a
comparison between various approaches in both amplicon and shotgun
metagenomics sequencing using various primer binding regions and next generation
sequencers. We found disparities between both 16S rRNA gene variable regions and
metagenomic sequencing techniques, the latter of which was largely due to the
taxonomic classifier. We finally emphasise the requirement for careful study design
and caution when comparing microbiota studies.
Proton Pump Inhibitors are prescribed to prevent gastric reflux and duodenal
ulcers but concern has been raised due to associations with C. difficile infection. We
assessed the microbiota of long-term PPI users versus controls, but found no
similarities to the microbiota of C.

infection. However we did uncover microbial

alterations including by a decrease in biodiversity and an increase in Holdemania
filiformis along with a decrease in Pseudoflahonifractor capillosiis in the PPI
microbiota. Although we found no microbiota associations with C. diff, caution
should be taken when prescribing PPI medications due to the negative impacts on the
gut microbiota.
Changes in the gut microbiota have been associated with IBD, although there is
disparity between the alterations. We conducted the largest longitudinal IBD
microbiota study to date, whilst also collecting a large quantity of metadata. We
compared the microbiota of patients with IBD in both active and inactive disease
states to controls. Although we found significant differences in biodiversity and

taxonomic composition between patients with IBD and controls, there was a lack of
significant change between disease activity states. However, there was a significant
decrease in microbiota stability in patients with altering disease aetivity. Age, diet,
medications, resection and geographical location significantly impacted the gut
microbiota in both diversity and composition. This study provides evidence that
when confounding factors are controlled for through longitudinal sampling, the
microbiota is subjected to little change when transitioning between states. We also
show the importance of collecting metadata such as age, dietary habits and
medication status as they were seen to influenee the microbiota. Analysing the most
comprehensive and largest longitudinal IBD cohort to date, we found that the gut
microbiota composition of patients with IBD differs significantly from controls.
However, separate to other cross-seetional studies using smaller sample sizes, we
found no differences disease activity states.
The research conducted in this thesis provides evidence of stool microbiota
alternations as a result of diet, medications and disease, while also highlighting
potential methodological biases in sequencing analysis.

Chapter I

Literature Review

Table of Contents
Section 1: Sequencing...................................................................................................... 8
1.1

The History of DNA Sequencing.................................................................... 8

1.1.1 First Generation Sequencing Technologies................................................... 8
1.1.2 Second Generation Sequencing Technologies............................................. 10
1.1.3 Third Generation Sequencing Technologies................................................ 11
1.1.4 Conclusion......................................................................................................12
1.2. Sequencing a Microbial Community.................................................................. 12
1.2.1 Gene Amplification Sequencing................................................................... 13
1.2.2 Shotgun Metagenomic Sequencing.............................................................. 16
1.2.3 Conclusion...................................................................................................... 17
1.3 Tools for Bioinfonnatic analysis..........................................................................18
1.3.1 Metagenomic shotgun sequencing................................................................ 19
1.3.2 Marker gene analysis.....................................................................................22
1.4 Comparison of Sequencing Technologies and Methods.................................. 25
1.4.1 Primers and 16S rRN A gene variable regions.............................................25
1.4.2 Bioinfonnatic tools........................................................................................26
1.4.3 Sequencing Platfonns....................................................................................27
1.4.4 Conclusion..................................................................................................... 27
Section 2: The Microbiome............................................................................................ 29
2.1 Introduction to microbiome..................................................................................29
2.1.1 The Human Microbiota..................................................................................30
2.2 The Gut microbiota.............................................................................................. 33
2.2.1 Development of the Microbiota and changes through time........................33
2.2.2 The gut microbiota of a healthy adult...........................................................35
2.2.3 The effect of diet on the gut microbiota...................................................... 37
2.2.4 The effect of Antibiotics on the gut microbiota...........................................39
2.2.5 The Effect of Proton Pump Inhibitors on the gut microbiota.................... 41
2.2.6 Clostridium difficile infection....................................................................... 42
2.2.7 Associations between C diff and PPI medications..................................... 43
2.2.8 Faecal Microbiota Transplantation...............................................................44
2.3 Diseases and the gut microbiota.......................................................................... 44
2.3.1 Cancer.............................................................................................................44
6

2.3.2 Celiac Disease...............................................................................................45
2.3.3 Neurological disorders................................................................................. 45
2.3.4 Diabetes........................................................................................................ 46
2.3.5 Obesity.......................................................................................................... 46
2.3.6 Conclusion.................................................................................................... 47
Section 3: Inflammatory Bowel Disease......................................................................48
3.1

Introduction.................................................................................................... 48

3.2

Complications.................................................................................................49

3.3 Epidemiology...................................................................................................... 49
3.4 Diagnosis..............................................................................................................52
3.4.1 Faecal Calprotectin.......................................................................................52
3.4.2 Clinical Indices of IBD................................................................................ 55
3.5 Management and Treatment............................................................................... 58
3.5.1 Medications and Supplementation...............................................................58
3.5.2 Surgery.......................................................................................................... 59
3.6 Risk Factors of IBD.............................................................................................60
3.6.1 Genetics........................................................................................................ 60
3.6.2 Oral Contraceptive Pill................................................................................ 63
3.6.3 Antibiotics..................................................................................................... 63
3.6.4 Appendectomy..............................................................................................63
3.6.5 Breast Milk................................................................................................... 64
3.6.6 Smoking........................................................................................................ 64
3.6.7 Vaccinations, Infection and Living Conditions..........................................65
3.6.8 Diet.................................................................................................................66
3.7 Microbiota........................................................................................................... 67
3.7.1 Taxonomic alterations in IBD......................................................................68
3.7.2 Relapse versus Remission............................................................................ 71
3.7.3 Significance of differentially abundant taxa...............................................72
3.7.4 Oxygen Hypothesis.......................................................................................72
3.7.5 Virome and Mycobiome.............................................................................. 73
3.7.6 Longitudinal studies......................................................................................73
3.7.7 Conclusion.................................................................................................... 75
4. Bibliography...............................................................................................................76

Section 1: Sequencing
1.1 The History of DNA Sequencing
Since the discovery of DNA (deoxyribonucleic acid), then named nucein, in 1869 by
Swiss physiological chemist Friedrich Miesher (Pray 2008), scientists have pondered
its purpose and tme significance which has lead us to investigate and widen our
understanding of its complex yet perfect nature. In 1929, there were a number of key
discoveries by Phoebus Levene including the three major components of DNA
(phosphate, deoxyribose and the four nitrogenous bases), while in 1949 Ewin Chargaff
discovered that despite base composition varying between species, the bases are
continually present in fixed ratios (Dahm 2005). In 1953 the two most synonymous
names with DNA discoveries, James Watson and Francis Crick, solved the 3dimensional stmcture of DNA through the use of Wilkins and Franklin's X-ray
crystallography data (Pray 2008). In 1957, the “central dogma” proposed by Crick
stated that DNA is translated into proteins via RNA. Thus, almost 90 years after the
discovery of DNA, it became clear that the series of bases code for infonnation, or
proteins, which are involved in general homeostasis and therefore can effect organism
function and health. Reading sequences of DNA opened endless opportunities for
discovery, comparisons and experimentation.
1.1.1 First Generation Sequencing Technologies
Early sequencing methods were limited to sequencing proteins as they are shorter in
length and contain more variability compared to more complex DNA. This resulted in
a 15 year delay between the Watson-Crick discovery and the first in-vitro DNA
experimental synthesis in 1965 (Holley et al. 1965). The first nucleic acid sequenced
was by Robert Holley’s research group, while the first complete protein coding gene
sequence, bacteriophage MS2, was sequenced by Fiers and colleagues in 1972 (W
Fiers et al. 1972), followed by its complete RNA genome 4 years later (Walter Fiers
etal. 1976).
Fred Sanger’s group sequenced the first DNA genome, bacteriophage XI74 (PhiX)
using the plus and minus system, which involved synthesis from a primer though DNA
polymerase and radiolabelled nucleotides (F. Sanger et al. 1977a). The group made

another major leap in DNA sequencing in 1977 with the chain-temiination technique
which makes use of deoxyribonucleotide (dNTP) monomers (Frederick Sanger et al.
1977b) - see Figure 1.1. Briefly, this technique involves four parallel lanes on a
polyacrylamide gel and a mix of standard dNTPs along with modified versions which
have been radiolabelled - dideoxynucleotides (ddNTPs).

As the ddNTPs lack a

3’hydroxyl group and are unable to bind with the adjacent 5’phosphate, they cause
sequence synthesis termination. The result is the fomiation of each possible DNA
length with the radiolabelled ddNTPs being incorporated where appropriate, thus
enabling the original sequence to be read using autoradiography.
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Figure 1.1: Sanger chain termination sequencing. (Figure adapted from (Fleather and Chain 2016)).
Left; The original sequence followed by the chain termination approach where short fragments are
generated when a ddNTP is randomly incorporated. Right: Fragments generated from the sequencing
are visualised by electrophoresis where the shortest fragments travel furthest. The sequence is then
read from bottom to top.

Although this method would be the chosen sequencing technique for many years due
to its accuracy and simplicity, a number of improvements made in the subsequent
years, including a fluorometric based detection superseding radiolabels, allowed for
more automated machines. Over time, more large scale sequencers were developed,
resulting in hundreds of samples sequenced in parallel beginning with the ABl PRISM
range developed in a collaboration between Leroy Hood at Caltech and Applied
Biosystems (L. M. Smith et al. 1986).

1.1.2 Second Generation Sequencing Technologies
The second generation of DNA sequencing technologies evolved from the discovery
of measuring pyrophosphate synthesis via luminescence by Nyren (1987). Briefly, two
enzyme reactions result in light emission proportional to the amount of pyrophosphate
produced which is then measured to infer the sequence base, or put simply, the
elongation of the DNA strand is marked by the emission of a signal. The addition of
one of the four deoxynucleotide triphosphate bases results in the release of
pyrophosphate. ATP sulfurylase converts pyrophosphate to ATP in the presence of
adenosine 5’ phosphate. The resulting ATP then acts as a substrate along with
luciferase in the conversion of luciferin to oxyluciferin which creates light (Nyren
1987). Major benefits of this new method included the output being produced in real
time, along with experiments using natural nucleotides. However there was an issue
with homopolymers. The intensity of light coiTesponded to the length of the identical
bases but noise caused a non-linear relationship after 4 or 5 bases (Ronaghi et al.
1998). Nonetheless the incoiporation of beads and adaptor sequences allowed for
sequencing of 400-500 base pairs for over 1 million sequences at once (Margulies et
al. 2005). This technique was licenced to 454 Life Sciences, later to be purchased by
Roche Diagnostics.
The Solexa method (subsequently purchased by Illumina) was a rival to the 454
technology described above. While both are classed as sequencing by synthesis
approaches, Solexa relies on solid phase PCR producing clonal clusters after the DNA
has been bound to the flow cell (Figure 1.2). For each cycle, DNA polymerase,
modified nucleotides (containing a single base and a removable fluorophore) and
primers are introduced. During each cycle the fragments incorporate just one
lluorophore labelled nucleotide (the unincorporated are washed away), which are
excited by lasers and the fluorescent signal is measured. After washing and removal
of the fluorophores, the process is repeated to sequence the next base in the DNA
fragment (Goodwin et al. 2016).
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Figure 1.2: Illumina sequencing approach (Figure adapted from (Goodwin el al. 2016)).

Paired-end sequencing was later introduced to the Illumina HiSeq, MiSeq and
NextSeq platforms, where the reverse orientation of the DNA is also sequenced during
a second subsequent stage. Having the forward and reverse reads not only doubles the
amount of information but can also increase accuracy when mapping to a reference
sequence (Quail et al. 2012).
The PGM Ion Torrent, uses an alternative approach by measuring the release of FT
ions during polymerisation through the difference in the pH, resulting in very rapid
sequencing (Rothberg et al. 2011). However this technology, like the 454, struggles to
interpret homopolymers (Toman et al. 2012).
1.1.3 Third Generation Sequencing Technologies
There is no clear or defined boundary between the second and third generation of
sequencing technologies. However, it has been suggested that Single Molecule
Sequencers (SMS), which remove the requirement for amplification, and real time
sequencers be used as a point of divergence (Heather and Chain 2016). The removal
of amplification is advantageous as it avoids unwanted biases and errors (Pareek et al.
2011). Although a costly method of sequencing, and limited to short reads, the first
SMS sequencer was run by Helicos Biosciences (Braslavsky et al. 2003), however
there have been several notable improvements since then. The most widely used SMS
sequencer is the Single Molecule Real Time (SMRT) developed by Pacific
BioSciences (PacBio) (van Dijk et al. 2014). This technology involves a flow cell
containing many wells with fixed DNA polymerases attached. As the DNA passes
through the polymerase and a laser and camera record the colour and duration of light
11

emission as a labelled dNTP is incorporated. The PacBio platforms possess a number
of advantages over the second generation sequencers. Firstly, they can produce reads
of 15 kb in length, while the SMRT also uses a circular sequence which allows for the
template to be sequenced multiple times resulting in a consensus sequence. This
process can dramatically decrease the error profdes from over 13% to less than 1%
(Glenn 2011).
The latest technology to emerge in the DNA sequencing field is the use of nanopores
to detect biological and chemical changes (Haque et al. 2013). The Minion, developed
by Oxford Nanopore Technologies, became available in 2014, and was in the format
of a small portable USB device (Loman and Quinlan 2014). The dynamic nature and
ease of transportation has offered new exciting opportunities not previously available
for example the Ebola vims in Guinea (Hayden 2015) and its use in the International
Space Station (McIntyre et al. 2016). The method involves passing the DNA through
a pore which contains a current and as the DNA Hows, the voltage is intermpted. The
shift in voltage is characteristic of a particular sequence of DNA and the sequencer
recognises over 1,000 of these different “A-mers" (Goodwin et al. 2016). However, the
method is overcome by errors with early en'or profiles of over 30% reported, although
recent improvements have reduced this to 13% (Weirather et al. 2017).
1.1.4 Conclusion
DNA sequencing technologies are continuously being developed and improved, and
with this, the number and variety of applications increase. However, conducting a
study involving DNA sequencing is not straight forward. There is a myriad of options
with regard to sequencers, type of sequencing, primers and analysis tools, all of which
must be considered.

1.2. Sequencing a Microbial Community
In relation to microbiota studies, sequencing can be broadly divided into two major
categories: targeted gene amplification sequencing and shotgun metagenomic
sequencing. Both of these methods, or approaches, come with a number of advantages
and disadvantages and the method selected for a study depends on the
question/hypothesis along with budget.
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1.2.1 Gene Amplification Sequencing
Targeting a particular gene for sequencing is a widely used approach for the
identification of taxa. The first step in many microbiota studies and investigations is
to identify the taxa present and the abundance of each. When the bacteria present are
known, comparisons can be made between samples, disease states, environments etc.
In amplicon sequencing, a sample or selection of samples are collected and the DNA
extracted from all cells. PCR is carried out on a DNA marker which is common to all
(or as many as possible) the organisms of interest. The amplified DN A is sequenced
and subjected to bioinfonnatic processing and analysis. The most widely used
amplicon for bacterial compositional profiling are the 16S rRNA gene variable
regions.
1.2.1.1 The 16S rRNA Gene Sequencing
Dubnau and colleagues first noted the similarity in the 16S gene sequence between
Bacillus species in 1965 (Dubnau et al. 1965), while Woese obseiwed that the gene
was a type of molecular chronometer, whereby the rate of mutation is constant and
can be used to construct phylogenetic trees (Woese 1987). The number 16 refers to its
sedimentation rate, while the S the unit of measurement, Svedberg (S) units. Few other
genes are as highly conserved and this is due to being critical for cell function. The
16S rRNA gene is located in the small subunit of the ribosome (30S in bacteria and
archaea). The small subunit functions to decode mRNAs and here, the I6S 5’ end
functions in the codon-anticodon interaction (Lafontaine and Tollervey 2001). The
length of the 16S gene is approximately 1,500 bp long and comprises of both
conserved and variable regions. There are nine variable regions in total (VI-V9)
flanked either side by the conserved regions, thus providing a stretch of bases for
primer targeting followed by differentiation. The nucleotide substitution rate of the
conserved regions is 7000 times slower than that of the hypeiwariable regions (Van de
Peeretal. 1996).
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Figure 1.4: The differing variability along the hypervariable regions of Pseudomonas. The graph
represents an alignment of 79 strains of Pseudomonas (Bodilis et al. 2012).
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The 16S rRNA gene is the main focus of sequencing when deciphering between
bacterial taxonomy due to a number of key characteristics. Firstly, it is present
universally amongst bacteria allowing for comparisons and analysis of phylogenetic
relationships (Hugenholtz et al. 1998), and secondly, the length of the gene is
advantageous to sequencing and computational analysis. The presence of conserved
regions allow for targeting of primers without particular taxa being unamplified, while
the variable regions allows for sufficient diversification.
1.2.1.2 The23S rRNA Gene
As previously mentioned, the 16S rRNA gene is found in the small subunit of the
ribosome, while the 23 S (length of approximately 2,900nt) is found in the large subunit
(SOS in bacteria and archaea). The SOS functions in peptidyl-transferase activity which
is catalysed by 23S (Lafontaine and Tollervey 2001). While the 16S and 23S rRNA
genes are in good agreement in temis of phylogenetic trees, the 23S region is not
widely used as the conserved regions are located close together and are less conserved
than 16S (Isenbarger et al. 2008).
1.2.1.3 Internal Transcribed Spacer and the 18S rRNA gene
Eukaryotic cells like fungi do not contain 16S rRNA genes but with over 180 fungal
species detected in the human gut it is important to use an alternative approach
(Hoffmann et al. 2013). The 40S small subunit of eukaryotic ribosomes contains 18S
which is approximately 1870 bp in length (Brimacombe and Stiege 1985) and can be
targeted for taxonomic classification and detection.
An alternative to 18S rRNA gene sequencing is the ITS region, or Internal
Transcribed Spacer located between the 18S and 28S rRNA genes (Schoch et al.
2012). The ITS consists of two hypervariable regions with a combined length of
approximately 600 bp. Between these two regions is the highly conserved 5.8S rRNA
gene (Porras-Alfaro et al. 2014) and with a growing number of curated fungal
sequences in databases, the ITS region has been used for taxonomic identification and
diversity (Z. Wang et al. 2011). A study by Porras-Alfaro and colleagues found that
ITSl and ITS2 yielded similar classification accuracy with greater than 97.7%
accuracy as far as family (Porras-Alfaro et al. 2014). Liu and co-authors found the ITS
regions to be more precise than I8S for fungal community analysis upon evaluating
various primer sets (J. Liu et al. 2015a).
15

1.2. i .4 Disadvantages of Amplicon Sequencing
Amplicon or marker gene sequencing provides an effective method for deteiTnining
the taxa present in a sample/community and the abundance of each. However, while
being cost effective and relatively non-computationally demanding compared to other
methods, it does come with a number of disadvantages. The first issue is that no single
hypervariable region can distinguish between all taxa and different degrees of
similarity/dissimilarity are found for bacteria within each region. T herefore, there is
no gold standard variable region (Chakravorty et al. 2007). Secondly, the copy number
of the 16S rRNA gene varies widely between genomes and there can be as many as
15 copies per cell (Klappenbach et al. 2001) with differences reported between species
and strains (Acinas et al. 2004). The third issue relates to sequencing of target regions
in general, as they rely on PCR amplification. As a result, in order to design primers,
prior knowledge of the target is required and therefore removes the capability to
discover new taxa or variants. Also, PCR bias are very common, as the annealing of a
primer to taxa is uneven and leads to inaccurate results and falsely underrepresented
communities (Acinas et al. 2004). As previously mentioned, sequencers come with a
high degree of enors which can make the results of amplicon sequencing difficult to
be classified into known taxa. Finally, marker gene analysis is limited to providing
insights to the composition of a community. Bacterial communities, along with viruses
and fungi are very complex and the most interesting findings may be in the detailed
information, for example functional potential along with species variation and novel
taxa.
1.2.2 Shotgun Metagenomic Sequencing
The first whole genome {Haemophilus influenzae) to be sequenced utilising shotgun
sequencing was by Venter and Smith in 1995 (Fleischmann et al. 1995). Since then,
the field of microbiology has been rapidly advancing and evolving away from clonal
isolates and exploring the 90% of microbial species which are unable to be cultured
in the lab (Rappe and Giovannoni 2003). Shotgun sequencing opened up new
avenues for comparative genomics, phylogenetic diversity and metabolic pathway
analysis. Shotgun metagenomics is also perfonned for microbiota analysis as it
offers an alternative to amplicon sequencing and overcomes many of the previously
discussed limitations.

16

Shotgun metagenomic sequencing does not target one particular gene or loci
therefore avoiding PCR bias and allowing the sequencing of novel genes and
genomes. Like amplicon sequencing preparation, all the DNA is extracted from the
cells. However the DNA is sheered into tiny fragments, all of which are
subsequently sequenced. The resulting sequence reads will consist of DNA from
microbial and non-microbial sources, the latter of which can easily be removed using
bioinformatics methods. The microbial sequences will contain DNA from both
marker genes, for compositional analysis, and also coding regions which offer the
opportunity to analyse functional profdes (Sharpton 2014). Shotgun metagenomics is
not confined to just bacteria and archaea allowing for sequencing of eukaryotes,
vimses and phageome (Nornian et al. 2015) — an area which has recently gathered
great momentum (Lopetuso et al. 2016; Paez-Espino et al. 2016).
1.2.2.1 Disadvantages of Shotgun Sequencing
However, shotgun metagenomic sequencing is not without its challenges. As the
resulting dataset is much larger than marker gene sequencing, a much higher level of
expertise is required along with more computational power and infrastructure.
Amplicon sequencing is also 20-30 times cheaper than shotgun metagenomics. The
vast amount of data (1TB from a single HiSeq mn) also leads to computational
storage issues which must be addressed beforehand. The presence of many taxa in
samples often leads to genomes not being entirely sequenced and therefore sequence
alignment is not always possible (Sharpton et al. 2011). When the fragments of DNA
do not overlap bioinfonnatics techniques like assembly (discussed later) are often
challenging and not easily overcome.
1.2.3 Conclusion
The type of sequencing approach employed for a study is largely selected based on
the budget, sample size and above all, hypothesis. The advantages, disadvantages
and requirements must be assessed during the study design stage. A crucial step
often overlooked at the design stage is the large array of tools available for the
bioinfonuatic analysis. There is an ever growing list of software, pipelines, and
recommendations available which must also be taken into consideration.
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1.3 Tools for Bioinformatic analysis
The following section (1.3), figures and table have been adapted from the
publication ‘'A clinician’s guide to microbiome analysis” - Marcus J. Claesson^'^*,
Adam G. Clooney'~^* and Paul W. O’Toole^ ~ published in Nature Reviews in
Gastroenterology and Hepatology Aug 9'^ 2017, doi: 10.1038/nrgastro.2017.97.
’^Contributed equally

Microbiota data analysis is usually tailored to the question and data type and there are
many methods and protocols, even for analysing the same type of data. A large
repertoire of free and open-source software is available for the various analytical steps,
from quality-filtering of the raw data to the final stages of visualizing results. The
application of these methods is largely dependent upon the study design and dataset,
the most notable constraint being marker gene amplicons or shotgun metagenome
sequencing (see Figure 1.5 for an outline of bioinfonnatie analysis). The value of a
study is ultimately circumscribed by the quality of the data to be analysed so it is
essential to quality check and assess all sequencing reads before proceeding with the
downstream analysis and inteipretation, as low-quality reads will inhibit the assembly
of eontigs and reduce annotation efficiency. A key starting point is the assessment of
the data quality. Software tools such as FastQC can be applied to assess the overall
quality of the sequencing runs, while Trimmomatic (Bolger et al. 2014) and tools in
the FASTX-Toolkit can be used to filter and trim sequencing reads based on PHRED
quality scores, by setting desired lengths or thresholds.

18
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Study design, sample coUection. storage and DNA/cDNA/RNA extraction

Figure 1.5: Flowchart of the major steps involved in bioinformatic analysis of the microbiome. The
analysis is divided into two sections depending on the type of sequencing. This schematic describes the
basic .steps and might vary depending on the aim of the analysis. OTU, operational taxonomic unit.

1.3.1 Metagenomic shotgun sequencing
1.3.1.1 Assembly
A valuable feature of shotgun sequencing is that it enables assessment of the functional
potential of the microbiome because (ideally) a majority of the genetic material is
sequenced, as opposed to targeting one particular gene. After sequencing, shorter read
fragments are often assembled into longer continuous sequences (contigs: see Figure
1.6), potentially covering complete protein coding genes and operons. Metagenome
assembly also pennits simpler analysis by decreasing the number of overall sequences
(reads

are

collapsed

into

contigs),

whose

abundance

can

still

be

quantitatively analysed. Assemblies are either based on reference genomes (Treangen
et al. 2013) or perfonned de novo (Luo et al. 2012; Namiki et al. 2012). Referencebased assemblers are less computationally demanding and map sequencing reads onto
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reference genomes to construct contigs joined in silica from individual reads.
However, they are limited by the quality and availability of reference genomes and
rely on previously characterized species. De novo methods, on the other hand, do not
require reference genomes and instead use graph theory algorithms such as de Bruijn
graphs to assemble sequencing reads (Compeau et al. 2011). Metagenome assembly
was initially carried out using single-genome assemblers (Simpson et al. 2009), but
now tools have been adapted to handle multiple genomes with varying abundances.
Such tools include MetaVelvet (Namiki et al. 2012), IDBA-UD (Peng et al. 2012) and
SOAPdenovo2 (Luo et al. 2012). MetaVelvet, and its latest update MetaVelvet-SL
(Sato and Sakakibara 2014), increases accuracy by using a streamlined assembly
approach, while also orientating the contigs into longer assemblies called scaffolds.
Original A^-affolds are assembled from contigs, while contigs are assembled from reads
iequence v.
J

Reads
Quality checked
and filtered
sequencing reads

Read 1 (

contigs are
(<ead 2

J

re assembled ^
Read 3

ed from reads ^

Assembly into contigs |
Contigs ^caffolds are assembled from contigs while (contigs are assembled from reads
Additional sequencing to I
close contig gaps |
Scaffold (^Scaffolds are assembled from contigs, while contigs are assembled from reads ^

Figure 1.6: Sequence read assembly. A mock example explaining bioinformatic sequence assembly
along with the terms sequence, reads, contigs and scaffolds.

1.3.1.2 Sequence taxonomy
Most metagenomic shotgun tools are aimed at phylogenetic binning, which is the
process of grouping sequencing reads or assembled contigs by their likely host
genomes and subsequently assigning taxonomy, much like grouping words in a
sentence into verbs, nouns or adjectives. Binning is perfonned either through similar
DNA compositions, such as distinguishable nucleotide patterns like )^-mer (DNA
sequence with fixed length k) frequency or GC content, or by gene homology
(sequence similarity to known genes). Each method has its limitations; compositionalbased approaches perform poorly on short reads, whereas homology-based approaches
struggle to be discriminative when the dataset contains many closely related species.
Some of the most frequently used binning software are composition-based and include
TETRA (Teeling et al. 2004), PhyloPythiaS (Path et al. 2012) and Kraken (Wood and
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Salzberg 2014), which compares unique distributions of /:-mers across the
metagenomie sequenees. In contrast, the homology-based MetaPhlAn2 (Truong et al.
2015) software uses a set of core marker genes to differentiate between mierobial taxa.
A hybrid approach (implemented by PhymmBL (Brady and Salzberg 2009),
MetaCluster-TA (Y. Wang et al. 2014), AMPHORA2 (M. Wu and Scott 2012) and
MaxBin (Lin and Liao 2016)) can also be performed, combining DNA compositional
and homology-based methods. However, considerable differences between the
perfomiance of binning tools have been observ ed (Clooney et al. 2016; Peabody et al.
2015) and for some datasets, CLARK (Ounit et al. 2015) and Kraken were the best
performers (Lindgreen et al. 2016). The accuracy of binning methods will increase as
new sequencing technologies offer longer reads combined with a greater number of
referenee genomes becoming available in databases.
1.3.1.3 Functional analysis
Once a metagenome is assembled, genes within the assembled contigs are then
identified, which is a prerequisite for deducing the functional potential (annotation) of
a mierobiome. Although a number of tools exist for this task, such as MetaGeneMark
(Zhu et al. 2010), FragGeneScan (Rho et al. 2010) and MetaProdigal (Hyatt et al.
2012) , the computational challenges they address (with variable suceess) are greater
than for single genomes. As the metagenome assemblies are generally of poorer
quality than for single genomes, even when performed at an optimal level, many genes
still remain fragmented and incomplete. Following gene identification (gene calling),
functional annotation is earned out using computationally demanding homologybased searches (often BLAST (Altsehul et al. 1990)) against databases of orthologues
(EggNOG (Huerta-Cepas et al. 2015), COG or KOG (Tatusov et al. 2003)), enzymes
(KEGG (Kanehisa and Goto 2000)) and protein domains and families (Pfam (Finn et
al. 2013), TIGRFAMs (Haft et al. 2003), InterPro (Hunter et al. 2008)). Owing to the
vast number of possible combinations of tools, along with their various computational
prerequisites, a number of publicly available pipelines have been developed. These
tools have particular concatenations of methods or software with predefined
parameters, and include MG-RAST (Meyer et al. 2008), IMG/M, CAMERA (Seshadri
et al. 2007) and the European Bioinformatics Institute's Metagenomics (Hunter et al.
2013) service. These pipelines provide quality-filtering, gene calling, functional
annotation, basic statistics and visualization in easy to use online platfonns. Although
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these approaches suit many users without relevant experience in command-line usage
of bespoke methods, they have a level of less-controlled analysis and the seiwices often
become user-saturated.
1.3.2 Marker gene analysis
A number of pipelines and software packages are available for analysing 16S rRNA
gene amplicons, most notably QIIME (Caporaso et al. 2010), Mothur (Schloss et al.
2009), and UPARSE (Edgar 2013), which are all highly flexible and versatile. One
study concluded that QIIME, Mothur and MG-RAST produced comparable results
when analysing stool samples, and similar microbial composition was found
irrespective of the pipeline chosen (Plummer et al. 2015). A typical pipeline starts with
quality-filtering and de-multiplexing of raw sequencing reads into appropriate sample
bins. This process is possible as barcode sequences of short DNA sequences, unique
to each sample, have been added to the primers before amplification. A typical
approach following this step is to cluster reads into operational taxonomic units
(OTUs), which are grouped on the basis of DNA sequence similarity. A 97% similarity
level is usually applied as this is considered suitable for binning reads derived from
the same species. The main methods for this are de novo, closed-reference and openreference clustering, each with their own set of advantages and disadvantages. De
novo methods cluster reads without the use of a reference database, whereas the
opposite is tme for the closed-reference clustering (exclusively reference based). The
latter method is much faster because reads with no alignment to the database are
discarded. However, some evidence suggests de novo clustering is the optimal method
(Westcott and Schloss 2015). Open-reference clustering combines both de novo and
closed reference methods, in which any reads discarded during closed reference are
subjected to de novo clustering, leading to some performance improvements (JervisBardy et al. 2015). One comparison of older and newer clustering methods found the
newer methods superior to the more traditional methods (Kopylova et al. 2016).
Another important step in the analysis of marker gene sequences is the removal of
chimeric sequences, a known artefact of PCR amplification in which hybrid sequences
are produced from unrelated parent sequences. The majority of chimaeras are
relatively easy to detect using existing reference databases, and software applications
for detection (integrated into the commonly used pipelines QIIME and Mothur)
include UCHIME88 and ChimeraSlayer (Haas et al. 2011), although all methods
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might not be 100% effective. QIIME also provides a framework for taxonomic
assignment to the created OTUs. The most commonly used classifiers are Mothur
(Schloss et al. 2009) and the RDPclassifier (Q. Wang et al. 2007). Taxonomic
classification requires a reference database of previously classified sequences, such as
SILVA (Quast et al. 2012) (16S and 18S rRNA genes), Greengenes (DeSantis et al.
2006) (16S rRNA gene), Ribosomal Database Project (Maidak et al. 2000) (16S rRNA
gene) and UNITE (Koljalg et al. 2005) (ITS region). These classifiers are very accurate
to family taxonomic ranks and are often accurate to genus level with some occasional
misclassifications for obligate anaerobes (due to lack of reference sequences) and
Enterobacteriaceae (due to highly similar reference sequences from different genera),
but lose much of the specificity and accuracy at species level. More dedicated speciesclassifiers such as SPINGO (Allard et al. 2015) or UTAX (Edgar 2010) are better
options for higher taxonomic resolution. Sequencing errors can greatly affect OTU
clustering perfonuance, and methods removing erroneous reads or alternatives to
clustering are desirable (Chen et al. 2013). One published alternative to standard OTU
clustering is the Divisive Amplicon De-noising Algorithm (DADA2) (Callahan et al.
2016), which corrects for noise and errors in Illumina MiSeq generated sequences.
DADA2 also offers a full amplicon workflow including quality filtering,
de-replication (the process of consolidating identical sequences for efficiency) and
chimaera identification. For statistical analysis and visualization, QIIME and MEGAN
(Huson et al. 2016) require a count table (OTUs as rows and their abundances for each
sample in columns). However, many other packages and software exist for
microbiome related statistics. A standard count table is used when carrying out
analysis in R, the most commonly used statistical programming language. Useful
R libraries for such analysis include Vegan, Phyloseq (McMurdie and Holmes 2013)
and ggplot2, which all provide methods, ample documentation and vast flexibility for
statistical and visual analysis of both metagenomic and marker gene studies. Finally,
as an attempt to bridge the gap between metagenomics and marker gene analysis,
PICRUSt (Langille et al. 2013) and Tax4Fun (ABhauer et al. 2015) can assign
metabolic functions to 16S rRNA genes based on their read mappings to previously
annotated genomes. PICRUSt applies a two-step process involving gene content
inference followed by metagenome inference, resulting in estimated abundances of
gene families. Although acknowledging the imperfect link between the marker gene
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and its host genome, PlCRUSt and Tax4Fun can be used as exploratory tools to
investigate the potential need for more in-depth metagenomic shotgun sequencing.
Category
Quality tools
Shotgun read
assemblers

Description
Tools for run assessment, read filtering and
trimming to ensure high quality data
Software for aligning and merging
fragments of DNA to form longer contigs
and scaffolds in an attempt to reconstruct
an original sequence

Grouping contigs or reads based on a
specific features to assign taxonomy.
Methods include composition and
alignment or a combination of both

Shotgun
binners or
classifiers

Shotgun
gene and
functional
analysis tools
Shotgun
gene and
functional
databases
Shotgun
statistical
analysis tools

Tools for predicting genes in contigs and
assigning functions

Software
FASTQC, Fastx-Toolkit(Hannonlab), Trimmomatic,
PRINTSEQ, NGS QC Toolkit, Meta-QC-Chain
SOAPdenovo2, IDBA-UD, Meta-IDBA,
MetaVelvet, MetaVelvet-SL, Velvet, Ray-Meta,
MEGABIT, MetaBAT, Omega, METACAA,
metaSPAdes, MetaORFA, MetaAMOS
MetaPhlAn2, Kraken, GSTaxCIassifier, Ray Meta,
mOTU, CLARK, CLARK-S, Amphora2, TACOA,
NBC, MLTreeMap, PhymmBL, GOTTCHA,
CARMA3, LMAT, PhyloPythiaS, Taxator-tk,
MetaClusterTA, RITA, SORT-Items, SPHINX,
Ralphy, WGSQuiker, S-GSOM, Treephyler,
TaxSOM, ClaMS, Genometa, Woods,
DiScRlBinATE, MetaCV, INDUS, MetaBin,
MetaPhyler, TAC-ELM, metaBEETL, SPANNER,
DUDes, Kaiju, MaxBin, MetAnnotate, MyTaxa,
Tamer, TaxyPro, TWARIT, WSVDD
MetaGeneMark, FragGeneScan, MetaProdigal,
ShotgunFunctionalize R, RAMMCAP, GlimmerMG, Orphelia, MetaGUN, Genometa, Metaphor,
MetaPath

Databases containing functional
information tor aligning predicted genes

PFAM, COG/KOG, SEED, eggNOG v4,
TIGRFAM, KEGG

Tools for visualisation and analysis of
metagenomic shotgun data

HUMAnN2, LEfSe, PPANINI, StrainPhlAn

•

Software containing all or subset of
steps involved in shotgun
MG-RAST, MEGAN, IMG/MER, WEBMGA,
Shotgun
metagenomic analysis.
MetaAMOS, EBl Metagenomics, METAREP,
Parallel-META, MOCAT, GALAXY Portal,
pipelines
•
Steps include, quality filtering,
assembly, classification and functional BIOMaS, PHACCS, Smashcommunity
assignment along with visualisation
Methods for clustering reads against each
Closed Reference, Open Reference, De Novo,
OTU picking other or aligning reads to a database, or
Mothur, uclust, UP ARSE, DOTUR, CD-HIT,
methods
both, to obtain a set of Operational
CROP, ESPIRTI-Tree, DNA Clust, GramCLuster,
Taxonomic Units (OTUs)
M-pick, Swarm v2, oclust, MtHc
Tools for removing chimeric sequences
Chimera
(reads erroneously consisting of two
UCHIME, UCHIME2, ChimeraSlayer, CATCh
removal
transcripts)
Software to assign taxonomy to 16S marker
16S
Mothur, RDP-Classifier, Utax, rTax, 16S Classifier,
amplicon
gene OTUs or reads at each taxonomic
SPINGO
classifiers
level including species for some classifiers
Databases containing sequences used for
Amplicon
SILVA, Greengenes, RDP, rmDB, PhylOPDb,
assigning taxonomy to OTUs/reads through
databases
HITdb, Unite
alignment
16S
Tools and software packages for the
UniFrac, PlCRUSt, Phyloseq, LEfSe, MaAslin,
statistical
analysis and statistical comparisons of 16S
MetagenomeSeq, CopyRighter, OTUbase
analysis tools marker gene datasets
A package of tools and commands
16S
QIIME, Mothur, SILVA, Megan, FASTGroup2,
contained in a pipeline to analyse 16S
amplicon
PANGEA, CLOTU, Jaguc, DADA2, MICCA,
marker gene data from raw data to
pipelines
FunFrame
visualisation
Table 1.1: Categorization and description of software tools and packages used for published
microbiome analysis.
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1.4 Comparison of Sequencing Technologies and Methods
When conducting a microbiota study, there are a number of decisions which must be
made during the study design stage. Hypothesis, sample size, demographics of
participants/samples along with budget are of the utmost importance. However, an
additional factor, the bioinformatics analysis, is often forgotten along with the type of
sequencing and associated approaches. As discussed previously, there are a plethora
of bioinfomiatics tools and two major sequencing strategies; Amplicon sequencing
and Shotgun Metagenomics. When delving further into the methods available for the
sequencing stage of the experimentation, there are a number of key decisions with
regard to amplicon, sequencing technology and software.
1.4.1 Primers and 16S rRNA gene variable regions
Prior to sequencing, DNA extraction protocol and library preparation can have an
impact on results as shown in Sinclair et al., where there were significant differences
in beta diversity results dependant on a one-step versus two-step PCR protocol
(Sinclair et al. 2015). Library preparation aside, there are many other influence results,
particularly 16S rDNA amplicon sequencing. Using in-silico analysis a publication by
Klindworth et al. provided evidence to a bias in the primers selected for PCR
(Klindworth et al. 2013) and as previously mentioned, the 16S gene has 9 variable
regions each suiTounded by highly conserved regions of DNA which are targets for
PCR primers. Although it would be advantageous to sequence the complete gene or
the majority of regions, current high-throughput sequencing technologies are unable
to produce sequences of this length when offering large sample numbers per run to
prevent a potential run bias. Unfortunately there is no gold standard region(s) to
sequence (VI-V9) when perfonning 16S analysis, and a number of studies have been
eonducted comparing results from different variable regions, finding discrepancies
between counts (Claesson et al. 2010; Kozich et al. 2013; Tremblay et al. 2015).
Claesson and co-authors investigated differences between sequencing results from 6
combinations of 16S rRNA gene variable regions (VIV2, V2V3, V3V4, V4V5, V5V6
and V7V8) from DNA extracted from human faecal samples. The V4V5 primer
perfonned best based on consistency, classification efficiencies and simulation
accuracies across two classification approaches, RDP-Classifier and MEGAN. In a
separate study, Kozich et al. studied 3 variable regions (V4, V3V4 and V4V5) in
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mock, human faecal, mouse faecal and soil samples. Mock community results showed
that the V3V4 and V4V5 obtained far more spurious OTUs than that of the V4 region
alone. When looking at the environmental samples, there continued to be a laek of
consistency with more OTUs for the mouse samples compared to the human samples
in the V4, vice versa for the V4V5 and a similar number for each in the V3V4.
Similarly Tremblay et al. investigated 3 regions: V4, V6-V8 and V7-V8 using both a
mock community and environmental samples. Primer choice had an effect on
abundance estimates with the V4 region being most similar to the expected mock
community. It can therefore be concluded that selecting a primer or region for
amplification is not a simple task and there are many factors to be considered. It is of
the utmost importance to keep primers and primer binding regions consistent within
studies and also between studies if canying out a comparison.
1.4.2 Bioinfonnatic tools
As discussed previously, there is a myriad of tools and pipelines available for the
analysis of next generation sequencing outputs. Pylro and colleagues investigated the
difference between three of these approaches (varying quality filtering parameters and
OTU clustering algorithms) when carrying out 16S V4 rRNA gene amplification
analysis (Pylro et al. 2014). The first method was to use QIIME with default quality
filtering parameters and open reference OTU picking, the second involved QIIME
with modified quality filtering parameters and the final method was a combination of
both UPARSE and QIIME. Edgar reported that between 27% and 67% of OTUs
generated from QIIME were chimeric (Edgar 2013), and this may explain why default
QIIME parameters yielded a higher alpha diversity for samples. Despite this, all three
methods correlated with regard to taxonomic classification and beta diversity, while
the authors recommend using UPARSE in conjunction with QIIME for its chimera
filtering.
Two recent studies investigated differences in classification results obtained from
various metagenomics sequence classifiers. Lindgreen and colleagues tested 14
elassifiers using a synthetic dataset based on the complexity, nature and abundance of
real soil samples (Lindgreen et al. 2016). The results were based on a number of
parameters including runtime, fraction of reads mapped, specificity and sensitivity.
Although the majority of classifiers had a false positive rate of less than 1%, most
classifiers results were significantly different compared to the known taxonomic
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abundance. Four of the tools also classified eukaryotes, however the abundances were
underrepresented in each case. Peabody et al. examined the classification results from
11 tools, some of which overlapped with the previous study (Peabody et al. 2015).
Both authors concluded that there was no single best method and results varied in each
case. Again, it is important to be cautious when comparing studies and selecting of a
classifier for use.
1.4.3 Sequencing Platforms
When comparing previous generations of sequencing platforms to the current leading
brand (Roche 454 to lllumina MiSeq) it is largely agreed that the results from both are
similar with alpha, beta and taxonomic composition comparable onee methods remain
consistent (Claesson et al. 2010; Sinclair et al. 2015), despite lllumina MiSeq
obtaining higher quality reads (Tremblay et al. 2015). However, there is a requirement
for the platfonns currently available to be compared. Pylro and co-authors undertook
a second comparison in their study and compared results from the V4 region of the
16S rRN A gene when sequencing on two frequently utilised teehnologies; the lllumina
MiSeq and the PGM Ion Ton'ent. Salipante et al. conducted a similar comparison using
the same two technologies but with the V1V2 region using a selection of human
samples and mock communities (Salipante et al. 2014). Here, they sequenced the mock
communities in triplicate and only minor differences were detected between these
replicates and also found that both teehnologies gave an accurate representation of the
moek eommunities, however only 5 of the 18 human samples were greater than 90%
similar. Despite this, Pylro found few differenees between technologies with regard to
alpha and beta diversity along with taxonomic classification when stringent quality
cut-offs were used. Procmstes analysis showed significant con-elation between the
teehnologies while alpha diversity and taxonomie classification were also highly
comparable. The difference between both research groups may be due to method of
processing (quality-filtering and classification) and assessment, or due to the region
of the 16S gene.
1.4.4 Conclusion
Although there have been many studies comparing primer regions, library
preparation and bioinformatic methods, the conclusions comparing technologies are
unclear and there is laek of investigation between metagenomic sequencing and
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marker gene analysis. Caporaso et al. compared sequencing the V4 region of 16S
rDNA on both a MiSeq and a HiSeq and found consistent results, however, there is a
lack of studies comparing shotgun sequencing across platforms. High-throughput
sequencing is a costly method and in an attempt to reduce the cost, there is a potential
for using lower throughput technologies (e.g. MiSeq and Ion Torrent) for shotgun
sequencing, if results were consistent and reliable.
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Section 2: The Microbiome
2.1 Introduction to the microbiome
Microorganisms exist ubiquitously in nature, ranging from environments such as the
human gut (Lozupone et al. 2012) and mouth (Wade 2013), to geothermal hot springs
(Chan et al. 2015) and the upper troposphere (DeLeon-Rodriguez et al. 2013).
Microbes rarely exist in isolation but in complex multispecies communities. These
communities of cohabiting microorganisms are known as a microbiota and can have
three possible relationships with their host environment: a negative effect, lack any
effect or, a positive effect - often they provide essential, and in some cases critical
benefits and services to the host environment. For example, the microbiota of the
rhizosphere aid plant growth, stress response and defend against pathogens, therefore
contributing to the longevity of the plants life (Shaipton 2014). The microbiota of
humans also have a large impact on development and perfonuance throughout life.
However, many of these microbes are difficult to culture in a lab and this led to a
plateau in discoveries and analysis of microbiota along with false reports. Early studies
suggested that E.coli was an abundant and highly prevalent member of the human gut
microbiota due to a bias in culturing methods (Lozupone et al. 2012). Culturing of
microbes is labour intensive and on selective media it was difficult to distinguish
between species. Advancements and improvements in next generation sequencing
along with decreases in cost, has allowed for a transition away from culture dependent
methods and enabled the exploration of the human microbiota through sequencing.
Table 1.2 below outlines a number of techniques available for microbiota analysis.
Approach

Pros and Cons

DaU

Biomartcer sequencing (e g .
16S rRNA gene or internal
transcribed spacer region)*

Community composition

Next generation sequencing

Is cost effective, is semiquantitative. permits resolution of genus level
and in some cases species level, shorts reads may make accurate
classification difficult

Metagenomics

Generation of draft genomes,
functional capacity, growth
dynamics

Next-generation sequencing

Has capacity for strain-level reconstruction, is quantitative, allows for
hjnctional anrvXation with pathway predictions; is currently very costly,
has community coverage that may be relatively shallow in more com
plex assemblages

Metatranscriptomics (RNA
sequencing)

Gene expression

Next-generation sequencing

Highly expressed genes arc more likely than others to be delected, deple
tion of human transcripts is possible, requires immediate preservation
or processing of fresh or snap-frozen intestinal specimens

Metaproleomics

Protein expression

Liquid or gas chromatographymass spectrometry

Primarily detects dominant proteins, makes removal of host-derived pro
teins impossible

Metabolomics

Metabolic productivity

liquid or gas chromatographymass spectrometry or magnetK
resonance spectroscopy

Is semiquantitative: can be targeted or untargeted, detects metabolites
that are platform- and database-dependent: detects metabolites that
may onginate from microbes, diet, or host

Table 1.2; A description of some techniques for analysing the microbiome (Lynch and Pedersen
2016).
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2.1.1 The Human Microbiota
The human microbiota is very complex and is composed mostly of bacteria but also
viruses (virome), phages (phagome), fungi (mycobiome) and archaea. It is estimated
that 3.8x10'^ microbial cells inhabit the human body with the colonic microbiota being
the most abundant (Sender et al. 2016). Microorganisms are found throughout the
human body and each play key roles in benefiting their host.
Location

Typical concentration of bacteria
(number/mL content)

Volume (mL)
^

400

Order ot magnitude bound
for bacteria number

Colon (large intestine)

10"

Dental plaque

10"

<10

10'®

Ileum (lower small intestine)

10®

400®

10"

Saliva

10®

<100

<10" perm^

lO’"'

1.8 m®

10"

Stomach

10®-10*

250 ®-900

10®

Duodenum and Jejunum (upper small intestine)

10^-10"

400

10®

Skin

Table 1.3: The number of bacterial cells residing in and on the human body (Sender et al. 2016).

2.1.1.1 The Skin Microbiota
The skin's primary function is to form a physical bamer protecting against hannful
pathogens, however the bamer also contains an ecosystem of approximately 1.8 m^
inhabited by many commensal microbes. There are various habitats on the skin defined
by factors such as folds, hair follicles, glands and skin thickness leading to changes in
pH, temperature, moisture and sebum content (Grice and Segre 2011), while factors
such as age and sex also affect inter-individual variation (Ying et al. 2015). It is
possible that gender-related differences in microbiota composition are attributed to
physiological and anatomical difference along with hormones, sweat rate and cosmetic
use (Giacomoni et al. 2009).
There is a strong symbiotic relationship between the host and the skin microbiota,
however exogenous disturbances such as cleaning can lead to a number of alterations
(Fierer et al. 2008). When examining the median microbial abundance across 20 skin
sites on 10 healthy humans, four primary phyla reside on healthy skin: Actinobacteria
(51.8%), Firmicutes (24.4%), Proteobacteria (16.5%) and Bacteroidetes (6.3%),
although with significant variations in abundance dependent on the site. Moist areas
such as the naval, the soles of the feet, the popliteal fossa and the antecubital harbour
Staphylococcus and Corynebacterium species as the most dominant taxa (Grice et al.
2009), while Propionihacterium species dominate the sebaceous sites (such as alar
crease, behind the ear and forehead), although these sites have been observed to be the
least diverse (Costello et al. 2009). The most diverse areas of the skin are the dry sites,
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exhibiting more diversity than the gut and oral eavity from the same individuals
(Costello et al. 2009; Griee and Segre 2011). Predominant fungi present on the healthy
skin include species of Malassezia and are most often associated with the sebum rich
areas (J. Xu et al. 2007), while Demodex of the Arthropoda also favour these sites
(Lacey et al. 2011).
However, alterations of the skin microbiota can lead to a number of different
conditions and diseases, f^or example, altered bacterial colonisation is observed in skin
acne where Propiojuhacterium acues is increased in abundance. This species
colonises the sebaceous follicles and the secretion of hyaluronidases, lipases and
proteases cause local inflammation (McDowell et al. 2011), while in psoriasis
Finnicutes tlourish at the expense of Actinobacteria in the psoriatic lesions (Cho and
Blaser 2012). Alterations of the skin microbiota are not limited to bacteria as Demodex
is increased on the skin of rosacea patients (Casas et al. 2012), while in the less serious
but more common Dandmff is associated with increases in members of the genus
Malassezia (M. restricta and M. globose) and is treated with anti-fungal medication.
2.1.1.2 Vaginal Microbiota
The vaginal microbiota is less diverse than the oral microbiota as Solt et al. reported
finding 112 unique genera (Solt and Cohavy 2012). This is in accordance with the
Human Microbiome Project which concluded that the microbiota of the vagina is more
simple but contains a higher proportion of Lactobacillus species (HMP 2012). Van de
Wijgert and colleagues conducted a meta-analysis of 63 articles investigating the
microbiota of the human vagina (van de Wijgert et al. 2014), and while there were
some discrepancies, many of the studies resulted the similar conclusions for the
healthy vaginal microbiota. Longitudinal studies also showed women to have a stable
vaginal microbiota (E Biagi et al. 2009; dos Santos Santiago et al. 2011; Wertz et al.
2009). A vaginal microbiota highly abundant in Lactobacillus was associated with a
pregnancy outcomes with a reduced risk of pre-tenn birth and increased success rate
of IVF (Hummelen et al. 2011; Hyman et al. 2012; Hyman et al. 2014). Pregnant
women have shown higher levels of Lactobacillus species, L. crispatiis L. Jensenii
and L. johnsonii, along with lower diversity (Aagaard et al. 2012; Petricevic et al.
2012). However, studies do not report to any differences between women of different
age groups when comparing adolescent, reproductive and post-menopausal women
(Datcu et al. 2013; Yamamoto et al. 2009).
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Similar to microbiota of other body sites, dysbiosis of a community can result in
disease or infection, however unlike others, it is often characterised by an increase in
diversity opposed to a decrease. Bacterial vaginosis results in decreases of vaginal
Lactobacilli, while facultative anaerobic bacteria, e.g. Leptothchia amnionii and
Eggerthella species, appear to thrive along with an increase in bacterial diversity
(Srinivasan et al. 2012). This condition is generally non-inflammatory and therefore
often asymptomatic however contrary to this. Vaginal Candidiasis is highly
inflammatory with the inhabitation of Candida species (van de Wijgert et al. 2014).
2.1.1.3 Oral Microbiota
After the colon, the human mouth is the second most diverse environment in the
human body, and is highly complex with over 600 prevalent species identified
(Dewhirst et al. 2010). The oral microbiota consists of viruses, fungi, archaea,
protozoa and bacteria. Many of the vimses present are pathogenic, although a study of
the healthy microbiota found that the highest abundance of vimses were
bacteriophage, perhaps due to the large quantity of bacteria present (Pride et al. 2012).
Viral diseases such as mumps and rabies are caused by infection of the salivary glands
(Kumaraswamy and Vidhya 2011). Conversely, protozoa, fungi and archaea are found
in the healthy microbiota, and while the protozoa Entamoeba gingivalis and
Trichomonas tenax are found in the healthy human mouth, there is an increase of both
with poor oral hygiene (Wantland et al. 1958). A study of 20 healthy individuals
identified 85 different fungal species in the mouth with the most prominent genera
hCmg Aspergillus, Aiireobasidiiim, Saccharomycetales and Candida (Ghannoum et al.
2010).
The most characterised microbial component of the oral microbiota is bacteria,
which are dominated by species of the phyla Bacteroidetes, Proteobacteria,
Acintinobacteria, Spirochaetes and Fusobacteria, combined encompassing 96% of all
detected oral bacteria (Dewhirst et al. 2010). However, like many other sites in the
body, there is inter-individual variation. Nasidze et al. investigated the oral microbiota
of 120 individuals across 12 locations and found that variation (distribution of genera)
between geographical locations was 11.7% and between subjects from each location
was 1.8% (Nasidze et al. 2009). It is noteworthy that the oral microbiota is difficult to
compared across cohorts and individuals due to the impact of frequent exogenous
substances such as air, food and fluids (Wade 2013).
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1 he oral microbiota possesses a number of key functions in the mouth including
colonisation resistance (Vollaard and Clasener 1994). A quarter of the nitrate ingested
from the diet is converted to nitrite in the mouth by the oral microbiota which is then
absorbed into the bloodstream and converted to nitric oxide. Nitric oxide aids vascular
health by acting as an anti-hypersensitive agent, causing the blood vessels to relax and
allow optimal blood flow (Kapil et al. 2010).
Despite the benefits, in some instances, the oral microbiota can cause disease of the
mouth. Tooth decay (dental carries) occurs when the oral bacteria produce acid
thi'ough the fennentation of carbohydrates leading to the erosion of teeth. The pH of
the environment becomes reduced allowing for the bloom aciduric species like
Streptococcus mutans (Takahashi and Nyvad 2011), along with species of
Bifidohactcriiinu Propionihactcrium and Scardovia which have also been associated
with caries disease (Wade 2013).

2.2 The Gut microbiota
The high abundance of microbial life in the human gut may be due to the large surface
area (250-400m") and the 60 tonnes of food passing through in an average lifetime
which offers an ideal source of energy for the microbes (Bengmark 1998). Previously,
it was estimated that there are 10 times more bacterial cells in the human gut than host
cells (Backhed et al. 2005), however recent estimations suggest that this is closer to
1:1 (Sender et al. 2016). The human intestinal microbiota plays a critical role in
protection against pathogen overgrowth (Kamada et al. 2013), intestinal endocrine
functions (Neuman et al. 2015), energy biosynthesis (Canfora et al. 2015), vitamin
biosynthesis (Yatsunenko et al. 2012), neurologic signalling (Yano et al. 2015),
metabolising bile acids (Devlin and Fischbach 2015), modifying medications and
removing toxins (Haiser et al. 2013). In return, the host provides the microbes with a
nutrient-rich environment in which to thrive.
2.2.1 Development of the Microbiota and changes through time
Formerly considered sterile environments, the placenta (Aagaard et al. 2014), the
amniotic fluid (DiGiulio et al. 2010) and the meconium (Gosalbes et al. 2013) contain
bacterial species. The gut microbiota of neonates delivered vaginally have
taxonomically similar bacterial profiles to that of the mother’s gut and vaginal
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microbiota (Backhed et al. 2015), with these infants showing high levels of
Lactobacillus species (Avershina et al. 2014). On the contrary, Caesarean section has
provided an enrichment of Haemophilus, Staphylococcus, and Enterohacter species
(Backhed et al. 2015; Dominguez-Bello et al. 2010), which are generally considered
opportunistic bacteria. The stark difference can be summarised comparing the faecal
microbiota of the infant to the faecal microbiota of the mother, where naturally
delivered infants mimic the maternal microbiota (72% of species in common) while
similarities are less (41%) in caesarean section delivery (Backhed et al. 2015).
Compositional differences have also been described between breast fed and bottle
fed infants. The main constituents of the microbiota of breastmilk are Staphylococcus,
Enterohacteriaceae and Pseudomonas (Urbaniak et al. 2016) and although
Bifidobacteria is the most abundant species in both breast and formula milk (Fallani
et al. 2011), human milk contains growth factors, cytokines and immunoglobulins
which formula milk lack (Le Huerou-Luron et al. 2010; Roncada et al. 2012). There
are some differences in the abundance of Bifidobacteria species between the feeding
methods, with both containing Bifidobacterium breve, adolescentis, longum and
bifidum, while breast milk contains more Bifidobacteria infantis (Mackie et al. 1999;
Penders et al. 2006). These appear to have an effect on the microbiota as breast-fed
new-borns have a more stable microbiota composition when compared to fonnula-fed
(Bezirtzoglou et al. 2011). However, as solid food is introduced to the diet the
microbiota differences are no longer observed with breast-fed infants transitioning to
fonnula-fed profiles with increases in Enterococcaceae and

Enterobacteria

(Adlerberth and Wold 2009; Mackie et al. 1999). The microbial differences in milk
composition appear to have an effect on health with breast milk associated with
decreased risk of diarrhoea enterocolitis as a new-born (Mackie et al. 1999), along
with autoimmune diseases (Akobeng et al. 2006; De Palma et al. 2012) and type 1
diabetes (Kramer 2011) in childhood. Interestingly, breast milk energy composition
varies depending on the gender of the infant with breast milk from mothers with male
infants containing a higher fat concentration (Powe et al. 2010). Despite this, a study
of 39 Canadian mothers milk found no difference in the microbiota profiles based on
delivery mode, gestation length or gender of the child (Urbaniak et al. 2016). The
World Health Organisation recommends exclusive breast feeding for the first 6
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months of life, however this only occurs in 41% of cases in infants between 4 and 6
months of age with the lowest compliance in Europe (Le Huerou-Luron et al. 2010).
A high degree of gut microbial change is observed in infancy, before slowing down
between 1 and 5 years of age, but is generally dominated by 2 phyla: Actinobacteria
and Proteobacteria (Rodriguez et al. 2015). As the infant progresses to childhood, the
gut microbiota increases in diversity. The gut microbiota of children remains stable
but lower in diversity than that of an adult until preadolescence where the microbiota
begins to resemble that of an adult (Cheng et al. 2015). However, preadolescent
individuals generally have enriched members of the family Lachnospiraceae and the
genera Faecalihacterium and Bifidobacterium when compared to adults.
The adult gut microbiota is dominated by 2 phyla: Bacteroidetes and Fimiicutes,
while the less abundant Actinobacteria, Proteobacteria and Ven-ucomicrobia are also
present (HMP 2012; Qin et al. 2010). Once individuals become elderly, the microbiota
begins a final shift with an increase in the Bacteroidetes phyla and Clostridium Cluster
IV (Claesson et al. 2011). However, these findings are not universally agreed as
another study showed that there was no difference in the gut microbiota of 70 year
olds vs younger controls, but a reduced diversity in centenarians (Elena Biagi et al.
2010). Claesson and co-authors found decreases in Ruminococcus and Blaiitici and
increases in Escherichia coli in elderly subjects compared to younger controls
(Claesson et al. 2012). The centenarian gut microbiota was also characterised by an
increased abundance in Escherichia coli and a decrease in Faecalihacterium
prausnitzii (Elena Biagi et al. 2010).
2.2.2 The gut microbiota of a healthy adult
Over 1000 unique bacterial species have been identified in the human gut (RajilicStojanovic and de Vos 2014) with the colon having the largest number of microbial
cells than any other body site by an order of magnitude (Sender et al. 2016). The
MetaHIT consortium cohort, a study involving 124 European adults, found
approximately on average 160 species in the gut per individual, and between 10001150 species noted overall (Qin et al. 2010). However, as with other sites in/on the
body, bacteria are not the only inhabitants, as the human gut microbiota also contains
viruses, eukaryotes and archaea. The virome is an area gathering interest in recent
years largely due to improvements in sequencing techniques, while Candida,
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Malassezia and Saccharomyces are the most commonly identified fungal taxa in the
human gut (Huffnagle and Noverr 2013; Lukes et al. 2015; Parfrey et al. 2014;
Underhill and lliev 2014; Virgin 2014).
An important consideration are differences in the microbiota composition
depending on the site of the gastrointestinal tract (Figure 1.7). In the small intestine,
bacterial growth is limited due to the acidic environment and the short transit time
(Donaldson et al. 2016), therefore allowing only rapidly growing, facultative
anaerobes sur\4ve (Gu et al. 2013). The colon however, contains a dense community
of bacteria with members of the families Prevotellaceae, Lachnospiraceae and
Rikenellaceae dominant in this region (Donaldson et al. 2016; Gu et al. 2013).
Dominant gut phyla:
Bacterokletes. Firmicutes, Actinobacteria. Pioteobacteria. Verrucomicrobia

Predominant families in the:
Small intestine
Lactobacillaceae.
Enterobactefiaceae

Colon
Bacteroldaceae. Prevotellaceae.
Rikenellaceae. lachnospiraceae,
Ruminococcaceae

Inter-fold regions
Lachnospiraceae.
Ruminococcaceatt

Digesta
Bacteroidaceae.
Prevotellaceae,
Rikenellaceae

Bacterial load
pH
Antinticrobials
Oxygen
Proximal

Distal

Figure 1.7: The biogeography of the gastrointestinal tract (Donaldson et al. 2016).

Early research aimed to establish a “core" composition for a “healthy" microbiota
or optimal state, while dysbiosis leading to disease, would be a diversion away from
this core state. One such method was the development of enterotypes, or robust
clusters, which were based on the variation of a particular genera: Bacteroides,
Prevotella and Riiminococcus (Arumugam et al. 2011). However, discrete clusters
were not universally accepted (Jeffery et al. 2012), did not take confounding variables
or stability over time into account and were not reproducible (Knights et al. 2014).
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The authors later published an addendum stating that enterotypes are not discrete
clusters but a method for stratifying subjects (Ammugam et al. 2014). Studies have
found that the microbiota of a healthy adult adjusts and alters whilst maintaining a
healthy state, meaning there is a large degree of intra-individual variation (Tumbaugh
et al. 2007). However in recent years there has been a shift in hypothesis to a possible
“core functional" microbiota. Under this hypothesis irrespective of composition, if
particular functional requirements are met, the microbiota maintains a healthy “state"
and therefore dysbiotic related events do not occur (Lloyd-Price et al. 2016). It has
been observed that there is a large degree of variation between individuals in the gut
microbiota (beta diversity), however when assessing the functional pathways, there
are many more similarities between people and body sites. The most conserved
pathways included ribosomal and translational machinery, ATP synthesis and
glycolysis (HMP 2012). Further hallmarks of a healthy state included high diversity
(Tumbaugh et al. 2007) along with high levels of stability (Flores et al. 2014), while
others consider a gut microbiota as healthy when it can efficiently return to a healthy
state after alternation e.g. antibiotics (Dethlefsen et al. 2008).
The MetaHlT consortium (Qin et al. 2010) and Human Microbiome Project
(Tumbaugh et al. 2007), conducted in Europe and America respectively, along with a
large Chinese diabetes cohort (Qin et al. 2012), allow for geographical and inter
individual comparisons. The HMP conducted 16S rRNA gene profiling on 242 healthy
adults along with metagenomic sequencing on a subset of 129 subjects, while the
Chinese cohort consists of 145 gut metagenomes half of which were healthy controls.
These three large studies along with smaller international studies (De Filippo et al.
2010; Takeshita et al. 2014; Yatsunenko et al. 2012) have shown there to be
differences between populations. There are a number of possible causes for this
including diet, life exposure and genetics (Camiody et al. 2015; J. Li et al. 2014a).
These results provide evidence that the gut microbiota is influenced by external forces
even when considered healthy.
2.2.3 The effect of diet on the gut microbiota
Since the dawn of agriculture, food has been selectively grown and bred by humans in
order to meet their palate rather than their requirements. Although impressive, it is not
solely a positive feat with two-thirds of US adults being over-weight (Ogden et al.
2014) and less than 20% consuming what is deemed a healthy balanced diet (L. P.
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Smith et al. 2013). As a vast quantity of food passes through the GI tract each day,
there has been much interest into the effect of foods and diet on the gut microbiota,
and it is well established that particular microbes favour certain nutrients which allow
them to flourish
Whey and pea protein extract result in Bifidohactehwn and Lactohacilliis to be
increased (Dominika et al. 2011; Romond et al. 1998), along with increases of ShortChain Fatty Acid (SCFA) levels and anti-inflammatories (Kim et al. 2014), while
whey protein decreases the abundance of Bacteroidetes fragilis and Clostridium
perfriugens (Romond et al. 1998). However, these results are not consistent with all
fomis of protein as animal based protein has shown increases in Bacteroides, Alistipcs
and Bilophila (David et al. 2014), while diets high in animal protein are associated
with an increased risk of developing IBD (Jantchou et al. 2010). The difference
between whey and pea based protein compared to animal based protein may be the
high fat content in the latter.
Fats can be divided into two broad categories: 1) high saturated and trans-fats,
considered harmful, and 2) mono and polyunsaturated fats, considered beneficial. The
Western diet consists of high levels of harmful fats and low quantities of beneficial
fats. When examining varying amounts of fat in diets, Fava et al. noted that low fat,
high cholesterol diets resulted in higher concentrations oi'Bifidohacteriunu while diets
high in monounsaturated fats led to higher levels of Faecalihacteriuni prausnitzii
(Fava et al. 2013).
Carbohydrates have also been studied in detail and like fats, can be divided into
two broad categories; 1) digestible and 2) non-digestible. Digestible carbohydrates
like glucose, fructose and other sugars and starches are digested in the small intestine
enzymatically (Saltiel 2015). Studies investigating high levels of digestible
carbohydrates found increases in Bifidohacteria and decreases in Bacteroides and
Clostridia (Eid et al. 2014; Jeffery and O'Toole 2013). Non-digestible carbohydrates,
e.g. wheat, barley and oats, travel to the large intestine where the microbiota begin the
fermentation process (Lozupone et al. 2012). As this is not carried out naturally by the
host, this is part of the symbiotic relationship and results in energy in exchange for a
habitat and nourishment. Diets high in non-digestible carbohydrates contain increases
in the genera Bifidohacteria and Lactohacilliis in the gut (Carvalho-Wells et al. 2010;
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Costabile et al. 2008). SCFAs, or short-chain fatty acids, are the end products of the
fermentation process of non-digestible carbohydrates carried out by the anaerobic
intestinal microbiota. Diets rich in fibre from fruit and vegetables promote the
production of SCFAs, which are important for optimal host health. They maintain the
gut baiTier by lowering the luminal pH and also, in particular butyrate, provide a
source of energy (approximately 10% of the caloric requirements). SCFAs also play a
role in the regulation of lipid, glucose and fatty acid metabolism (den Besten et al.
2013), along with being anti-inflammatory and anti-carcinogenic (van der Beek et al.
2017).
As previously mentioned, a typical Western diet consists of high quantities of
animal based protein and low fibre. However, there has been an emergence of selective
diets, particularly in Western populations, where individuals strive to be more diet
conscious. One such emerging diet is the gluten free, which results in decreased
abundance oi'Bifidohacterium and Lactohacillus and increases of E.coli (hallmarks of
an unhealthy gut microbiota) even when undertaken for short periods of time (Sanz
2010). Studies of the Mediten anean diet, considered the most healthy, found increases
in faecal SCFAs and Firmicutes, in particular prevotella, while higher increases
correlated with diet strictness (De Filippis et al. 2015).
Diet can clearly be seen to have an impact on the gut microflora and therefore
dietary intervention must be considered. Long-term dietary habits have been strongly
associated with microbial composition (Claesson et al. 2012; G. D. Wu et al. 2011).
Studies in mice have shown that dietary changes can broadly alter the microbiota
profiles in the gut even in a single day (Faith et al. 2011; Tumbaugh et al. 2009). A
study by David et al., using a human cohort, compared dietary intervention using an
animal based diet (high in fat and protein) versus a plant based diet (high in fibre and
a decrease in protein). Here, over a 5 day period, the diet altered the microbiota profiles
of the participants in both abundance and microbial gene expression. Upon ceasing
the animal based diet, the original microbiota profile return thus providing evidence
of the fast adapting nature of the microbiota (David et al. 2014).
2.2.4 The effect of Antibiotics on the gut microbiota
Antibiotics have been the comer stone of combating infection for the past 70 years.
Statistics for 2010 show that 70 billion individual doses were prescribed worldwide
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and this appears to be continuing to rise (Van Boeckel et al. 2014). Antibiotics are
taken to fight infection and kill pathogens in the body, however, with the discovery of
beneficial bacteria for the host, there may be an undesired consequence. A study of 18
healthy volunteers taking cephalosporin for 7 days found that the original microbiota
profiles recovered after 90 days (Raymond et al. 2016), however a separate study of
74 healthy volunteers taking amoxicillin, clindamycin, ciprofloxacin or minocycline
took 4 to 12 months to reach recovery (Zaura et al. 2015). A further study showed that
antibiotics, clarithi'omycin and metronidazole can cause alterations for as long as 4
years post exposure as seen in analysis of faecal microbiota (Figure 1.8) (Jakobsson et
al. 2010). A review by Fen'er et al. aimed to compile all the research carried out on the
interaction between antibiotics and the microbiota encompassing 68 different
antibiotics and a number of antibiotic cocktails (Ferrer et al. 2017). This analysis found
different effects on the microbiota depending on the antibiotic prescribed and if they
were in combination with another, while the key genera effected by the antibiotics
were Bifidohacterium,

Bacteroidcs,

Faecalihcicterium and Escherichia coli.

Treatment with multiple antibiotics in combination has differing effects than when
taken singly. There were 32 microbial changes at the genus level when taking
gentamicin and ampicillin in combination. However, taken alone ampicillin altered 8
and gentamicin just 1. In this case the combination appears to increase the severity of
the effect and in turn alter in the microbiota to a higher degree. However, other
combinations do not behave this way as ciprofloxacin altered 27 genera, while
ciprofloxacin in combination with metronidazole altered just 7.
Of particular concern is the type of alteration - decreased diversity and a reduction
in abundance of bacteria considered beneficial. Faecalihacterium, which is depleted
during inflammation and has an important role in the immune system, was reduced as
a result 30 of the 68 antibiotics while Bifidobacterium, which controls inflammatory
response and boosts the immune system, was also reduced by 40.
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Figure 1.8; The long-term microbiota effects of exposure to antibiotics (Jakobsson et al. 2010).

Much evidence has been provided lo indicate that antibiotics have a profound
impact on the microbiota. This combined with an increase in antibiotic resistance
points to the requirement for alternative options or at the very least change. Along
with more stringent use, instead of using broad-spectmm antibiotics which cause
wide-spread, non-targeted effects, it may be necessary to use narrow-spectrum where
specific pathogens are targeted, therefore minimising the damage to the microbiota.
However, this strategy would require an improvement in diagnostic tests to isolate
the pathogen (Blaser 2016).
2.2.5 The Effect of Proton Pump Inhibitors on the gut microbiota
Proton Pump Inhibitors, PPIs, are among the top 10 most commonly prescribed
medications and are utilised to prevent gastric and duodenal ulcers (Olbe et al. 2003),
although it has been found that 70% of prescriptions may be unnecessary (Akram et
al. 2014). PPIs increase the gastric pH by preventing acid production by inhibition of
hydrogen-potassium pumps, which prevent hydrochloric acid release into the lumen
(Katelaris 1998). Although they can be used to prevent and reduce heart-bum and
gastric retlux, they have also been associated with an increased risk of enteric
infections with a meta-analysis uncovering a 65% increased risk of being infected by
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Clostridurn difficile (Janarthanan et al. 2012). PPIs have also shown increased risk of
Salmonella and Campylobacter infection when compared to H2-receptor antagonist
alternatives (Leonard et al. 2007).
Early studies with small sample sizes concluded with some contradictory findings
regarding the effect of PPI medications on diversity with reports of no effects
(Freedberg et al. 2015; Tsuda et al. 2015) and decreases in species richness (Seto et
al. 2014). Jackson and colleagues investigated the long term effects of PPI usage using
1,800 healthy elderly twins (Jackson et al. 2015). PPI medication was self-noted over
a 10 year period and with positive PPI status considered as any usage in that period.
The study found decreased diversity among the PPI positive cohort along with 22
OTU’s reduced (all from the phyla Firmicutes), and 32 increased (20 from
Bacteroidales, 7 from Streptocoeeus). A study by Imhann et al. investigated the current
usage of PPI medications opposed to long-temi of history of prescription in a cohort
consisting of 1815 adults (11.6% taking PPI medications) (Imhann et al. 2016).
Similar the Jackson et al., a decreased alpha diversity was observed in the PPI cohort,
while Streptocoeeus was also increased. Other taxa including the genera Rotliia and
Lactobacillus were also increased across the entire cohort, while the family
Enteroccooceae and the genera Veillonella and Entercoccus were increased in the
individuals taking PPI medications, a finding found previously (Freedberg et al. 2015).
The over-population of Streptococcus after the administration of PPIs in the gut has
been reported by several other studies (Freedberg et al. 2015; Rosen et al. 2015).
Although there has been no relationship between PPI dose and microbial diversity
decreases, there has been evidence of a PPI dose relationship with the over growth of
Streptococcus (Rosen et al. 2015).
2.2.6 Clostridium difficile infection
Clostridium difficile (C. diff) is a gram positive anaerobe and accounts for 12.1% of
all nosocomial infections in the USA, 500,000 infections in 2011 and 14,000 fatalities
each year. C. diff colonises and infects susceptible guts where toxins are produced and
spores released resulting in diarrhoea and pseudomembranous colitis. Potent
cytotoxins, termed A and B, lead to the glycosylation of rho and rad proteins causing
dismption of cellular cytoskeletons and the intercellular tight junctions to loosen
resulting in diarrhoea (Ananthakrishnan 2011). Along with immunosuppression and
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increased interaction with hospitals being a risk factor, infection is 20 fold higher in
individuals over 65 (Bartlett and Gerding 2008).
2.2.7 Associations between C. diff and PPI medications
A meta-analysis carried out by .lanarthanan et al containing almost 300,000 people
observed a 65% increase in the occurrence of an infection of Clostridium difficile when
taking PPI medications (Janarthanan et al. 2012). Combined with a reduced alpha
diversity. Table 1.4 shows the taxa associated with PPI medication usage and
associations to C. <iz/^infection (Imhann et al. 2016). From the table it can be seen that
reductions in the family Ruminococcaceae and the genus Bifidohacterium are
observed in PPI cohorts and also during a Clostridium difficile infection. Similarly,
reductions in Enterococcus, Lactobacillus and Veillonella also occur during C. diff
infection. It is possible that the changes in pH in the stomach due to the PPI medication
removes one forni of defence (the acidic environment) against C. c//// infection.
Taxa or miaobiotne aspect

Direction in PPI users that itKreases
the risk of C. difficile infection

ReferetKes of role on risk of C difficile infection

a diversity

Buffie et al'^ Nature. 2015
Chang et
Journal of Infectious Diseases. 2008
Antharam et at* Journal of Clinical Mkrobioiogy. 2013

k__Bacterid
p__Firmicutes
c__Clostridia
o__Clostrid idles
f__Ruminococcaceae

Reeves et at* Gut Microbes. 2011
Antharam e( at* Journal of Clinical Microbiology. 2013.
BufBe ef al.'^ Nature 2015 (Extended Figure 3d and 3e)
Schubert et at' Mbio. 2014.
Rea et at* Journal of Clinical Microbiology. 2011.

k__Bacteria
p__Actinobacteria
c__Actinobacteria
0__Bifidobacteriales
f__Bifidobactenaceae
g__Bifidobacterium

Buffie et a/'° Nature Reviews Immunology. 2013
Rea et at* Journal of Clinical Microbiology. 2011
Baines ef at° Journal of Antimicrobial Chemotherapy. 2013

k__Bacteria
p__Firmicutes
c__Bacilli
o__Lactobacillales
f__Enterococcaceae
g__Enterococcus

Antharam ef at* Journal of Clinical Microbioiogy. 2013
Schubert ef at' Mbio. 2014
Rea ef at* Journal of Clinical Microbiology. 2011 (Figure 4)
Buffie ef at* Nature. 2015 (Extended Figure 3d and 3e)
Baines ef at° Journal of Antimicrobial Chemotherapy. 2013

k__Bacteria
p__Firmicutes
c__Bacilli
0__Lactobacillales
f__Lactobacillaceae,
g_Lactobacillus,
s__delbrueckii,
s__ plantarum
and
s__reuteri

Reeves et al** Out Microbes. 2011
Antharam ef at* Journal of Clinical Microbiology. 2013
Rea et al ** Journal of Clinical Microbiology. 2012
Buffie ef a/'° Nature Reviews Immunology. 2013
Buffie ef al'* Nature. 2015

k__Bacteria
p__Firmicutes
c__Clostridia
o__Clostrid idles
f__Veillonellaceae
g__Veillonella

Antharam ef at* The Journal of Clinical Microbiology. 2013

k__Bacteria
p__Proteobacteria
c__Gammaproteobacteria
0__Enterobacteriales
f__Enterobacteriaceae
g__Escherichia
s__coli

Antharam ef at* Journal of Clinical Microbiology. 2013
Reeves ef at* Gut Microbes. 2011
Schubert ef a/^' Mbio. 2014
Peterfreund ef at* PLOS ONE. 2012

PPI. proton pump inhibitor.
k___ kingdom; p___ phylum; c__, class; o__, order; f__, family; g__, genus; s___ species
associations are in bold

Table 1.4: Taxa associated between PPI use and the risk of C. c/z/f infection (Imhann et al. 2016).
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2.2.8 Faecal Microbiota Transplantation
A treatment which has been shown to be highly successful for treating C. (i/// infection
is Faecal Microbiota Transplantation (FMT). The conventional therapy for C diff is
antibiotics, however, this is associated with very high rates of repeat infection with the
efficacy of antibiotics decreasing after each reoccurrence (Rao and Young 2015). A
FMT involves the infusion of a faecal suspension from a healthy donor into the
infected recipient in order to recolonise the microflora. A meta-analysis by Kassam et
al. found that 89.7% of cases result in clinical resolution, while there was no evidence
to suggest adverse effects from the treatment even after a follow-up years later
(Kassam et al. 2013). Analysis shows that post-FMT there is an increase in the
abundance of Fimiicutes and Bacteroidetes and a decrease in Proteobacteria (Seekatz
et al. 2014). A meta-analysis involving 18 studies conducted by Li and colleagues
investigated the reoccurrence rates of C c/zZ/'after FMT and found an overall cure rate
of 91.2% (Y. T. Li et al. 2016). The success of FMT for C r/z// infections has generated
much interest in this therapy for other disorder such as IBD but has proven to be less
effective with a remission rate of 45% (Colman and Rubin 2014).

2.3 Diseases and the gut microbiota
2.3.1 Cancer
Cancer rates vary depending on geographic location with the prevalence of CRC
(colorectal cancer) highest in the Western world suggesting an impact by
environmental factors (Sandler 1996). There are one million fold more microbes in
the colon than the small intestine and with 12-fold more cancers in the colon, it is
conceivable that the gut microbiota may have an influence (Proctor 2011). Studies of
patients with CRC have identified Streptococcus hovis, Helicobacter pylori,
Bacteroides fragilis. Enterococcus faccalis, Clostridium septicum, Fusohacterium
species and Escherichia coli as potentially influencing the disease (Gagniere et al.
2016). There are a number of methods that the aforementioned taxa could cause or aid
the progression of CRC. One such mechanism is via bacterial genotoxins. There are a
number of cases, for example Fusohacterium micleatum, H. pylori and B. fragilis,
where toxins have been associated with cancer. CagA and VacA are produced by H.
pylori and have been shown to increase inflammation and cancer rates (Fox and Wang
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2007; Ohnishi et al. 2008). It has also been reported that E. faecalis along with other
Enterococci species generate hydroxyl radicals which in turn cause DNA damage and
mutations. Conversely Bifidobacterium breve and Lactobacillus rhamnosus decrease
DNA methylation and histone acetylation events along with inhibiting the generation
of pro-inflammatory cytokines all of which contribute to CRC (Marteau et al. 2001).
2.3.2 Celiac Disease
Celiac disease is caused by an inappropriate immune response to gluten and although
genetics play a role, they are not the sole cause as only 75% of twins have concordance
with celiac disease (Greco et al. 2002). There have been a number of associations with
disturbances of the gut microbiota in early life. Recun-ent rotavirus infections (Pavone
et al. 2007), neonatal infections (Myleus et al. 2012) and birth by C-section (Marild et
al. 2012) have been associated with celiac disease, therefore providing evidence of a
potential role of the gut microbiota and environmental factors. Celiac Disease was
associated with increased abundances of Prcvotella, Eubacteriuni and Atopobium and
the species Clostridium histolitycum (Maria Carmen Collado et al. 2007), along with
Bacteroides, Clostridium Icptum (Maria Carmen Collado et al. 2008), Acinctobacter
and Neisseria (Wacklin et al. 2013), while Bifidobacterium was decreased among
those with celiac disease (Maria Cannen Collado et al. 2008).
2.3.3 Neurological disorders
Much of the cun'ent knowledge related to the association between the microbiota and
behaviour is related to animal studies due to practical and ethical restraints. While
germ free mice show reduced anxiety versus house mice (Heijtz et al. 2011), studies
involving probiotics have been contradictory and often no differences in behaviour
have been observed. However a study involving 45 days of treatment with B. infantis
in rats normalised stress and depressive like behaviour (Desbonnet et al. 2010).
Similarly administration of Lactobacillus rhamnosus for 10 days removed the effects
of the anxiety causing parasite Trichuris miiris (Bercik et al. 2011). In human trials,
probiotics have reduced anxiety and depression measures (Messaoudi et al. 2011)
along with sad mood triggered by psychological stimulus (Steenbergen et al. 2015).
A method by which the microbes interact with the brain may be through their ability
to produce and recognise neurochemicals. Genera such as Lactobacillus and
Bifidobacterium are able to produce active neuroendocrine honnones like dopamine
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and norepinephrine (Asano et al. 2012; Bravo et al. 2011). Research into this area is
relatively novel and some of the questions behind the mechanisms are slowly being
answered. However, there is a needed for more progression from animal trials to
human based studies.
2.3.4 Diabetes
Type 1 Diabetes (TID) is primarily caused by a genetic predisposition however not in
all cases as seen in family studies and the steady increase in recent years. Human
studies investigating associations between the gut microbiota and type 1 diabetes
found increased abundances of Bacteroidetes ovatus and Bacterodies informis.
Patients with TID had decreased Bacterodies fragilis,

butyrate producers

{Faecalhacterium and Rosehiiria) and mucin degraders (Prevotella and Akkennansia)
(Giongo et al. 2011).
Type 2 Diabetes (T2D) is generally associated with being overweight combined
with genetic factors. There is a wide body of research associating the gut microbiota
to T2D including a study by Qin et al examining 345 Chinese individuals where T2D
subjects had lower levels of R. intestinalis and F. prausitzii, while LMctohacilliis
gasseri and Streptococcus mu tans and Proteobacteria were increased (Qin et al. 2012;
Tilg and Moschen 2014). However, a study by Forslund and colleagues examined the
confounding effects of metfomiin treatment. It was found that microbial differences
were less evident when analysing metfonnin-naYve T2D patients, although butyrateproducing genera remained decreased in patients with T2D after controlling for
metformin status (Forslund et al. 2015).
2.3.5 Obesity
Obesity is now considered an epidemic with cases rising from 400 million in 2005 to
700 million in 2015 (Kelly et al. 2008). Germ free mice gain less weight than wildtypes (Ellekilde et al. 2014) and obesity is associated to changes in the ratio of
Finnicutes to Bacteroidetes, however this is not universally observed or specific.
Obese individuals have lower alpha diversity, higher rates of inflammation and
increased insulin resistance. The gut microbiota of obese individuals have been shown
to harbour more Parabacteroides Ruminococcus, Staphyloccus and Anaerostipes
when compared to lean, high diversity, individuals, while the latter contain higher
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abundances of Faecalibacterium, Bifidobacterium, Lactobacillus, Akkennansia and
Methanobrevibacter (Le Chatelier et al. 2013).
2.3.6 Conclusion
The gut microbiota has been associated to many diseases and as knowledge of the
microbiota increases along with the advances in sequencing technologies, it will be
possible to uncover more regarding this “forgotten” organ. The focal point of disease
related to the gut microbiota is Inflammatory Bowel Disease largely due to it being an
enteric disease of the gastrointestinal tract, with an unknown aetiology causing shifts
between disease relapse and remission.
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Section 3: Inflammatory Bowel Disease
3.1 Introduction
Inflammatory Bowel Disease (IBD) is a complex chronic inflammatory condition of
the Gastrointestinal (Gl) tract. Although Crohn’s Disease (CD) and Ulcerative Colitis
(UC) are the primary types of IBD there are some less common subtypes including
Microscopic colitis, Diversion colitis and Behcet’s disease. Crohn’s disease was
initially described in 1903 by Lesniowski and further characterised by Crohn in 1932,
while UC was first described by Sir Samuel Wilks 1859 (Mulder et al. 2014). Due to
their severity, complex aetiology, prevalence and lack of cure (without surgery in UC
cases), Crohn’s disease and Ulcerative colitis are the most widely known and
researched types of IBD. Although their symptoms are similar (diairhoea, abdominal
pain, fever, rectal bleeding/bloody stools and fatigue) the diseases are distinguishable
via endoscopy. Crohn’s disease can affect anywhere along the GI tract and occurs in
skip lesions, while ulcerative colitis is restricted to the colon and continuous. CD is
also transmural with fistulae, abscesses and strictures commonly found compared to
UC which affects the mucosa and submucosa. Abdominal cramps in CD are usually
located in the lower right quadrant or around the umbilicus. The pain presents in the
lower left quadrant of the abdomen in moderate to severe UC disease.
Ulcerative Colitis

Crohn's Disease
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Table 1.5: The history of IBD history (Mulder et al. 2014).
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3.2 Complications
The common symptoms of IBD are a burden on patient’s lives, however complications
associated wdth the disease also impact patient’s quality of life. Perfuse bleeding from
the ulcers in the GI tract occurs most commonly in UC, although this haemoiThaging
is also observed in 5-10% of CD cases in the stomach and duodenum. Inflammation
characteristic with IBD can lead to narrowing of the bowel and result in stricture and
obstruction. Strictures in CD are often caused solely by inflammation and can be
resolved through medication or surgery. Intra-abdominal abscesses are a risk in CD,
while fistulas and perianal disease are a hallmark. Surgical treatment is often required
for these fistulas and there is a high rate of reoccurrence. A further complication with
fistulas is connection to the urinary tract or vagina resulting in urinary tract infections
and inflammation of the area. Although very rare, toxic megacolon is life-threatening
and requires urgent medical attention. The condition is more common in UC than CD
and can occur in combination with bowel perforation. Studies have also shown an
increase in malignancy rates in patients with IBD (Table 1.6). Although rates are
higher in UC, there is also an increased risk in CD if the disease occupies a large area
of the colon (C. N. Bernstein et al. 2016). The risk factor increases with early IBD
onset, prolonged disease duration and a familial history of sporadic colorectal cancer.
Rates of malignancy in IBD are decreasing which may be attributed to more effective
medications against inflammation and more stringent surveillance (Castano- Mil la et
al. 2014).
Cancer type
Colorectal cancer*^'
Small bowel
adenix'arcinoma'^’
Intestinal lymphoma'’*'
Anal cancer'”''
Cholangiocarcinoma'^’'

Sundardized incidence ratio
5.7 (95%Ci: 4.6-7.0)
27.1 (95%CI: 14.9-19.2)
17,51 (95%CI: 6.4.5-58.11)
Data not available
916.63 (95%CI: 297.88-2140.99) in UC

Table 1.6: Increased cancer risk as a result of chronic intestinal inflammation (Axelrad et al. 2016).

3.3 Epidemiology
In the United States around 1.5 million people suffer from IBD along with an estimated
2.2 million Europeans (Molodecky et al. 2012). The highest incidence rates of both
CD and UC have been reported in North America and Northern Europe. However,
countries which are becoming more industrialised in recent years, such as China,
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South Korea, India and Thailand, are also experiencing increases. A meta-analysis by
Molodecky and co-authors investigated IBD incidence rate studies over time which
involved 167 studies from Europe (1930 - 2008), 52 from Asia and the Middle East
(1950 - 2008) and 27 from North America (1920 - 2004) (Figure 1.9). Three quarters
of CD studies and almost two thirds of UC studies observed increased rates over time.
The incidence of UC in Europe was as high as 24.3 per 100,000 and 19.2 per 100,000
in North America. These rates were much higher than that of Asia and the Middle East
with up to 6.3 per 100,000. Similar trends were uncovered when examining CD up to
12.7, 20.2 and 5.0 per 100,000 for Europe, North America and Asia/Middle East
respectively (Molodecky et al. 2012). The highest reported prevalence for UC was in
Noi*way, Europe with 505 per 100,000 (Bengtson et al. 2009) and 322 per 100,000 for
CD in Italy (Cottone et al. 2006), along with Canada with reported rates of 248 per
100,000 for UC and 319 per 100,000 for CD (Charles N Bernstein et al. 1999).
The number of cases in in Asia is less than that of the West, however Asia is under
going a substantial increase and cases are likely to match that of the West over time
(Thia et al. 2008). Cases of CD in Japan have risen from 2.9 per 100,000 in 1986 to
13.5 per 100,000 in 1998 (Yao et al. 2000), while in South Korea cases of UC have
quadrupled from 7.6 per 100,000 in 1997 to 30.9 per 100,000 in 2005 (S. K. Yang et
al. 2008).
There are notable differences within regions with higher incidence rates in Ireland,
Scotland and the Netherlands compared to the UK and Germany (Shivananda et al.
1996). National differences have also been reported in a number of countries including
Canada (Blanchard et al. 2001), Scotland (Armitage et al. 2001) and France (Nerich
et al. 2006). Emigration figures also offer insights to the aetiology behind IBD.
Individuals who left a developing country, lived in an industrialised country and
subsequently returned to the origin of birth, exhibited increased risks of developing
IBD (Barreiro-de Acosta et al. 2011). Studies conducted in both the UK and Sweden
observed an increase in IBD risk amongst the second generation of immigrants, while
the first generation maintained the risk values of the country they emigrated (X. Li et
al. 2011). Older age when immigrating also posed a decreased risk of being diagnosed
with IBD.
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Figure 1.9: Worldwide CD (left) and UC (right) incidence rates and/or prevalence for countries
reporting data (Top) before 1960, (Middle) from 1960 to 1979, and (Bottom) after 1980. Incidence
and prevalence values were ranked into quintiles representing low (dark and light blue) to
intermediate (green) to high (yellow and red) occurrence of disease. Figure adapted from (Molodecky
et al. 2012).

The Meta-analysis concluded that the diagnosis of IBD was not gender specific,
with male to female ratio varying between studies from 0.51 tol.58 for UC and 0.34
to 1.65 in CD (Molodecky et al. 2012). However, there was an apparent influence by
age on subjects. The majority of CD and UC cases showed a peak in diagnosis in the
second to fourth decade of life with 78% and 51.1% of studies reporting the largest
incidence in the category of 20 to 29 years old for CD and UC respectively
(Molodecky et al. 2012). There is also a notable ethical divergence with a three-fold
higher increase of IBD in Jews (Charles N Bernstein et al. 2006) and a lower
prevalence in African-American and Hispanic ethnicities (Reddy and Burakoff
2003).
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Thus a large body of epidemiology research has determined that there is a clear
geographical difference between rates of disease. However, it must be noted that a
portion of the increases may be due to increased awareness from physicians and the
public, along with better methods of diagnosis and more widely used colonoscopy,
particularly in developing countries.

3.4 Diagnosis
Abdominal pains and diaiThoea can be non-specific and therefore a number of other
criteria have to be met for physicians and gastroenterologists to diagnose and
differentiate inflammatory bowel diseases. After symptoms, general signs of illness
and malaise are examined, followed by the abdominal region for tenderness,
obstmction or any mass. The perianal region is also examined for tags, abscesses,
fistulas or fissures. Laboratory tests on stool samples are important to exclude any
possible viral or bacterial infections, in particular Clostridium difficile, causing the
symptoms like dianhoea. Blood tests are also required to assess for malabsorption,
confimi inflammation and exclude celiac disease (C. N. Bernstein et al. 2016).
When initial tests have not lead to an alternative diagnosis and there is a suspected
case of IBD, it may be necessary to can'y out an endoscopy for imaging and potentially
take a biopsy for examination. Sigmoidoscopy and colonoscopy are utilised for the
investigation of ulcers, bleeding and inflammation. Diagnosis is finally confinned
through endoscopy even though the symptoms along with faecal calprotectin, a
biomarker for intestinal inflammation, can indicate a probable case of IBD.
3.4.1 Faecal Calprotectin
Diagnosis via endoscopy is an invasive procedure, and although necessary to confimi
IBD, there is a requirement for non-invasive tests to mle out like disorders like Irritable
Bowel Syndrome (IBS), which does not present with inflamed mucosa. Existing noninvasive methods include blood samples for full blood counts to rule out anaemia,
markers for inflammation such as erythrocyte sedimentation rate (ESR) and C reactive protein (CRP), while tests for transglutaminase antibodies may also be carried
out to investigate for coeliac disease. Faecal Calprotectin (FCal) was first described
by Fagerhol et al. in 1980 (Fagerhol et al. 1980) and is now available in the form of a
validated ELISA assay (Ton et al. 2000). Calprotectin is a 36kDa protein belonging to
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the S-100 family of zinc-binding proteins and functions in calcium binding.
Calprotectin is found predominantly in neutrophils, macrophages and monocytes and
is regulatory in important inflammatory, antibacterial and anti-proliferative activities
(Johne et al. 1997). During active intestinal inflammation, neutrophils move towards
the intestinal mucosa. Figure 1.10 describes the process by which disturbance of the
mucosa due to the inflammation will lead to a leakage of neutrophils into the lumen
and subsequently e.xcreted in faeces (Ikhtaire et al. 2016).

Feces
Calprotectin

Gut lunoen
Mucus
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I
j

InBamed
Gut
Epithelium

Transepithelial migration

Neutrophil
Monocyte

Blood
vessel

Figure 1.10: Representation of the release of calprotectin into faeces. During inflammation,
neutrophils and monocytes undergo trans-epithelial migration of across inflamed gut mucosa. After
cell disruption, calprotectin is released (Ikhtaire et al. 2016).

Meta-analysis conducted by Von Roon et al. consisting of 30 studies and 5,983
patients, found that FCal was significantly higher in IBD patients than controls (Von
Roon et al. 2007). FCal is also carried out to assess disease activity in IBD patients.
For patients with CD, FCal correlates well with an endoscopic score for activity
(r=0.75) (Schoepfer et al. 2010), while for UC the correlation coefficient was 0.83
(Schoepfer et al. 2009). The aim of IBD treatment is to both reduce the symptoms of
the disease and to also allow for mucosal healing. Assessment of treatment is
traditionally canied out using clinical indices and scores, however these are subjective
and don’t measure the healing of tissue. A study of patients with CD found that FCal
could identify mucosal healing with 94% sensitivity and 62% specificity (D'haens et
al. 2012). Calprotectin is found homogeneously in faeces and is stable for up to 7 days
at room temperature (Roseth et al. 1992). After 7 days the concentration begins to
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decline with a mean decrease of 28% (Lasson et al. 2014). FCal is also advantageous
as it is simple, cost effective and it is not affected by any dietary substances although
alcohol may cause some elevation (Foster et al. 1995).
The use of FCal is clearly of benefit to clinicians, however there remains a number
of limitations. Although non-invasive, some patients are unwilling to provide faecal
samples. There is also a degree of inter-individual variation with one study reporting
16% of patients with CD in remission experiencing significant variability across 3
samples (Naismith et al. 2013). CuiTently, there is no standard cut of value for IBD
diagnosis or differentiating between relapse/remission using FCal. However, Nancey
and colleagues found an accuracy of 88% and 74% in detecting disease activity in UC
and CD respectively when a cut off of 250 ug/g was applied (Nancey et al. 2013).
Elevated levels of FCal are not specific to IBD and also occur in celiac disease, cystic
fibrosis and liver cirrhosis to list just a few, while FCal also cannot differentiate
between CD and UC. A full list of conditions and causing leading to abnonnal FCal
levels are listed below in Table 1.7.
Non-IBD causes of abnormal fecal markers
Infections

{most studies in calprotectin)
Bacterial enteritis
Viral gastroenteritis
Helicobacter pylon gastritis
Giardia lamblia
Diverticulitis

Malignancies

Colorectal cancer
Gastric carcinoma
intestinal lymphoma

Drugs

Nonsteroidal anti-inflammatory drugs
Proton pump inhibitors

Other gastrointestinal diseases

Gastroesophageal reflux disease
Cystic fibrosis
Celiac disease (untreated)
Diverticular disease
Protein-losing enteropathy
Colorectal adenoma
Juvenile polyposis
Autoimmune enteropathy
Microscopic colitis
Liver cirrhosis
Food allergy (untreated)
Nonspecific abdominal pain (in children)
Young age (- 5 years)
Older age
Obesity
Immunodeficiency (in children)

Table 1.7: A list of non-IBD causes of abnormal FCal levels (Abraham and Kane 2012)

A number of alternative markers for inflammation have been suggested including
Lactoferrin, a neutrophil-derived iron-binding protein (Abraham and Kane 2012),
where sensitivity and specificity for IBD has been found to be 0.82 and 0.79
respectively. However, its use in the clinical setting is limited due to its short stability
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at room temperature (Mosli et al. 2015). S10()A12, a pro-inflammatory calcium
binding protein, and Faecal Immunochemical test are both highly sensitive and
emerging possibilities for inflammation in IBD, however research is currently lacking
(Kaiser et al. 2007; Nakarai et al. 2013).
3.4.2 Clinical Indices of IBD
Faecal calprotectin is a useful measure for disease severity, and while endoscopy is
the gold standard, both of these procedures are time consuming, invasive and costly.
As a result, a number of questionnaires or indices have been developed with patient’s
opinion of their own symptoms and daily habits.
3.4.2.1 Crohn’s Disease
In 2005, the Montreal classification was devised as an improvement on the earlier
Vienna classification (Satsangi et al. 2006), which divided diseases based on age of
diagnosis, disease location and disease behaviour. However, several weaknesses,
particularly with age of diagnosis, were identified in the Montreal classification when
perfonning on paediatric patients and therefore the Paris classification was devised.
This is largely based on the Montreal classification but with more detailed age
categories, locations, and an additional section for growth retardation.
Vienna
Age of
diagnosis

A,, below 40 years
A„ above 40 years

Location

L, ileal
L., colonic
L,, ileocolonic
U, upper Gl tract

Behavior

B, non-striauring, non penetrating
B.;, stricturing
Bj, penetrating

Montreal

Paris

A„ below 17 years
A,,, between 0 and 10 years
between 17 and 40 years A,^ between 10 and 17 years
Aj, above 40 years
Aj, between 17 and40 years
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Aj, above 40 years_ _ _ _ _ _ _ _ _ _
_______
L,, ileal
L,. disease in 1/3 of dKtal ileum
Lj, colonic
L;, colonic
L}, ileocolonic
Lj, ileocolonic
U, separated upper Gl tract*
L,,. upper Gl tract disease proximal to ligament of Treitz’
Uo, upper Gl tract disease distal to ligament of Treitz'
B„ non-stricturing,
non-penetrating
B^, stricturing
Bj, penetrating
p perianal disease modifier

Growth
retardation

B, non-stricturing, non penetrating
B;, stricturing
B„ penetrating
B,B), penetrating and stricturing disease
p perianal disease modifier
Go, no growth retardation
G|, growth retardation observed

‘L4 modifier can be added K LI, 12. U if co exists with upper Q tract disease.

Table 1.8: Progression of clinical indices for Crohn's disease (Fabisiak et al. 2016).

Until the 1970’s there was no index in existence to measure the degree of
sickness/symptoms and disease activity for Crohn’s disease. The members of the
National Cooperative Crohn’s Disease Study devised the Crohn’s Disease Activity
Index (CDAl) (Best et al. 1976), which is based on eight clinical variables, three of
55

which require a 1 week patient diary. In the following years, the CDAI was invaluable
for measuring patient sickness and was the most widely used clinical index for CD
with over 1000 eitations. However, there were a number of drawbaeks, most notably
the need for a seven day patient diary making calculations cumbersome. To address
these issues, Harvey and Bradshaw altered the existing index and ereated the HarveyBradshaw Index (HBI), which does not require multiple daily reeords and excludes
body weight and haematocrit (Harvey and Bradshaw 1980). The HBI has largely
replaced the CDAI and has reeorded over 1750 citations. A study examining the
performance of HBI vs CDAI found a correlation coefficient of 0.93 (Vermeire et al.
2010). A HBI score of less than 5 is eonsidered remission, 5 to 7 is elassed as mildly
active, 8-16 as moderately active and greater than 16 as severely active disease.
Variable

Description
General well-being

Abdominal pain

Number of liquid
stools daily
Abdominal mass

Complications

Scoring
0
1
2
3
4
0
1

=
=
=
=
=
=
=

2 = moderate
3 = severe
1 per occurrence
0
1
2
3
1

= none
= dubious
= definite
= definite and tender
per item:
•
•
•
•
•

Total score

very well
slightly below par
poor
very poor
terrible
none
mild

Arthralgia
Uveitis
Erythema nodosum
Aphthous ulcer
Pyoderma gangrenosum

• Anal fissure
• New fistula
• Abscess
Sum of variable scores

Table 1.9: Harvey-Bradshaw Index for disease activity (Vermeire et al. 2010).

The paediatric version of the CDAI was also devised (PCDAI), to measure disease
activity in paediatric patients (Ryzko and Woynarowski 1995), with seores between
0 and 100 and a lower value indicating better prognosis.
3.4.2.2 Ulcerative Colitis
UC ean be classified into three subtypes as devised by the Montreal Working Party:
Uleerative Proetitis (distally to the rectosigmoid junction), left sided UC (distally to
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the splenic flexure) and Pancolitis, where the whole colon is involved (Satsangi et al.
2006).
The Truelove and Witts Severity Index was devised in 1955 for UC activity
(Truelove and Witts 1955) and contained 6 variables including patient symptoms and
laboratory results. The Powell-Tuck Index was first described in 1978 as a method of
comparing the effects of treatment for active UC. The score involved 10 clinical
variables, as outlined in Table 1.10, with a score of less than or equal to 3 indicating
remission, 3-10 mild activity, 11-14 moderate activity and greater than 14 being severe
activity. In the late 1980’s Schroeder and colleagues established the Disease Activity
Index or the Mayo score (1987) (Schroeder et al. 1987), while Sutherland et al devised
the Ulcerative Colitis Disease Activity Index (1987) (Sutherland et al. 1987) and
Rachmilewitz et al. created the Clinical Activity Index, or CAl (1989) (Rachmilewitz
1989). The CAl involves 7 parameters combined with the results of laboratory tests
and is now widely utilised to measure the effectiveness of medical intervention in UC.
A more simplified version, the Simple Clinical Colitis Activity Index (SCCAl) was
devised by Walmsley and co-authors in 1998 and was recommend for symptom
measurement in a review of clinical indices for UC (Walsh et al. 2016).
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Index
Va/aWe
Powel'Tuck
Numfati of slool]

< J/24 h = 0
3-6/?4h = 1
> 6/24 h = 2

Stool corBistency

normal = 0
semrlormed = 1
iquid - 1

Rachmilewit/
(CAI)

Lichtigef

Mayo

SCCAI

0-2/24 h = 0
3-4/24 h = 1
S-6/24 h - 2
7-9/24 h - 3
> 10/24 h = 4

l-3/24h-0
4-6/24h = 1
7-9/24 h-2
>9/24h = 3

Nocturnal (farrhoa

absent = 0
present = 1

1-3-1
4-6-2

< IS/weel - 0
I8-35/«*eeli = I
36-6a/«eek«
2
> 6CI/weelt = 3

ucss

normal - 0
1-2 mote than normal - I
3-4 more = 2
> 5 mote = 3

Similar 10 Mayo

none = 0
suealis of blocG m stool visible - 1
olwous blood m stool visibie = 2
blood passes alone - 3

Simiat 10 Mayo

very good - 0
fair • t

qeneialh good - 0
fail - 1

Sifflilat 10 Mayo

poot-2
very poor« 3
terrible-4

poof 2
teinble - 3

Urgency of

absent = 0

if hurry - 1

defecation

present - 1

if immedlalefy - 2

Nwdfcr
aniidiairlwal dnqs

no = 0

If mcoolinence - 3
VPS= 1

Blood in stool

no sign - 0
liace = 1
more than a trace = 2

none = 0
little-2
alal>4

none = 0
m < SOSofsiooh - I
in >S04b of stools = 2
in 100% of sloob - 3

Abdominal pain Of
ciampiog

no abdomindl pain 0
with bowel acboris •
1
more continuous = 2

none • 0
mild • 1
moderate - 2
seveie = 3

nooe = 0
rmld = 1
moderate = 2
severe = 3

traces = 1
occasiondlly » 2
usuatty * 3

Nausea or vomiting absent = 0
present - 1
Abdomitiai
tenderness

none = 0
mild ■ 1
marked = 2

none = 0
mM. kxatued - 1
m4d to moderate, diffused = 2

rebound « 3

severe or rebound - 3

Pymia

< 371 =0
371-38 • 1
>38-2

37-38 - 0
>38-3

txtra-Intestinal
manifestation

none = 0
mild on 1 site - 1
severe or mild on 2
sites - 2

if any of these

General conditian

no tfnpdirment = 0
impaved. able to

perfect - 0
very^ood ■ 1
good - 2
average - 3

continue activities - 1
acbvtfy reduced = 2
unable to work « 3
Physician's global
asanynent

Laboratory tests

if any of these
appears
arthritK pyoderma
gangrenosum.
erythema nodosum.
uveitis - 1 / each

appears, iritis.
erythema
nodosum.
antinlis» 3 /
each

poor - 4
teniWe - 5

from rKMmal to severe

good-0
average - 1
poot-2
vtfvpooi-3

0~3

fiomquiescem
to severe - 0-3

ESS > so in r
h- 1
ESK> lOOin 1"
h-2
Hemoglobinc
100g/l«4

erythncYrr itdimmtatiOt ratr

Table 1.10: A summary of the UC clinical Indices (Fabisiak et al. 2016).

3.5 Management and Treatment
After Crohn’s disease or Ulcerative Colitis diagnosis, therapy is often in the form of a
combination of medications, many of which may have complications and side effects.
Although there is no cure for IBD without surgery, treatment methods must aim to
improve a patient’s general well-being, reduce the number of relapse occurrences,
eliminate symptoms and prevent complications and the need for surgery.
3.5.1 Medications and Supplementation
Aminosalicylates, including 5-aminosalicylate acids and mesalazine, are anti
inflammatory agents used for treating patients in relapse and maintaining stages of
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remission. Corticosteroids are also anti-inflammatory agents and provide patients with
rapid symptom relief, however are associated with a number of side effects including
muscle pain and fever. There are three forms of administration: intravenous, oral and
rectal depending on the disease location and severity. Corticosteroids are useful for
inducing a period of remission but not maintaining an inactive disease state, while
thiopurines are used once remission is reached. Thiopurines can cause stomach pain,
headaches and fever. Anti-tumour necrosis factor (Anti-TNF) agents, or Biologies,
have a role in inducing and maintaining a state of remission. Treatment with anti-TNF
agent Infliximab is supplied intravenously as its effects last for approximately 8 weeks,
while Adalimumab is administered subcutaneously every 2 weeks. Infliximab has
been shown to treat fistulas and also reduce hospitalisation and surgery rates (Costa et
al. 2013), although, along with the other anti-TNF agents, it does lead to a slight
increased rate of malignancy amongst users (Zhang et al. 2013), along with increased
susceptibility to opportunistic infections (Ford and Peyrin-Biroulet 2013). Antibiotics,
like Metronidazole and Ciprofloxacin, are commonly used to treat CD complications
such as bacteria overgrowth in the strictures.
3.5.2 Surgery
Surgical inteiwention is more common in CD (70-75% of patients) than UC (25-30%
of patients). While surgery results in long term remission in some patients with CD, it
is rarely a cure in CD, as symptoms frequently return, but acts as an intervention when
medications fail or to relieve some complications. As CD can occur anywhere along
the GI tract, complete removal is not an option, however surgeries for CD include
drainage of abscesses, segmental resection and Ileocolic resection, while total
proctocolectomy and ileal pouch anal anastomosis can be undertaken for patients for
UC. As UC is limited to the colon, surgery can offer a theoretical '‘cure'’, however
early and late complications from surgery occurs for one third of patients (PeyrinBiroulet et al. 2016), while follow-up studies show that 81% of people experienced
major mal-effects such as depression, body image and sexual function issues (Brown
et al. 2015). Surgery is avoided where possible and medications are the first point of
treatment, however in cases with severe disease or when medications continually fail,
surgery may be a necessary step.
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3.6 Risk Factors of IBD
Intlammatory Bowel Disease is a complex autoimmune condition with no clear
aetiology yet established, although there have been a number of associations with
environmental and genetic factors reported, summarised in Figure 1.11.
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Figure 1.11: Potential influences on IBD development and progression (Ananthakrishnan 2015).

3.6.1 Genetics
A risk factor for developing IBD is genetic influence as confiiTned in familial and twin
studies. Between 2 and 14% of patients with CD report a family history of the same
condition, while 8 and 14% of patients with UC reported a family history of IBD (Ek
et al. 2014; Gordon et al. 2015; Halme et al. 2006). When an individual has a first
degree relative with CD there is a 5% risk of CD, while the corresponding risk of UC
with a first-degree relative is 5.2%. In cases where both parents have IBD, the risk of
developing IBD before age 30 is reported to be as high as 33%. Further evidence of
genetic associations have been reported in twin studies with monozygotic and
dizygotic twin concordance rates at 20 to 50% and 10% respectively. Ulcerative colitis
twin concordance rates are lower with 16% and 4% of monozygotic and dizygotic
twins (Ananthakrishnan 2015).
60

Genome Wide Association Studies (GWAS) investigate statistically significant
differences, based on a cohort of diseased compared control individuals, in alleles or
genotype frequencies across SNPs in the genome. In 2012, meta-analysis using
GWAS and Immunochip, a custom made chip with a dense map of markers, identified
163 loci associated with IBD, of which 140 were for CD. Interestingly, only 9 of the
140 CD loci were variants of coding regions of genes. This highlights the role of the
noncoding variation in disease risk. A further 39 loci were identified by Liu et al
(2015) (J. Z. Liu et al. 2015b), with in total 137 loci were associated with both CD and
UC, 37 were specific to CD and 27 to UC. Since then, there have been a further novel
loci added from various studies (Ellinghaus et al. 2016; Huang et al. 2017) resulting
in a large increase over the last 10 years (Figure 1.12).
Many of the genes identified are related to the innate immune system and processes
such as antimicrobial activity, maintenance of the epithelial barrier and injui*y repair.
There appears to be some population specific findings with regard to IBD risk loci.
The NOD2 variant is a risk factor found in Europeans and to a less extent African
Americans (Adeyanju et al. 2012; M. H. Wang et al. 2012; Weersma et al. 2009), while
there are no associations between NOD2 variants and CD in East Asian studies (Inoue
et al. 2002; Mahurkar et al. 2011). This provides evidence that certain risk loci are
more prevalent to some populations. Furthennore, despite the lack of association with
ATG16L1, there are links with ATG16L2 in Korean and Japanese CD GWAS studies
(Yamazaki et al. 2013; S.-K. Yang et al. 2013).
The contribution and influence of genetics on the prognosis of IBD is less
understood. Early studies investigating the same variants that lead to susceptibility of
IBD but largely failed to find any significance (Weersma et al. 2009). The NOD2 gene
variant was initially associated with increased surgery requirement in CD, however
this was later attributed to the prognosis of ileal disease (Cleynen et al. 2016; Jung et
al. 2012). A study by Lee et al., perfoiTned within-case GWAS to identify possible loci
causing differential prognosis (Lee et al. 2017). Using patients with extreme
differences in prognosis, four loci passed genome wide significance: FOX03, XACT,
a region upstream IGFBPl and the major histocompatibility (MHC) region.
Additionally, the 170 known loci for suitability were not associated with disease
prognosis.
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Figure 1.12: The number of disease loci identified for IBD by year (1996 - 2016) (Mirkov et al.
2017).

3.6.1.1 Nucleotide-binding oligomerization domain-containing protein 2 (NOD2)
NOD2 (IBDl) along with HLA-regions (IBD3) and IBD5 are the most replicated risk
loci in GWAS and Immunochip studies (Van Limbergen et al. 2014). Homozygosity
of the NOD2 locus increases the risk of CD 20-40 fold, while heterozygosity has a
more modest 2 to 4 fold increase of risk (Naser et al. 2012). The NOD2 gene is located
on chromosome 16 and encodes an innate intracellular pattern recognition receptor
which functions to recognise both microbial and viral components (Girardin et al.
2003; Sabbah et al. 2009). Peptidoglycan is found on the cell walls of gram-negative
and positive bacteria is broken down into MDP (Muramyl dipeptide), which is bound
to ATP by NOD2 in the recognition process. The 3 major variants of NOD2 are
described in Figure 1.13 (Van Limbergen et al. 2014): Gly908Arg, JWl and
1007(SNP13). NOD2 is key in the optimal functioning of the gut mucosal barrier and
the variants lead to loss of function as shown in HEK293 cells with the lOOTframeshift
NOD2 variant. Risk alleles found in RIPK2, RELA, LEI, VIM and ATG16L1 encode
for proteins which interact with NOD2 (Van Limbergen et al. 2014).

Figure 1.13; The position of the most established variants in CD - SNP13, JWl and Gly908Arg (Van
Limbergen et al. 2014).
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Despite the number of loci and genes associated to IBD, they are not the sole cause,
as observed in twin studies, and the risk loci only account for less than 25% (Loddo
and Romano 2015) of the disease cases indicating the strong influence from the
environment.
3.6.2 Oral Contraceptive Pill
Since a study in 1995 associating oral contraceptive pills (OCP) to CD (Godet et al.
1995), there has been much scepticism about the strength of the association. However,
a meta-analysis 13 years later found positive coiTelations between OCPs and both CD
and UC (Cornish et al. 2008). This study also presented evidence that OCP duration
increased the risks with CD and tennination of the medication reversed the effects.
The correlations established are modest and the mechanism of action is unknown,
although it is possibly due to the levels of oestrogen acting as an immune enhancer
resulting in proliferation of macrophages.
3.6.3 Antibiotics
There is evidence that exposure to antibiotics in the first year of life increases the risk
of developing IBD along with a dose-response relationship, however these
associations are not unifonnly found. A study by Shaw et al. found that 58% of
paediatric patients with IBD received antibiotics in early life versus 39% of controls
(S. Y. Shaw et al. 2010), while a further Danish study found the same trends albeit
higher risks for CD compared to UC (Hviid et al. 2010). A more recent investigation
reported an association between patients with IBD and antibiotic use 2-5 years before
diagnosis (S. Y. Shaw et al. 2010), while a UK study observed a dose-response
relationship with regard to antibiotics in childhood and IBD risk (Kronman et al.
2012). Results are not always in agreement as a large population based analysis in
Asia found a protective effect against IBD with antibiotic exposure (Lok et al. 2008).
3.6.4 Appendectomy
Meta-analysis found increased risk in developing CD with the highest risk 1 year after
appendectomy, while the risk reached baseline levels 5 years post-surgery (Kaplan et
al. 2008). However, it must be noted that a proportion of appendectomies may have
be due to undiagnosed CD. Increased risk of CD after appendectomy has been reported
in several other studies (Andersson et al. 2003; Frisch and Gridley 2002) but
interestingly a decreased risk of UC (Koutroubakis and Vlachonikolis 2000). The
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increased risk in CD was also higher in women compared to men and for those with
perforated appendieitis versus non-perforated as found in a cohort of over 200,000
people (Andersson et al. 2003). Like many risk factors for IBD there is not a eonsensus
with some studies reporting an inverse association with CD (Radford-Smith et al.
2002) or the laek there of (Molodecky and Kaplan 2010). The mechanism of action is
again unclear but it is possible that the appendix is a reservoir for bacteria which
regulate the immune response to the microbiota, however this does not explain the
differing assoeiations of appendectomy with CD and UC.
3.6.5 Breast Milk
The benefits of breastfeeding have previously been discussed (Section 2.2.1) and there
may be a further benefit in the protective role against IBD (Geairy et al. 2010).
Although studies have failed to find an assoeiation (Koletzko et al. 1991), a meta
analysis concluded a protective role against both CD and UC (Klement et al. 2004),
while there was no association with frequency of milk ingestion as a child (Charles N
Bernstein et al. 2006). A recent meta-analysis of over 14 thousand IBD patients also
found that being breastfed reduced the risk of both CD and UC. The duration of
breastfeeding also exhibited a dose-dependent association (L. Xu et al. 2017). Breast
milk contains lactoferrin which is absent from formula milk and possess anti
inflammatory properties along with antibacterial and antiviral effeets (Brock 2002).
3.6.6 Smoking
There is a widely accepted theory that smoking has an impact on IBD risk. The
relationship is paradoxical when examining the two diseases, CD and UC. Low
frequency of smoking amongst a cohort of patients with UC versus eontrols has been
observed (Harries et al. 1982), and was subsequently reported that smoking increases
the risk of developing CD twofold (Mahid et al. 2006). Interestingly, the risk of UC
increases to that of CD when smoking ceases for 5 years and remains elevated for 20
years (Ng et al. 2013), however the risk of CD does not remain increased with
termination of smoking (Odes et al. 2001). Smoking is assoeiated with a more
aggressive form of CD (Cosnes 2008) and a more frequent requirement of
immunosuppressant medications in women (Cosnes et al. 2004). Current smokers with
UC experienee a milder fonn of disease with fewer surgeries and less dependency on
immunosuppressant medieations (Ananthakrishnan 2015). A dose-relationship
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between smoking and IBD has also been described, although second hand smoke does
not affect the risk of IBD in children (Jones et al. 2008). The hypothesis behind the
paradoxical relationship with IBD diseases centres around the integrity of the gut
mucous barrier (McGilligan et al. 2007), while the nicotine may regulate T-cell
function (Razani-Boroujerdi et al. 2007). Smoking also causes alterations in the gut
microbiota by increasing Finnicutes at the expense of Proteobacteria and
Bacteroidetes (Biedennann et al. 2013).
3.6.7 Vaccinations, Infection and Living Conditions
There has been evidence of an association between the measles vaccination and IBD,
with vaccinated patients two to three times more likely to developed CD or UC
(Thompson et al. 1995), although further studies have been unable to repeat these
results (Feeney et al. 1997; Moms et al. 2000). An analysis by Gearry et al. found that
immunisation for mumps lead to a decreased risk of UC (Gearry et al. 2010), while
Bernstein et al. also found no associations between IBD and the bacilli CalmettteGuerin vaccination (Charles N Bernstein et al. 2006).
The risk of developing IBD was increased in subjects exposed to Salmonella or
Campylobacter infection versus controls (Gradel et al. 2009), while H. pylori was
found to be negatively associated with IBD in a meta-analysis involving 23 studies
(Luther et al. 2010).
There have been several other associations between environmental factors and IBD
which have yet to be reproduced and in many cases and lack a hypothesis in their
mechanism of action. Patients with CD are significantly more likely to live in smaller
houses, have fewer siblings (Charles N Bernstein et al. 2006) and live in the town/city
with a hot water tap and separate bedrooms opposed to rural areas (Charles N
Bernstein et al. 2006; Gearry et al. 2010). Lower birth rank increases the risk factor
for both CD and UC (Hampe et al. 2003), while in a large-scale study there was no
statistical difference in IBD risk between C-section and natural birth (Bruce et al.
2014). Patients with CD were less likely to have advanced education (Charles N
Bernstein et al. 2006), work in artificial conditions, have sedentary occupations
(Sonnenberg 1990) and also single in relationship status (Charles N Bernstein et al.
2006). Stress and depression have also been associated with both CD and UC (Gearry
et al. 2010).
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3.6.8 Diet
The previously mentioned geographical differences in IBD prevalence may in part be
due to dietary habits, particularly when examining the increase in disease incidence in
the Western world and amongst migrants. Associating diet to IBD and uncovering
particular associations is not very well establish largely due to the vast number of
factors, both food items and combinations, as well as host factors such as genetics.
Before examining macronutrients, observations of the diet as a whole reveal some
interesting trends. The rising rates of IBD in Europe and the USA (1940-1960) and
Asia (1990s) coincide w ith increases in processed and “fast food”, the latter of which
has been associated with both CD and UC (Persson et al. 1992), w'hile a study in the
Netherlands also found soda drinks and chocolate to be potential risk factors for IBD
(Russel et al. 1998). Differences between the North (high IBD incidence) and South
(low IBD incidence) of France may be attributed to diet as the South consume more
fruit, vegetables, olive oil and fish compared to the North, while the North eat more
butter, eggs, ham and potatoes (Nerich et al. 2006).
A meta-analysis highlights of 19 studies and 2,609 IBD patients (1,340 UC and
1,269 CD) highlights associations of diets with inflammatory bowel disease, however
results showed that not all observations are in agreement (Hou et al. 2011).
3.6.8.1 Crohn’s Disease
From on the Hou et al. research, there was a significant association with fat intake and
an increased risk of CD. Associations were found between high intake of
monounsaturated fat (MUFAs), polyunsaturated fat (PUFAs) and omega-6 fatty acid
intake and an increased risk of CD. There was a significant association between high
intake of monosaccharides and disaccharides and an increased CD risk. No significant
associations between high protein intake and a risk of CD were found. Fmit decreased
the risk of CD but no significant results were found with regard to vegetables (Hou et
al. 2011). Deficiency of vitamin D has also been observed in patients with newly
diagnosed CD (Mouli and Ananthakrishnan 2014), while those with low levels also
have an increased risk of hospitalisation and surgery (Ananthakrishnan et al. 2013).
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3.6.8.2 Ulcerative Colitis
The effects of diet on UC were also investigated by Hou and colleagues (Hou et al.
2011). Assessment of individual fats found that increased risk of UC was associated
with MUFA and PUFA intake. There were signifieant assoeiations between high
mono- and disaecharides and increased UC risk, along with protein and increased risk
of UC. No significant associations were found between fmit, vegetables, fibre and the
risk of developing UC. Both meat and seafood were associated with an increased risk
ofUC (Hou et al. 2011).
3.6.8.3 Conclusion on diet associations
The work by Hou and colleagues found evidenee of a protective effect against CD for
individuals with a higher consumption of dietary fibre and fruit, while foods high in
docosahexaenoic acid were found to be significant for decreasing the risk of UC.
Seafood was associated with an increased risk of developing UC, while fats (monoand polyunsaturated), carbohydrates (mono- and disaccharides), meat and protein
increased for both cases of IBD. The protective effect of dietary fibre may be down to
the soluble fibre being metabolised by intestinal bacteria to short ehain fatty acids,
which in turn inhibit transcription of pro-inflammatory mediators.

3.7 Microbiota
Since the advancement of Next Generation Sequeneing technologies making them
more available and affordable, there has been a sharp increase in mierobiota studies
with IBD on the forefront of disease investigations. Originally, research centred on
searching for a single causative bacteria, or group of bacteria that would satisfy Koch’s
postulates, however this was unfruitful. The success, albeit limited, of Faecal
Microbiota Transplants to induce remission in both CD and UC (Colman and Rubin
2014), along with the use of antibiotics for disease management point towards a
mierobial influence. Despite the aiTay of IBD mierobiota studies, there has often been
a lack of cohesion between findings. However, there is large eonsistency in results
regarding decreased alpha diversity amongst patients with IBD compared to controls
(Frank et al. 2007; Manichanh et al. 2006; Tong et al. 2013; B. P. Willing et al. 2010).
The taxonomy behind these differences, be it in presence/absence or abundance, is the
point where results beeome unclear. There are a number of potential contributing
67

factors for a lack of consistency including small sample size, sample types,
experimental proeedures, disease status (relapse/remission), variations in age and
genetics, and a lack of metadata collection for adjustment of eonfounding factors.
Medications, age, antibioties history and diet, as previously discussed, have a bearing
on the microbiota composition and this must be taken into account during the study
design or when comparing studies.
The MetaHit consortium sequenced

124 European adults using shotgun

metagenomics and found that patients with IBD had 25% less mierobial genes when
compared to healthy individuals (Qin et al. 2010). The stability of the IBD microbiota
is also much lower than that of an individual in health. Faeeal samples collected from
IBD patients over the course of a year shows that only one third of the dominant taxa
were continuously detected, compared to 80% stability in the healthy cohort (Martinez
et al. 2008). Lower stability is observed for patients with CD in relapse and remission,
while there is higher stability in CD remission compared to relapse (Scanlan et al.
2006).
3.7.1 Taxonomic alterations in IBD
There have been several findings supporting alternations in the gut microbiota of IBD
patients compared to controls. A comprehensive list for alterations in CD is found in
Table 1.11 (Wright et al. 2015), and Tables 1.12 and 1.13 for UC (Ohkusa and Koido
2015).
A decrease in the abundance of Finnieutes in the gut microbiota of patients with
IBD versus controls has been extensively reported (Frank et al. 2007; Gophna et al.
2006; Haberman et al. 2014; Manichanh et al. 2006; Sokol et al. 2008; Walker et al.
2011). Several studies have found Clostridium speeies C. coccoides (Manichanh et al.
2006; Takaishi et al. 2008) and C. leptiim (Kabeerdoss et al. 2013; Manichanh et al.
2006; Takaishi et al. 2008) decreased in IBD patients. Several other species, Rosehiiria
faecis (Juste et al. 2014), R. hominis and R. intestinali (Machiels et al. 2013),
Rumminococcus alhii, R. homii, R. callidus and Eiibacterium rectale (Kang et al.
2010), Dialister invisus (Joossens et al. 2011) are also deereased according to the
literature. Faecalihacterium prasnitzii is also consistently observed to be decreased in
patients with IBD compared to healthy eontrols (Gevers et al. 2014; Joossens et al.
2011; Maehiels et al. 2013; Sokol et al. 2008). However, despite there being a deerease
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in the overall phylum Firmicutes, the species Ruminococcus gnavus (Joossens et al.
2011; B. P. Willing et al. 2010) and R. ohiiem (Juste et al. 2014) are also increased in
CD, while, interestingly, these species were decreased in UC (Nishikawa et al. 2009).
Increases and decreases in the abundance Bacteroidetes is reported in patients with
IBD (A Andoh et al. 2009; Akira Andoh et al. 2011; Gophna et al. 2006; Kaakoush et
al. 2012; Walker et al. 2011). However, decreases in members of the Bacteroidetes
phylum, B. vulgatus, and B. unifonnis (Jansson et al. 2008; Noor et al. 2010) are
decreased in IBD. B. hiophilia (Gevers et al. 2014) has also been reported as decreased
in patients with CD, while B. ovatis (Noor et al. 2010; Takaishi et al. 2008) was found
to be less abundant in UC compared to controls. Although the commensal species B.
fragilis has been reported to be decreased in patients with IBD (Kang et al. 2010;
Takaishi et al. 2008), a subset termed enterotoxigenic B. fragilis (ETBF) are associated
with IBD in children and adults with 19.3% of patients in active IBD harbouring ETBF
(Prindiville et al. 2000). Furthermore, EFBF is associated with severe intlammation
and colitis in animal studies. Interleukin-17, a regulator of intlammation is also over
produced in these inoculated animals (Rabizadeh et al. 2007).
There has been a number of consistent reports of the phylum Proteobacteria
increased in IBD (Frank et al. 2007; Gophna et al. 2006; Walker et al. 2011) including
the class Gammaproteobacteria (Gan'ett el al. 2010) and family Enterobacteriaceae
(Gevers et al. 2014; Ijaz et al. 2017; Walker et al. 2011; B. P. Willing et al. 2010). E.
coli, is consistently found to be of higher abundance in the microbiota of patients with
IBD compared to healthy controls (Kang et al. 2010; Lopez-Siles et al. 2014;
Schwiertz et al. 2010; Thomazini et al. 2011; B. Willing et al. 2009)
Consistent results have been reported within the Actinobacteria phylum with
Bifidobacteria (Schwiertz et al. 2010; Takaishi et al. 2008; Venna et al. 2010), and in
particular the genera, B. adolescentis, BJongum, B. hifidum, and B. dentiim found
decreased in paediatric patients with CD (Gevers et al. 2014).
Fusobacteria have been found to be increased in patients with IBD compared to
controls, including the species F. micleatiim (Gevers et al. 2014; Strauss et al. 2011),
and F. varium increased in UC (Strauss et al. 2011).
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Population

N

Sample Type/Sile

Method

Taxa hnnehed in CD

Taxa Decreased in CD

Pediatric
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Tissue
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Prntet)hacteha, Seissenaceae.
Genietluceac,
Fusohactenaceae.
VeiUonellaceae.
Pasturellaceac.
E/Herohacienaceut

Firmiciites, Frysipelotrichaceae,
Lachnaspiraceae,
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Bi/iHlohadenaceue

Pediatric

447
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lllumina

I'eUlonella, Haemophilus,
Fscherichiu, Fusf>hacfenum

Dialister, BUophila, Sutterdla,
RikeneUaccae Bacteroides,
iMchnospiraceae,
Coprococcus, Ruminococcus,
Erysipelotrichaccae, Dorea.
Rumin(Ko<‘cuceoe.
Faet. ulihucterium,
Oscillospira

Adult

6

Feces

2I)-DIGF

Bot teroides vulf^atiLs,
Ruminococcus oheum

Rosehuria /aecLs,
Fact alibactenum prausnicii

Adult

160

Feces

T-RFI.P

Desulfovihno, Lawsonta

Faecalibacierium Copr<K(x:cus,
Rosehuria, Dorea

Adult

22

Feces

qK R

Adult
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Feces
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Adult
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Tissue

qKR

Adult

X

Tissue

T-RFI P

Adult
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Feces

ITGF,
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13

Tissue

Pyro

Faecalthacienutn
(Fuecalihaclerium
prausnifziu

Adult

121

Tissue
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(Esiht'richia/Shii’vlUi}

Adults

47

Feces

T-RFI P

Faecalihadenuin prausmtzu,
Clostridia cluster IF,
Rosehuria
Enterohat'tenaceae

Faecalihacleriu

Eschenchia colt

Fuecalilhiitenum prausnitzii

Finnicutes. Adinomyx etOi ear

Bacteroides
C. leptum, Faeculihactcnum
prausntcii

Rosehuria.
Phascolardohactenum.
Rummoi. tH cai cue
(Faccalihaderiiim)
Faecalihacttnum prausnitzii

Pediatnc

40 Tongue and buccal
mucosa brushmgs

PMA

SptnK haetes Svnetyt •nvtcs
Bach’rotdete.s

Fusohai teria, Firmirules

Pediatric

Id

Feces
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Biu leroideles Proteohadenu

Clostridia, Coprot oi cus.
Rosehuria, RiiminiH tM caceae.

Adult

H

Tissue (rectum)

Culture

Tissue

Gl

.Adult

Eschenchia colt
Entvrohuctenaceae.
RummoctK cus ^nadts

.Adult

31

Feces

T-RFLP

Baderotddcs

Ch>slidium

Adult

6

Tissue

C'l. qPC R

Baddoidde.s,
Enierohadenaceae

Fimin ute.i, Bacteroides vul^atus

Adult

6X

Teces

IXKil

RtomniH <KX U\ ^naxus

Ihahster invisu\. Clostndnim
cluster Ml'a.
Faecalihuderiuni fyramnirzii,
Bijidohactenum adole.scenhs

Adult

20

Feces

Pyro

RummiH iK'rtds y'nax'us.
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Adult
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qPGR

Fuhacicniini
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Rumtniuoccus. Iau tohactlius.
Bifidithai tenu ni,
HiiitiTiuddc^
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4t)
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qP( R

Esi henchiu colt

Ftiecalihui lerium prausnitzii.
Bifidohacientim

Adult

6

Feces

PMA, qlX R

Pedcatnc

22

T issue

Culture

Adult

14

Tissue

T-RFI.P. Cl, qP( R

Adult
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Feces

T-RFLP

Bucieroides, Enlerobai tenales

Clostridium cluster /I . XlVa
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2y
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iMdohacilhis Enterococcus
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T-RFLP
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Bucieroides wlgatus

Bacteroides uniformis

Adult
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Tissue

ARISTA, T-RFLP

Clastridiu

Bactenudetes

Adult

6

Ftxes

Adult

16

Feces

FISH. CT
IXiGF

Adult

1.3

Feces

FISH

Adult

20

Tissue

FISH. CT

BactiToideies Fcrrucomicrvhiu

Adult

6

Tissue

CT

Bucterotdetes, Proieohucteria

Adult

20

Tissue

FISH

Adult

26

Tissue

CT

Adult

17

Feces

TTGi;

EntertHXKCus \pp.. Closindtum Euhat icrium redale, Bacteroides
difficiU'. Es< herU hta coli,
fraf(ilis firoup, B culgatus.
Shif(ella fle.xneri. l.tstena sp
RumintHXHX us aihus. R
callidus, R. hromii.
Faes alihui lerium prausnitzii
StreptodK-cus Bifidohat teriu
Eu henchia colt

Faei alihiu tenum prausnitzii

Finnicutes (C. leptum)
Bacteroides
Clostridium leptum

Bacteroides fra^ihs,
Bucteroideie.s-Prox'etellu

F.uhacteria rectale
Bacteroidetes. Fuhacienum.
lAMiohacillus

Ententhuefena

CA>.v/ri<y/Mm Coenudes

Table 1.11: Microbial alterations in patients with CD compared to controls. (Adapted from (Wright
et al.2015)).
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Phylum

Class

Proteobacteria

Gamma proteobacteria
Gammaproteobacteria
Gammaproteobacteria
Gammaproteobacteria
Gammaproteobacteria
Gammaproteobacteria
Deltaproteobaaeria
Clostridia

Fimicutes

Bacteroidetes

Bacteroidetes

Fusobacteria

Fusobacteria

Aclinobacteria

Actinobacteria

Euryarchaeota

Methanobacteria

Family

Genus

Enterobacteiacea
Enterobacteiacea
Campylobaaeriacea
Campylobacteriacea
Campylobacteriacea
Desulfovibrionacea
Lachnospiracea
Eubaaeriacea
Clostridiacea
Clostridiacea
Enterococcacca
Bacteroidacea

Enterobacter
Escherichia
Campylobacter
Campylobacter
Campylobacter
Desulfovibrio
Ruminococcus
Eubacterium
Clostridium
Clostridium
Enterococcus
Bacteroides
Baaeroides
Fusobaaeiium
Fusobacterium
Fusobacterium
Bifidobacterium
Rhodococcus
Methanobevibacter

Fusobacteriaceae
Fusobactenaceae
Fusobacteriaceae
Bifidobacteriacea
Nocard laceaea
Met hanobacteriaceae

Species

Escherichia coli
Campylobacter concisus
Enterohepatic Helicobacter
(sulphate-reducing bacteria)

Type F Oostridium perfringem
Enterococcus fecalis
Bacteroides vulgatus
Fusobacterium varium
Fusobacterium nucleatum
Rhodococcus erythropolis
Methanobevibacter smithii

Table 1.12: A list of taxa increased in the microbiota of UC patients. (Adapted from (Ohkusa and
Koido 2015)).
Phylum

Class

Family

Genus

Species

Bacteroidetes

Bacteroidetes
Bacteroidetes

Bacteroidacea

Bacteroides
Bacteroides

Bacteroides fragillis

Firmicutcs

Closridia
Closridia

Lachnospiraceae
Lachnospiraceae

Ruminococcus
Ruminococcus
Rosebuna
Rose buna

Lachnospiraceae
Lachnospiraceae
Closridia

Clostridiacea

Clostridiacea
Closridia

Protetjbacteria

Gammaproteobacteria

Actinobacteria

Actinobacteria

Eubactenacea
Enterococcacea
Enterobacteiacea
Campylobacteriacea
Bifidobacteriacea

Laaobacillus
Clostridium
Clostridium
Clostridium
Faecalibacterium
Butyricicoccus
Eubacterium
Eubartenum
Enterococcus
Escherichia
Campylobacter
Bifidobacterium

Ruminococcus albus
Roseburia intestinalis
Roseburia hominis
Oostridium leptum (subcluster XlVab. cluster IV)
Oostridium butyncum
Clostridium coccoides
Faecalibaaenum prausmtzii
Butyricicoccus pullicaecorum
Eubacterium rectale

Enterohepatic Helicobacter

Table 1.13: A list of taxa decreased in the microbiota of UC patients. (Adapted from (Ohkusa and
Koido 2015)).

3.7.2 Relapse versus Remission
A systematic review by Prosberg and colleagues investigated differential taxonomic
abundance between patients with IBD in relapse and remission (Prosberg et al. 2016).
The analysis involved 18 studies in total which based activity on clinical indices and/or
endoscopic assessment. A lower abundance of Clostridium coccoides was observed
with patients in relapse for UC compared to remission but not CD, while Clostridum
leptum was decreased for relapse patients for both UC and CD. Interestingly, despite
the large number of studies noting differences in E.coli between IBD and controls,
there was no difference between activity states. The genus Bifidobacteria and the
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species Faecalihactehiim prasnitzii, decreased in IBD versus controls, was lower in
active disease compared to inactive.
3.7.3 Significance of differentially abundant taxa
As discussed, there is a plethora of taxa differentially abundant between IBD cohorts
and controls, however in some cases little is known about the implications of such
differences. Fusohacterium is a gram negative anaerobe and a common member of the
oral microbiota but is also found in the IBD microbiota at increased levels.
Fusohacterium species are also enriched in tumour tissue in colorectal cancer
(Castellarin et al. 2012; Kostic et al. 2012) and isolates directly promote tumorigenesis
in mouse models (Kostic et al. 2013; Rubinstein et al. 2013). Patients with IBD have
an increased risk of developing colorectal cancer and Fusohacterium may pose as a
potential link.
Bifidohacteriiim and Faecalihacterium genera are commonly found to be decreased
in IBD and therefore may possess protective effects against IBD. These taxa may have
an impact on several pathways including down regulation of inflammatory cytokines
(Llopis et al. 2009) and stimulation of IL-10 (Sokol et al. 2008). The importance of
Faecalihacterium in IBD is evident as lower abundance oi'F. praiisnitzii is associated
with higher requirement of surgery, while higher levels after relapse leads to longer
levels of clinical remission (Varela et al. 2013). Rosehuria (also decreased in IBD)
and Faecalihacterium also fenuent dietary fibre which results in Short-Chain Fatty
Acids (SCFAs) including acetate, propionate and butyrate. These SCFAs induce
colonic regulatory T cells and provide energy to colonic epithelial cells.
3.7.4 Oxygen Hypothesis
It is not yet known if differences in microbiota between IBD patients and healthy
controls, or patients in relapse versus remission, are due to the inflamed habitat or if
the alternative ecosystem drives the inflammation. One plausible hypothesis involves
the increase of oxygen to the environment due to the damaged epithelial cells and entry
of blood into the gastrointestinal tract. The additional oxygen levels in the gut allow
for the excess growth of facultative anaerobes or aerobes and thus a more competitive
environment. The oxygen in the gut would also be detrimental to obligate anaerobes
which are sensitive to oxygen, e.g. Faecalihacterium, which are notably decreased in
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both CD and UC (Rigottier-Gois 2013). Increases in oxygen would also lead to
increases in E.coli being a facultative anaerobe (Rigottier-Gois 2013).
Further evidence of mierobial alterations due to oxygen shift was based on
analysing patients undergoing a small bowel transplantation with ileostomy (Hartman
et al. 2009). The environment shifted from being rich in obligate anaerobes to
facultative anaerobes after transplantation, however this effect was reserved upon
closure of the ileostomy, a potential source of oxygen.
3.7.5 Virome and Mycobiome
Alterations in fungal communities are also present in patients with IBD. Lie et al.
found increased fungal diversity in inflamed mucosa compared to non-inflamed in
patients with CD (Q. Li et al. 2014b), while there is also an inerease in Candida
albicans at the expense of Saccharomyces cerevusuae (Q. Li et al. 2014b; Liguori et
al. 2015; Sokol et al. 2016).
Advancements in teehnology and methods have allowed for the analysis of virome
in IBD. The healthy virome, or more specifically the healthy phageome, is dominated
by the double-stranded

DNA Caudovirales and the single-stranded

DNA

Mieroviridae. Interesting the IBD virome has exhibited an increase in phage diversity
along with increases in the members of Caudovirales, although no changes have been
observed in the Micoviridae. Research in this field is relatively new and unexplored
and with methods and databases continually improving this area is sure to expand
(Norman et al. 2015).
3.7.6 Longitudinal studies
Longitudinal studies may be key to deciphering complex information regarding the
gut microbiota and Inflammatory Bowel Disease. Although studies were previously
limited, in recent years there has been an immergence of studies utilising longitudinal
sampling for microbiota studies (Bergstrom et al. 2014; Caporaso et al. 2011; Kostic
et al. 2015; Zhou et al. 2015). A study by Shaw et al. investigated the microbiota of
29 individuals, 15 of which were CD, 4 UC and 10 healthy controls (6 of which were
family members and 4 were unrelated) (K. A. Shaw et al. 2016). They focused on the
changes of mierobiota and inflammation status of patients with IBD based on exposure
to treatment rather than comparing patients while controlling for treatment. Both
patients with CD and UC showed improvements in alpha diversity and microbial
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dysbosis index when subjected to treatment. However, there was no difference in
dysbiosis index in patients with CD who responded well to treatment, evidence of
mucosal healing, and those who did not respond, thus indicating the index is not a
valid method for measuring response to treatment.
In an IBD study by Pascal and co-authors, 178 patients were recruited for
longitudinal sampling, consisting of 34 patients with CD, 33 with UC and 71 controls
(Pascal et al. 2017). Patients were required to provide faecal samples at 3 month
intervals for 1 year or in the event of relapse, which occurred in 38% and 15% of
patients with CD and UC respectively. Patients with CD differed from their healthy
relatives in ternis of microbial composition stability, with CD being more unstable.
Patient samples entering relapse were also compared to those who did not throughout
the year, however no significant differences were uncovered. The effectiveness of
Faecal Calprotectin (FCal) was also measured using the longitudinal dataset. FCal of
patients with IBD was higher than that of the controls throughout and the relapse was
significantly higher than the remission samples thus labelling FCal as a good indicator
of disease and disease activity. However, there were no differences between CD and
UC and therefore FCal cannot distinguish between diseases.
Halfvarson and colleagues assessed a longitudinal cohort of 137 individuals
collecting faecal samples at 3 month inteiwals (Halfvarson et al. 2017). There were 49
CD, 60 UC, 4 lymphocytic colitis, 15 collagenous colitis and 9 healthy controls
culminating in 683 samples in total. IBD subtypes fomied distinct clusters from
control samples using PCoA analysis with ileal CD most different from controls.
There were changes over time amongst the controls, however these samples were
limited to a specific region of the ordination space while the IBD samples variated
greatly and sporadically. Like Pascal et al, FCal was higher in all IBD subtypes
compared to healthy controls. Differences in the microbiota were also detected based
on medication status with oral corticosteroids leading to larger fluctuations and
therefore less stability based on PCoA analysis. When assessing the microbiota as a
predictive tool through random forest analysis, there was a 66.6% accuracy. Although
this study was the largest longitudinal study to date, the authors concede the small
sample sizes and a lack of metadata collection limited the number of statistical
comparisons that could be performed.
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3.7.7 Conclusion
Although differences between the microbiota of IBD patients and healthy controls
is observed in the literature, there are limited longitudinal IBD studies comparing
patients in relapse and remission. Longitudinal microbiota data together with the
eollection of metadata and other confounding influences on the microbiota, could help
to distinguish if alterations are a possible cause of disease state changes or are the
result of ehanges in the environment and therefore likely a consequenee.
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Abstract
Rapid advancements in sequencing technologies along with falling costs present
widespread opportunities for microbiome studies across a vast and diverse array of
environments. These impressive technological developments have been accompanied
by a considerable growth in the number of methodological variables, including
sampling, storage, DNA extraction, primer pairs, sequencing technology, chemistry
version, read length, insert size, and analysis pipelines, amongst others. This increase
in variability threatens to compromise both the reproducibility and the comparability
of studies conducted. Here we perfomi the first reported study comparing both
amplicon and shotgun sequencing for the three leading next-generation sequencing
technologies. These were applied to six human stool samples using Illumina HiSeq,
MiSeq and Ion PGM shotgun sequencing, as well as amplicon sequencing across two
variable 16S rRNA gene regions. Notably, we found that the factor responsible for the
greatest variance in microbiota composition was the chosen methodology rather than
the natural inter-individual variance, which is commonly one of the most significant
drivers in microbiome studies. Amplicon sequencing suffered from this to a large
extent, and this issue was particularly apparent when the 16S rRNA VI-V2 region
amplicons were sequenced with MiSeq. Somewhat suiprisingly, the choice of
taxonomic binning software for shotgun sequences proved to be of crucial importance
with even greater discriminatory power than sequencing technology and choice of
amplicon. Optimal N50 assembly values for the HiSeq was obtained for 10 million
reads per sample, whereas the applied MiSeq and PGM sequencing depths proved less
sufficient for shotgun sequencing of stool samples. The latter technologies, on the
other hand, provide a better basis for functional gene categorisation, possibly due to
their longer read lengths. Hence, in addition to highlighting methodological biases,
this study demonstrates the risks associated with comparing data generated using
different strategies. We also recommend that laboratories with particular interests in
certain microbes should optimise their protocols to accurately detect these taxa using
different techniques.
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1. Introduction
The use of Next Generation Sequencing (NGS) for the analysis of complex microbial
communities has increased dramatically in recent years. Reasons for this include a
continual decrease in cost and an ever greater appreciation of the ability of NGS to
more comprehensively characterise microbial communities than traditional culture
based methods. NGS has been advantageous in determining the role of the microbiome
in disorders like Inflammatory Bowel Disease (Gevers et al. 2014), diabetes (Zhou et
al. 2013), and obesity (Walters et al. 2014), or environmental communities like
wetland soils (Lv et al. 2014) and oceans (Sunagawa et al. 2015).
There are many methodological choices to be made when conducting a sequencebased microbiome study. These decisions have led to the introduction of a variety of
technical variables that affect the compositional signal to various degrees, potentially
limiting the ability to investigate the main hypothesis or to compare results relating to
communities that are similar but which have been investigated using different
methods. Factors such as sampling methods, DNA extraction protocol (Salonen et al.
2010), amplification, purification and quantification (Sinclair et al. 2015) along with
sequencing depth (Gihring et al. 2012) can significantly impact results. For instance,
using different purification and quantification methods can lead to a five-fold
difference in sequence counts while a one-step versus two-step PCR method can led
to significant differences in alpha and beta diversity between replicates (Sinclair et al.
2015).
The majority of microbiome studies have relied on 16S rRNA gene amplicon
sequencing. There are nine different variable regions within the prokaryotes
ubiquitous 16S rRNA gene (VI-V9), each flanked by highly conserved stretches of
DNA suitable for primer binding (Neefs et al. 1993). Depending on sequencing
technology and chemistry it is possible to sequence a number of adjacent variable 16S
rRNA gene regions. However, none of the currently available technologies offer fulllength gene sequencing at sufficient depth to allow for multiplexing larger numbers of
samples on the same run. Unfortunately no standard approach exists for selecting the
most appropriate primer pair suitable for all taxa and type of samples, and the decision
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is often made based on anecdotal evidence and/or advice from the published literature
(Claesson et al. 2010; Kozich et al. 2013; Sundquist et al. 2007).
One of the first considerations before embarking on a microbiota project is to select a
sequencing technology. Traditionally, the most common options are Roche 454 GSFLX, the Illumina iMiSeq (lower output, longer reads) and HiSeq (higher output,
shorter reads) and the Ion PGM, each offering a series of advantages and
disadvantages (see http://www.molecularecologist.com/next-gen-fieldguide-2014/ for
a guide). Both the Illumina and Ion instruments utilise a sequencing by synthesis
approach where Illumina use DNA templates immobilised on glass slides and optical
detection of tluorescently-labelled nucleotides, whereas templates for the Ion
Platforms are immobilised in wells on a semi-conductor chip followed by electrical
detection of released hydrogen ions. The Illumina and Ion technologies have been
compared for amplicon sequencing using various sampling environments, variable
regions of the 16S rRNA gene and analysis pipelines. In one case, when stringent
quality filtering and lower sequence similarity cut-off when clustering operational
taxonomic units (OTUs) were applied on V4 reads sequenced, negligible differences
in alpha and beta diversities were obseiwed within and between soil samples when
comparing the MiSeq and the PGM (Pylro et al. 2014). This concordance was further
supported when comparing MiSeq and PGM derived microbiota composition as
detennined by sequencing VI-V2 amplicons generated using a 20-species mock
community and human-derived samples (Salipante et al. 2014). In the latter case it
should be noted that, some significant differences were attributed to the PGM failing
to produce Iiill-length reads for certain organisms. Furthemiore, while not comparing
amplicon sequencing and using relatively early versions of sequencing chemistry on
an isolated E. coli species, Loman and colleagues found MiSeq to have lower eiTor
rates and longer reads than the PGM, which on the other hand had the fastest turn
around-time (Loman et al. 2012).
Comparative studies were also conducted to assess the initial potential of the MiSeq
to replace the Roche 454 GS-FLX, while also evaluating the effect of the variable
region studied. Kozieh and co-authors established a dual-index barcoding approach
suitable for variable MiSeq read lengths and amplicon regions, in particular V3-V4,
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V4 and V4-V5 regions (Kozich et al. 2013). In terms of read quality, MiSeq was either
comparable or better than the GS-FLX Titanium, and the V3-V4 better than the V4V5 region. Another study compared amplicon sequences of seven tandem variable
regions produced by the GS-FLX Titanium and Illumina GAII (predecessor of HiSeq)
and showed the V3-V4 and V4-V5 primer combinations performed worst and best in
terms of classification accuracy, irrespective of the technology used (Claesson et al.
2010). It is clear that the choice of primers can have a major effect on the outcome,
which was also further substantiated by Tremblay and co-authors, as the V6-V8 or
V7-V8 regions returned taxonomic composition from a synthetic community that
differed to higher degree than what the V4 region did (Tremblay et al. 2015).
With the ever increasing number of technological variables that have the potential
to have non-trivial effects on microbiota composition analysis, it is critically important
to maintain a consistent methodology within studies and when comparing studies, or
to have evidence that any inconsistencies that exist do not bias results. A more
expensive alternative to

16S rRNA gene amplicon sequencing is shotgun

metagenomic sequencing, which bypasses gene-specific amplification and potentially
sequences all fragmented DNA, including that from other microorganisms and vimses,
in a community. While providing much more infonnation, including encoded
functions of the microbiota, the vast amount of sequence data obtained however leads
to a new set of challenges in tenns of data processing, storage and analysis. For
instance, the Illumina HiSeq 2500 platfonn can yield over 1,000,000,000,000 bp (1
Tbp) of raw sequence data, which may increase several-fold during downstream
processing and analysis. Shotgun sequencing is also possible using both the Illumina
MiSeq and Ion PGM albeit with less throughput compared to HiSeq. Some nonmetagenomic studies have evaluated these platforms and demonstrated comparable
results when used to detect blood pathogens (Frey et al. 2014), diagnose dementia
(Beck et al. 2014), and detect gene variants across four microbial genomes (Quail et
al. 2012).
In the current study we investigated the impact of various amplicon primer
combinations and sequencing technologies on the analysis of complex microbial
communities. More specifically we compared amplicon and shotgun data generated
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by Illumina MiSeq, HiSeq and Ion PGM through the use of six human stool samples
using two primer sets covering two different 16S rRNA gene regions (VI-V2
(Tumbaugh et al. 2009) and V4-V5 (Caporaso et al. 2012)). We also assessed the depth
requirements for analysing stool shotgun datasets, and thus if the MiSeq and/or PGM
represent suitable alternatives to the HiSeq.

2. Materials and Methods
2.1 16S rRNA gene amplicon sequencing
Stool samples were collected from six elderly individuals and stored at -80°C during
the ELDERMET project (Claesson et al. 2012), approved by the Cork Clinical
Research Ethics Committee of the Cork Teaching Hospitals (CREC), which granted
full approval on the 19th February 2008 (Ref: ECM 3 (a) 01/04/08). Formal written
consent was obtained at the time of recruitment, on the basis of an Information
Sheet/Safety Statement, following an ethics protocol that was approved by CREC in
compliance with pertaining local, national and European ethics legislation and
guidelines to best practice. DNA was extracted from stool samples using previously
described methods (Yu and Morrison 2004), together with a modified Qiagen DNA
extraction procedure. Briefly, DNA was e.xtracted using a QIAamp DNA stool Kit
with the addition of an initial bead beating step. Microbial DNA from stool samples
was used as template for PCR, which contained 25pl Biomix Red (MyBio, Kilkenny,
Ireland), 1 pi forward primer (Sigma Aldrich. Dublin, Ireland) (lOpmol), 1 pi reverse
primer (Sigma Aldrich) (lOpmol), template DNA and PCR grade water (MyBio), to a
final reaction volume of 50pl. Conditions were optimised so that only 1 band of the
con'ect sizes was obtained and all PCR were completed in triplicate. Triplicate PCR
products were pooled and cleaned using AMPure magnetic bead purification system
(1:1.8 DNA:AMPure ratio) (Beckman Coulter, UK). Cleaned samples were quantified
using Picogreen Quant-iT quantification and the Nanodrop 3300 (Fisher Scientific,
Dublin, Ireland). Samples were subsequently pooled in an equimolar concentration of
lOpM and prepared for MiSeq sequencing using standard Illumina protocols. Libraries
were mixed with Illumina generated PhiX (20% of 12.5pM) control libraries and were
denatured using freshly prepared NaOH and sequenced using a V3 600-cycle kit. For
the PGM, libraries were pooled at a concentration of lOpM and sequenced according
to Ion PGM protocols.
106

2.2 Metagenomic shotgun sequencing
For Illumina MiSeq shotgun sequencing, samples were initially tagmented, whereby
the Nextera Transposome with sequencing adaptors combines to template DNA
resulting in fragmentation of the DNA and the addition of adaptors using the Nextera
XT kit from Illumina. A limited 12-cycle PCR was completed during which time
sequencing adaptors and indexing primers were added to the DNA. Amplicon samples
were then nonnalized and pooled, followed by sequencing on the MiSeq platform
using Illumina protocols for a 2 x 300 cycle run, with an insert size of 400 bases.
Shotgun libraries for Ion PGM were generated according to instructions from the
don Xpress™Plus gDNA Fragment Library Preparation' User guide (Publication
number MAN0007044). Libraries were sheared, size selected and individually
barcoded using the Ion Xpress Barcode Adapters. Following library quantification and
equimolar pooling, the Ion OneTouclf2 system was used to prepare template positive
ion sphere particles containing the clonally amplified DNA libraries using the ION
PGM'"’ Template OT2 400 Kit, allowing up to 400 bp single-end reads. Enrichment of
the template positive ISPs was perfonned using the Ion OneTouch'"' ES and an
enrichment percentage of 18% was obtained, which was within the range
recommended in the ION PGM'"’ Template OT2 400 Kit guide (Publication number
MAN0007218). Sequencing was perfonned on the Ion PGM using an Ion 318v2 chip
and the Ion PGM Sequencing 400 kit (guide number MAN0007242).
Shotgun Illumina HiSeq sequencing reads were obtained from the published
ELDERMET dataset (Claesson et al. 2012). The paired-end read lengths were 2 x 90
bp with an insert size of 300 bases. DNA was extracted from samples using the same
method as used above.

2.3 Bioinformatic analysis
MiSeq reads were merged and filtered using /om_paired_ends.py in QIIME version 1.8
using X\\Q fastq-join.py tool (Aronesty 2013), whereas the single-end PGM reads were
not.

Demultiplexing

of both

MiSeq

and

PGM

reads

was

carried

out

using splitJibraries.py also on QIIME (Caporaso et al. 2012) with default parameters
retaining only reads matching the main length distributed per primer and with an
average quality score of Q25 or above. The differences in quality filtering lengths is
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due to reverse primers being present in the MiSeq reads. Chimeric sequences were
removed via USEARCH version 7.0.1090 using the uchime_ref.py command along
with the ChimeraSlayer GOLD database (Edgar et al. 2011). OTUs were clustered
using the QIIME script pick_closed_reference_otLis.py and the RDP database version
11.4. The Mothur implementation of the RDP classifier was used to assign taxonomy
from phylum to genus (Schloss et al. 2009) with a bootstrap cut-off of 80%. Any
sequences with less than 80% bootstrap values were assigned as unclassified at that
particular rank. Species counts for amplicon data were generated using SPINGO with
default parameters (Allard et al. 2015).
All three shotgun datasets reads were aligned to the human genome version 20
(hg20) to filter out human-derived sequences using Bowtie2 version 2.2.3. Illumina
HiSeq and MiSeq reads were subsequently quality filtered and trimmed using
Trimmomatic version 0.32 (Bolger et al. 2014) and only allowing a quality PHRED
cut-off score of at least Q22 across a sliding window of 20 bp. Reads with a minimum
length of 30 bp were also removed. Only PGM reads with a quality score of greater
than 015 and longer than 30bp were retained for downstream analysis (Brozynska et
al. 2014).
All metagenome assemblies were performed using IDBA UD version 4.1.2 (Peng
et al. 2012) and MetaVelvet version 1.2.02 (Namiki et al. 2012). Phylogenetic binning
was achieved using MetaPhlAn version 2 (Segata et al. 2012), Kraken version 0.10.5beta (Wood and Salzberg 2014) and GOTTCHA version 0.7.5 (Freitas et al. 2015).
MetaPhlAn2 classifies sequences via clade-specific marker genes, Kraken uses exact
alignment of /:-mers and a lowest common ancestor approach, while GOTTCHA maps
reads to non-redundant signature databases to classify at multiple taxonomic levels.
Genes were predicted using MetaGeneMark version 3.26 (Zhu et al. 2010). Metaphor
was used to predict core and unique genes with thresholds set to 30% amino acid
identity across an alignment covering 50% of both sequence lengths (van der Veen et
al. 2014). The core and unique genes were then mapped against the EGGNOG
database version 4 using BLAST to create functional profiles for each of the samples
and datasets retrieving the top hit with an E-value of le-5.
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2.4 Statistics
All statistical analysis was performed in R version 3.1.3. In each of the heatplots,
Spearman coirelations, along with Ward D2 clustering, were perfomied on the relative
abundance at genus level of each sample. As the data was largely non-parametric,
Spearman eorrelations were chosen to prevent breaking the statistieal assumptions of
Pearson correlations. A Mann-Whitney test was used to analyse differences in the taxa
between clusters. Where necessary, the P-values were coiTected for multiple testing
using Benjamini and Hochberg (Benjamini et al. 2001). A P-value of <0.05 was
considered significant.

3. Results
3.1 Microbiota composition
The data generated reflected the different outputs of the three platforms. For the
amplicon datasets the PGM produced 57,720 (mean) ± 9,841 (SD) V1 -V2, and 33,454
± 10,488 V4-V5 reads per sample, respectively, while the MiSeq produced 181,758 ±
108,343 VI-V2, and 102,824 ± 22,154 V4-V5 reads per sample, respectively. For the
shotgun datasets there was also a marked difference between the three sequencing
technologies, with 26,590,475 ± 51,650 IliSeq. 1,352,748 ± 458,483 MiSeq and
962,226 ± 170,251 PGM reads were generated per sample, respectively.
We perfomied hierarehieal clustering analysis on the microbiota composition of all
six stool samples in order to assess the effect of the amplification primer combination
(where relevant), sequencing strategy (16S rRNA gene or shotgun), sequencing
technology and type along with metagenomie read classifier. Figure 2.1 shows a heatplot with hierarchical clustering of the proportional taxonomie abundances at the
genus level, with only genera in a minimum of 20% of the datasets included. All
shotgun datasets fell into one large cluster with three distinct sub-clusters, labelled 2,
3 and 4. It is worth highlighting that although the shotgun samples clustered together,
there were major discrepaneies between the taxonomie profiles (sub-clusters) dictated
by the metagenomie classifier used with one exception, sample 6 sequenced on the
PGM and classified by GOTTCHA, which clustered with the MetaPhlAn2 sample 6
datasets. In the MetaPhlAn2 cluster (cluster 4), the datasets grouped by sample in each
case, which is preferable as it suggests the technical variation is less than the inter109

individual variation. For all six samples, the HiSeq and MiSeq datasets clustered
together while the PGM sample was located to the side of the sub-cluster. For the
GOTTCHA classifier, datasets grouped by sequencer more than by sample. Here there
were no case where all three shotgun technologies clustered together by sample. For
the third shotgun classifier, Kraken (cluster 2), five of the six samples clustered by
sample with the exception of the MiSeq dataset for sample 2. Unlike MetaPhlAn2, the
PGM formed sample-wise sub-clusters with HiSeq or MiSeq, with the two Illumina
technologies not fomiing any sub-clusters. Out of a total of 163 genera, 23 were
statistically significant between cluster 3 (GOTTCHA) and 4 (MetaPhlAn2) in Fig
2.1 where the most significant genera included Ruminococciis (increased in cluster 3;
P-value = 9.88 x

Blaiitia (increased in cluster 3; P-value = 1.30 x 10“^^)

and Campylobacter (increased in cluster 3; P-value = 9.30 x 10“^^^). When comparing
Kraken, cluster 2, to the other two shotgun classifiers (cluster 3 and 4) there were 52
statistically

significant

different

genera.

These

included Buchneva, Cellulomonas and Cellvihrio, all increased in the Kraken dataset each
with an adjusted P-value of 1.82 x 10~‘'. Of the 15 most significantly different genera,
all but one were absent from the GOTTCHA and MetaPhlAn2 clusters, thereby
indicating possible false positives detected by Kraken. The three aforementioned taxa
are also not predominant colonisers of the human gut thus reinforcing the possibility
of inaccuracies in Kraken assignments.
For the amplicon datasets, sample-wise clustering was less prevalent than for the
metagenomic datasets. MiSeq V1V2 amplicons were contained in a distinctive sub
cluster, contained within the cluster labelled 1 in Fig 2.1, clearly separated from the
rest of the amplicon datasets. A second sub-cluster contained all the sample 3 and 6
amplicon datasets, with the exception of the V4V5 Miseq dataset and the
aforementioned VI-V2 MiSeq dataset. The third sub-cluster contained the majority of
the V4V5 MiSeq samples (4 of 6) along with two V4V5 PGM samples. In this case
the amplicons clustered by 16S rRNA gene primer combination, as opposed to by
sample or by technology. The final sub-cluster contained the majority of the V1V2
PGM datasets (4 of 6) along with 3 of the 4 sample 5 datasets (VIV2 MiSeq being the
missing dataset). Investigating the differences between cluster 1 (amplicon data) and
clusters 2^ (shotgun data), uncovered 91 genera to be statistically significant.
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therefore showing the large differences between amplicon and shotgun classification
methods of reads.
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As for bacterial taxa that were the most abundant across all of the datasets, there
were some families that differentiate the six subjects regardless of methodology used
(Figure 2.2): For example, Porphyromonadaceae genera were consistently high in
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Sample 6 datasets compared to the other samples, and so were genera belonging to
the Prevotellaceae family in Sample 3, irrespective of primer combination or
sequencing technology. For samples 1 and 5 the shotgun-based methods appeared
more sensitive with respect to detecting Enterohacteriaceae genera within
the Proteohacteria phylum compared to the amplicon-based approaches, which could
be attributed to the difficulty of discriminating such taxa at 16S rRNA gene level.

Composition - Family Level - Ordered by Phylum Abundance

S5^ ^ ^
■ Unclassified
■ Other
i Entefohacteriaceae
■

Sutterellaceae
Acidaminococcaceae
Eubacteriaceae

#

20S

I

Lachnospiroceae

I Rummococcaceae
i Prevotellaceae
i Rikenellaceae
I Porphyron)onadaceae
■ Bacteroidoceae

Sample 6

Fig 2.2. Bar-charts of taxonomic composition at family level. The families are first organised by
phylum abundance (highest to lowest) followed by family abundance (highest to lowest) in each of
the phyla. The numbers of observed species are located at the top of each bar.

Figure 2.2 also highlights the number of unique species in each dataset, as identified
by MetaPhlAn2 for shotgun data and SPINGO for amplicon data. Note that these were
species that could be confidently classified as such, and should not be mistaken as
number of unique OTUs. The highest numbers of unique species among all shotgun
methods were detected in the HiSeq datasets, comparable to those resulting from the
analysis of amplicons. The success of the HiSeq with respect to shotgun sequencing
is not surprising given the greater sequencing depth it can provide resulting in
detection of rarer species. The lowest number of unique species overall was detected
in the MiSeq shotgun datasets, which is not due to total number of reads as PGM had
fewer of these. For the amplicon datasets, the highest number of unique species was
detected with the PGM datasets for five of the six datasets. Although the species counts
for the pooled PGM amplicons was higher when compared to the MiSeq amplicons,
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the difference was not statistically significant (P-value = 0.24). However, when
comparing particular primer combinations, the difference in the V1 -V2 species counts
between the two technologies was significant at the 10% level (P-value = 0.093). We
further analysed the effect of varying sequencing depth on the number of unique
species detected for each amplicon mn (Figure 2.3). The highest numbers of species
were detected at each read depth by the VIV2 amplicon on the PGM, while the lowest
was the V1V2 on the lllumina MiSeq. All primer datasets reached saturation in the
number of new species detected, other than the V4V5 primer on the PGM which was
limited by the number of reads for some samples. However, despite this, more unique
species were detected with this primer/technology combination than both MiSeq
datasets, which had vastly more reads.
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Figure 2.3: Observed Species at various sequencing depths for the amplicon data using SPINGO.
The data points represent the median values across the 6 samples and the error bars are the 25% and
75% quart! le ranges.

3.3 Shotgun sequencing depth
To investigate which technology was most suitable for shotgun sequencing, we
perfonned random subsampling of reads to determine occuiTences at even sequencing
depths, in recognition of the fact that the HiSeq coverage was substantially higher than
the coverage for MiSeq and PGM. Figure 2.4 shows the median N50 values across
each of the six samples per technology, including three replicates (random sub113

samplings) for each sample (Figure 2.4). At the lowest sequencing depth selected
(150,000 reads) the assembly using the MiSeq data had the highest N50 (minimum
contig length above which 50% of all reads are assembled into), possibly due the
longer read lengths. However, as more reads were added, the HiSeq data began to
outperfonn the assembly from both the MiSeq and the PGM technologies. The MiSeq
and PGM datasets became limited by read number and their N50 value plateaued at
1.7 million and 950,000 reads, respectively. Due to the large number of HiSeq reads,
the N50 peaked at 10 million reads after a large increase at 1.7 million reads. Two of
the six HiSeq datasets (Samples 1 and 5) had a very large N50 at 600,000 reads. In
order to ensure that the results were not affected by the assembler selected, the datasets
were also assembled using both Velvet (Figure 2.5) and MetaVelvet (Figure 2.6).
Interestingly, the same two samples for the HiSeq datasets had an elevated N50 for
both Velvet and MetaVelvet, however at 1.3 million and 950,000 reads respectively.

Hiseq

— Mlseq

■PGM
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Number of Reads
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Figure 2.4: N50 values representing randomly subsampled reads at various sequencing depths after
assembly by IDBA_UD. Each point represents the median value across each of the 6 samples per
technology (including 3 replicates per sample). Error bars are the 25% and 75% quartile ranges.

114

Hiseq

Miseq
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Figure 2.5:N50 values representing randomly subsampled reads at various sequencing depths after
assembly by Velvet. Each point represents the median value across each of the 6 samples per
technology (including 3 replicates per sample). Error bars are the 25% and 75% quartile ranges.
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Figure 2.6: N50 values representing randomly subsampled reads at various sequencing depths after
assembly by MetaVelvet. Each point represents the median value across each of the 6 samples per
technology (including 3 replicates per sample). Error bars are the 25% and 75% quartile ranges.

115

Furthennore, unique species detection was also perfomied on the sub-sampled
shotgun sequencing-derived reads (Figure 2.7). At low sample depths the HiSeq,
MiSeq and PGM datasets were comparable with few differences in the number of
species detected. At 950,000 reads, the PGM data reached the read limit, but was still
similar to the other technologies in ternis of number of species. However, at 1.7 million
reads, the HiSeq species counts continued to increase while the MiSeq counts level
off. This could possibly be due to the fact that the longer MiSeq read lengths result in
more accurate species assignments relative to HiSeq, leading to earlier plateauing. In
the overall graph (Fig 2.7 insert) the HiSeq counts continued to increase without
levelling off completely even at the 25 million read point.

Hiseq

Miseq
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8,000,000

12 000 000 16,000,000 20,000,000 24,000,000
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1,000,000
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Figure 2.7: Number of species observed from randomly subsampled reads using MetaPhlAn2.
Each point represents the median value across each of the 6 samples per technology (including 3
replicates per sample). Error bars are the 25% and 75% quartile ranges.

3.4 Encoded functions
From within the categories of shotgun datasets, the core and unique genes were
predicted using Metaphor (Fig 2.8). This was carried out on 600,000 reads per dataset
in order to allow for comparative results at equal sequencing depth. For the core genes
all three technologies gave broadly the same results, however the HiSeq data had the
most poorly characterised genes out of the three datasets, along with the lowest
number of genes with a “Metabolism” function and the highest with no function.
Surprisingly, this technology did not predict any core genes for the categories, “Energy
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Production and Conversion” or 'inorganic Transport and Metabolism”, whereas both
of these categories were present in the core gene profiles of the MiSeq and PGM
datasets. The MiSeq datasets predicted the highest number of genes within the
"Metabolism” category, while the PGM data predicted the highest for “Information
Storage and Processing”, whilst also being the only technology to predict core genes
in the category “Cell Motility”. The number of genes predicted by MetaGeneMark are
listed in Fig 2.8. At a read depth of 600,000 sequences, the MiSeq datasets predicted
the most genes for each of the 6 samples while the HiSeq datasets gave the lowest
gene number of 5 of the 6 samples. This is a possible reason why this technology gives
the most detailed core and unique gene profile.
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Chromosome Partitioning

Transcripbon

Signal Transduction Mechanisms
Defense Mechanisms
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Figure 2.8: Core and unique genes acquired by Metaphor with 600,000 sequencing randomly selected
datasets for each of the samples. The numbers represent the total number of predicted complete or
incomplete genes for each metagenome.
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4. Discussion
The NGS technologies Illumina MiSeq, HiSeq and Ion PGM have shown significant
promise in delivering cost-effective, high-resolution insights into microbiomes from
various environments. However, due to a multitude of technical variables, careful
comparisons are required to provide recommendations for suitable methodological
approaches. In response to this, we compared the taxonomic composition of six stool
samples using two different primer combinations covering two 16S rRNA gene
variable regions. We then compared these results with those of shotgun sequencing
using Illumina and Ion technologies.
Following either OTU clustering of amplicon reads or taxonomic classification by
binning of shotgun reads, all at genus level, we compared microbiota composition of
the different datasets. Even though the gut microbiota is generally regarded as
individual specific, it was apparent that some amplicon datasets clustered according
to technology and/or primer set, rather than by subject. In particular, microbiota
composition from all VIV2 MiSeq and four of the six V4V5 MiSeq datasets grouped
together in separate sub-clusters. The V1V2 and V4V5 PGM datasets clustered by
sample opposed to technology in 3 of the 6 samples (samples 1, 3 and 6) while the
V4V5 MiSeq data clustered with V4V5 PGM data per sample in 2 of the 6 samples
(samples 5 and 6).
To ensure that the differences in classifications between shotgun and amplicon
sequencing were not simply due to a particular shotgun classification method, we
compared the compositional clustering with three classifiers of shotgun reads,
MetaPhlAn2, GOTTCHA and Kraken. The shotgun datasets grouped together in a
sub-cluster separated from the amplicon datasets, which might be expected as these
methods are independent of amplification bias and 16S rRNA gene copy number
differences. With MetaPhlAn2, all Illumina HiSeq and MiSeq datasets were
consistently closer to each other than to the PGM shotgun sequences. This is seen to a
smaller degree with GOTTCHA, where three of the six samples sub-clustered the
Illumina technologies, but not at all for Kraken assemblies. In terms of clustering by
sample over method, MetaPhlAn2 gave the most optimal results with all datasets
clustered by sample groups, closely followed by Kraken where this occurred for 5 of
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the 6 samples in separate sub-clusters. GOTTCHA failed to cluster any dataset by
samples, indicating its higher sensitivity for technological artefacts between
sequencing methods. However, it must be noted that measuring accuracy based on
individual sample clustering is not always a reflection of performance, as GOTTCHA
datasets clustered more closely to MetaPhlAn2 and although sample clustering is
observed when using Kraken, many of the taxonomic assignments may be false
positives as previously mentioned.
Unsurprisingly, Illumina HiSeq shotgun sequences translated to the highest number
of species, compared to the other two shotgun datasets, which were more than an order
of magnitude smaller. Sub-sampling that simulated lower HiSeq coverage revealed,
however, that even equal number of reads could result in more observed species for
HiSeq. As this technology produces shorter reads compared to MiSeq and PGM it is
possible that the number of species is artificially inflated as a result of higher sequence
variation created from incoiTect alignment to the reference marker genes. While not
directly comparable with species observed through shotgun sequencing, VI-V2
amplicons, which are expected to be more variable than V4-V5 amplicons, sequenced
by PGM resulted in the highest species counts.
Despite having the largest number of reads per sample, the VI-V2 region on the
MiSeq had at each subsampling point the lowest number of unique species identified.
This could be due to the questionable reliability for this primer combination in relation
to unexpected clustering and failure to detect expected genera. Curiously, Salipante et
al. (Salipante et al. 2014), found that sequencing using the same VI-V2 primers on
the PGM led to higher error rates when compared to the MiSeq, particularly for a mock
community of 20 organisms where deviating abundances of single strains have much
greater effect on the overall community composition than in a high-diversity sample.
Other reasons for the different results in Salipante et al. study could be attributed to
discrepancies in amplification (one-step PCR reaction) and taxonomic assignment
(older RDP-classifier version and BLAST).
The benefits to using metagenomic shotgun over amplicon sequencing are clear in
terms of increased information content and reduced biases related to amplification and
gene copy numbers. However, it is cun'ently not established what sequencing depth is
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required for the different technologies; this is a more pertinent issue for shotgun than
for amplicon sequencing, due to its much higher cost per sample. We therefore
assembled the randomly sub-sampled shotgun datasets and compared the common
N50 metric across the three sequencing technologies. As expected, the MiSeq
technology, with its non-overlapping 300 bp paired-end reads, had marginally higher
N50 values than HiSeq and PGM. An N50 peak occurred at 10 million reads for the
HiSeq data suggesting that this was the optimal point for sequencing depth for stool
samples and 100 bp paired-end reads with 300 bp insert size. There was no peak
obseiwed for the PGM or the MiSeq in the available coverage range, which may
suggest that the coverage may not be sufficient to reach an optimal level of assembly.
Somewhat suiprisingly, for two of the six samples there were drastically elevated N 50
values at 600,000 HiSeq reads, irrespective of which random sub-sampling set. Such
early N50 peaks were also observed using two other assemblers, albeit for a different
number of reads, and has previously been reported when assembling sub-samples of
an isolated bacterium (Lonardi et al. 2015). In that case, the authors reasoned that this
could be due to chimeric reads, duplications or sequencing en'ors, and recommended
that assembled contigs should be incrementally assembled in sub-sections before a
final merge. We also suggest that for our data, this read depth may be where the
majority of high abundant species are assembled and as more rare taxa are added the
assembly becomes less efficient.
In tenns of functional categorisation of assembled shotgun sequences, we found the
MiSeq and PGM datasets to largely contain equal proportions of predicted core genes
from the assembled contigs. For the HiSeq assemblies there were, however,
substantially fewer core genes involved in “Metabolism’' and more genes with
unknown function. This may be attributable to the fewer number of predicted complete
genes, which is plausible for this shorter-read technology.
To summarise, this is, to our knowledge, the first reported study comparing both
amplicon and shotgun sequencing for Illumina and Ion technologies. Although
shotgun sequencing did not suffer from the same degree of technology-dependent bias
seen with the amplicon sequencing, there were some major distinct differences
between phylogenetic binning software, with MetaPhlAn2 producing the most
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favourable results. GOTTCHA failed to eluster any datasets by sample, however subelustered with MetaPhlAn2, while Kraken elustered separately from the other two
binners and also appeared to produee a high number of false positive taxonomic
assignments. The variation of microbiota composition between the majority of gut
samples proved to be lesser than between the compared sequencing technologies and
variable 16S rRNA gene regions. In particular, the VI-V2 MiSeq showed poor
performance, while the V4-V5 region was marginally more reliable on both platforms.
There is evidence that the MiSeq and PGM offer valuable infonnation when used for
shotgun sequencing, however, in order to detect the majority of species in samples and
to perfomi a high quality assembly, deeper sequencing is required. Species assignment
is also dependent on read length, which is shorter for the HiSeq. We subsequently
showed that there may be no assembly-related benefit in sequencing greater than 10
million HiSeq reads per stool sample. Nevertheless, as the cost of shotgun sequencing
is lower on the HiSeq instrument compared to MiSeq or PGM, this platform may still
be preferable even though MiSeq produces longer reads and somewhat better
assemblies at low sequencing depth. Caution should however be applied with regards
to taxonomic binning, and comparisons such as those described in this study must be
caiTied out to prevent methodological biases eclipsing the true biological picture.
Hence, we advise laboratories with particular interests in certain microbes to optimise
their protocols to accurately detect these taxa using different techniques.
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Abstract
Proton pump inhibitor (PPI) use is associated with an increased risk of Clostridium
difficile infection (CDI), though the mechanism is unclear. PPI induced alterations to
the gut microbiome may facilitate the emergence of CDI, though the effects of PPIs
on gut microbiota are not well characterised. We used a population-based database to
identify individuals with >5 years of continuous PPI use along with non-PPI using
controls. Stool samples were subjected to microbiological analysis, with hierarchical
clustering at genus level, along with alpha and beta diversity measures comparing the
two groups. Metadata was accounted for using quantile regression to eliminate
potential confounding variables in taxonomic abundance comparisons. Sixty-one
subjects (32 PPI, 29 controls) were analysed. While no significant differences in alpha
diversity were found between the PPI users and controls, a moderate shift of the PPI
users away from the non-PPI user cluster in the beta diversity was observed. After
controlling for pertinent confounders, we discovered a decrease in Bacteroidetes and
an increase in Firmicutes at the phylum level. We also perfonned species
classifications and found Holdemania fillforniis and Pseudqflavonifnictor capillosus
to be increased and decreased in the PPI cohort, respectively. Long-tenn PPIs use has
an effect on the gut microbiome. The alteration in the ratio of Finnicutes to
Bacteroidetes may pre-dispose to the development of CDI.

126

1. Introduction
Proton pump inhibitors (PPIs) are widely used for both the treatment and prevention
of symptoms and complications associated with gastroesophageal reflux and peptic
ulcer disease. PPIs cause profound inhibition of gastric acid secretion; while the
sustained rise in gastric pH is essential for the healing of injured mucosa in the upper
gastrointestinal tract (Olbe et al. 1989; Yeomans et al. 1998) there are concerns that
this hypochlorhydria may have deleterious effects (Pereira et al. 1998). In addition to
aiding in digestion and activating pepsin, gastric acid is believed to play an important
role in limiting the survival of pH sensitive organisms involved in enteric infections.
There have been a number of studies which have suggested an association between
hypochlorhydria, whether due to surgical vagotomy or related to PPl use, and an
increased risk of common community acquired enteric infections, including
enterotoxic E. coli, Campylobacter jejuni and Salmonella spp (Bavishi and Dupont
2011; Giannella et al. 1973; Leonard et al. 2007). However, the data on the effects of
PPl use on the composition of the gastrointestinal microbiome are to date poorly
characterised, and is based on a small number of subjects over relatively short periods
of exposure (Freedberg et al. 2015b; Seto et al. 2014). However, the greater clinical
and public health concern pertains to the putative association of PPl use with the
development of Clostridium diffieile infection (CDl) (Bavishi and Dupont 2011;
Janarthanan et al. 2012; Kwok et al. 2012). It is possible that PPl-induced alterations
in the faecal microbiome may create an environment that is more receptive to
colonisation and subsequent infection by C difficile (P6'ez-Cobas et al. 2014).
Therefore, we aimed to evaluate the characteristics of the faecal microbiome which
are associated with long-term PPl use, with particular attention as to whether these
changes may plausibly increase the susceptibility to CDl.

2. Materials and Methods
2.1 Study population
Participants for this study were originally enrolled as part of a study with the aim of
evaluating the effect of long-term PPl use on bone health. Subjects who consented to
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participate were also asked to provide a stool sample to allow for eharacterisation of
their faeeal microbiome.
Study subjects were recruited from the Manitoba Health Population Health
Registry, which tracks all hospitalisations, physician visits and out-patient drug
dispensations among nearly all residents of the Canadian province of Manitoba
(population 1.3 million). Persons in the Registry aged 50 or over who had been
dispensed more than 180 PPl tablets in each of the 5 years prior to study enrolment
were eligible to be enrolled as long-term PPl users. All persons aged 50 or over who
had not been dispensed PPIs in any of the 5 years prior to the mailout could be
considered as potential controls.
We then mailed participation requests to all identified long-tenn PPl users and
potential controls who lived within 100 km of our study centre in Winnipeg, Canada.
Potential controls consisted of all persons who were never dispensed PPIs during the
same 5 year period. We randomly selected potential eontrols from this population so
that five potential controls would be sent a request to participate for every potential
long-term PPl users. The populations of potential cases and controls were matched on
their distribution of age and sex to increase the likelihood of comparability between
groups. Each mailout to potential enrolees was composed of 500 long-tenn PPl users
and 2000 long-term non-users, as we antieipated that PPl users would be more likely
to enrol than non-users. PPIs were only available in Manitoba by prescription at the
time of this study. A total of four mailouts were required to obtain our final sample
size. Data collection.

2.2 Data Collection
All persons who agreed to participate were interviewed to confinn that they were
either still using PPIs (for PPl users) or were not using PPIs (for long-tenn non-users).
The specifie PPl used, as well as the regularly administered dose were also confinned.
All subjects completed surveys detailing their personal history of gastrointestinal
symptoms, their indications for PPl use, and their use of other prescription and overthe counter medications. All subjects also completed a Food Frequeney Questionnaire
(FFQ) as was previously described by Claesson et al. (Claesson et al. 2012). This FFQ
was modified to better reflect common food items consumed by a Canadian
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population. Participants were asked to identify how often, on average, they consumed
a specified amount of eaeh food, to the nearest whole number during the past year.
The frequency of consumption of a medium serving or a common household unit was
asked for eaeh food item and later eonverted into quantities using standard portion
sizes. The frequeney eategories were: never or less than onee a month; one to thi'ee
times per month; one time per week; two to four times per week; five to six times per
week; one time per day; two to three times per day; four to five times per day and less
than six times per day.

2.3 Sample processing and sequencing
Subjects performed stool collection at home, and were instrueted to store stool in a
refrigerator until they were ready to ship it to the study centre in Manitoba. On arrival,
stool samples were stored in a freezer at -80°C. Once all stool samples were collected,
they were sent to Cork, Ireland for microbiologie analysis on dry ice in a refrigerated
container to maintain the samples in a frozen state. Faecal samples were completely
defrosted before performing DNA extraction. An aliquot of approximately 0.2 g was
transfeiTed into a tube with one 3.5 mm glass bead, 0.1 mL of 1.0 mm zirconia/silica
beads and 0.1 mL of 0.1 mm glass beads (Biospee, Bartlesville, OK, USA). QlAamp
Fast DNA stool kit (Qiagen GmbH, Hilden, Gennany) was used for DNA extraction.
First, 1 mL of InhibitEX buffer was added to the faecal samples, which were disrupted
by bead-beating in a Mini-Beadbeater-24 (Biospee) for 30 s three times at maximum
speed (3450 strokes/min). Samples were then heated at 95°C for 5 mins and following
this were processed according to the kit manufacturer's instructions resulting in
genomic DNA eluted in 200 IL of ATE buffer. DNA coneentrations were measured
using a NanoDrop 2000 Spectrophotometer (Thenno Scientifie, Wilmington, DE,
USA) and stored at -80°C until 16S rRNA gene amplicon sequencing library
preparation.
Library preparation was perfonned following the Illumina (San Diego, CA, USA)
recommendations with some modifications. An aliquot of 15 ng of extracted DNA
was subjected to polymerase chain reaction (PCR) amplification of the V3-V4
hypervariable region of the 16S rRNA gene in a total volume of 30 pi. The primers
were selected from Klindworth et al. (Klindworth et al. 2013) and Illumina adapters,
containing overhang nueleotide sequenees, were added to the gene-speeific sequences.
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The PCR primers (Eurofms Genomies, Ebersberg, Germany) at a eoneentration of 0.2
IM were used with the Phusion High-Fidelity DNA polymerase (Thenno Seientific,
Waltham, MA, USA). PCR amplifieation was performed on a 2720 Thermal Cycler
(Applied Biosystems, Foster City, CA, USA) under the following conditions: 98°C
for 30 s, followed by 25 cycles of 98°C for 10 s, 55°C for 15 s, 72°C for 20 s and a
final cycle of 72°C for 5 min. The presence of the amplified 16S rRNA gene band was
verified in an agarose gel. Post-PCR products were purified using Agencourt AMPure
XP magnetic beads (Beckman-Coulter, Brea, CA, USA) and eluted in 50 pi of EB
Buffer (Qiagen). After purification, 5 pi of DNA was amplified in a second PCR
employing Nextera XT Index primer (lllumina). This PCR was run at 98°C for 30 s,
follow'ed by eight cycles of 98°C for 10 s, 55°C for 15 s, 72°C for 20 s and a final
cycle of 72°C for 5 min. A second purification step with Agencourt AMPure XP
magnetic beads was carried out after the Nextera PCR. The 16S V3-V4 rRNA gene
amplicon containing the Nextera indexes was finally eluted in 25 pi of EB Buffer and
DNA concentration was measured using Quant-iT Picogreen dsDNA assay kit
(Thenno Scientific). A pooled library was created by adding 40 ng of each sample.
Finally, a diluted sample of this library with a 30 nM concentration was sent for MiSeq
sequencing (lllumina) to Eurofms Genomics. Bioinfonnatics analysis and statistics.

2.4 Bioinformatics analysis and statistics
The adaptors were first removed from the V3-V4 16S rRNA gene amplicon reads
using cutadapt (Martin 2011) allowing an eiTor rate of 0.2. Forward and reverse reads
were merged using fastqjnerge pairs from USEARCH version 7.0.1090.
Demultiplexing was earned out in QllME using splitJihraries, however only reads
with a minimum average PHRED quality score of Q25 and above, and a length of
between 390 bp and 465 bp were retained resulting in an average of 24 355 (6366 s.d.)
reads per sample. De novo clustering of Operational Taxonomic Units (OTUs) was
performed using USEARCH cluster_otus followed by chimera removal via
uchime_ref along with the ChimeraSlayer GOLD database (Edgar et al. 2011).
Taxonomy was assigned (phylum to genus) to the OTUs using the Mothur
implementation of the Ribosomal Database Project (RDP) classifier version 11.4. All
sequences contributing to each OTU were classified and those with a bootstrap cut-off
of 80% or above were retained. Any sequences with less than 80% bootstrap values
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were assigned as unclassified at that particular rank. A consensus approach was there
used from these sequences to assign taxonomy to each OTU (Schloss et al. 2009).
Species and Clostridium cluster classification was performed using SPINGO version
1.2 with default parameters on the demultiplexed, quality filtered sequence reads
(Allard et al. 2015). Alpha diversity and beta diversity were generated using the
alpha diversity.py and hetajdiversity’.py scripts in QIIME, respectively, followed by
Principle Coordinate Analysis (PCoA) plots via the R library ggplotl.
Statistics and plots were produced in R version 3.1.3. Speamian correlations along
with hierarchical Ward clustering were utilised for the heatplot {made4 library).
Quantile regression {qiiautreg library) was perfomied to analyse differences in the
taxa between the PPI and Non-PPI users, while adjusting for the metadata, including
age, gender, presence/absence of additional medication and the Healthy Food
Diversity (HFD) Index. 1 he HFD was calculated using the proportional numeric scale
data using the method described by Drescher et al. (Drescher et al. 2007). Principal
component analysis was earned out on the data using Euclidean distance on the
numerical data. The additional medications were fdtered to remove any exclusive to
one group (PPI or Non-PPI), while also only retaining medications used by a minimum
of three patients in each group.
A quantile multi-regression model was used to remove the potential effect of the
listed metadata by first correlating it with the investigated taxa and subsequently
subtracting the variation explained by the metadata. Wilcoxon tests were used to
compare differences in alpha diversity, followed by adjustment for multiple testing
using the Benjamini and Hochberg method (Benjamini et al. 2001). Kendall rank
correlations were perfomied to assess correlations between PCoA axes 1 and 2, and
the significantly different taxa between the PPI and Non-PPI users. A linear least
square model was used to investigate correlations between the HFD and the alpha
diversity of the subjects, while Proemstes {ade4 library) was carried out to evaluate
associations between the diet and the beta diversity. In all cases, adjusted P < 0.05
were considered significant. On the basis of the sample size of 61 subjects, we have
the power to detect an effect size of 1.78, with effect size defined as the ratio of the
difference of means of the two samples and the pooled standard deviation, when
considering comparisons of relative abundance between PPI users and non-users.
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3. Results
Sixty-one subjects were included in the analysis (32 PPI users, 29 non-users). A
description of baseline characteristics is shown in Table 3.1; no major differences were
seen in the measured characteristics between PPI users and non-users.
PPI users (n - 32)
Age (mean i s.d.)
% Male (n)
Body mass index (mean i s.d.)
% smokers (current/former)
PPI used
Omeprazole (n)
Rabepf azole
Other
PPI dose
% on demand
% once daily
% twice daily
PPI indications
Heartburn
Ulcer treatment
Ulcer prevention
Other
Food; healthy food diversity index (mean ± s.d.)
Medication use
Aspirin
Anti-hypertensives
Analgesics
Cholesterol reducing agents
Anti-depressants

PPI non-users (n - 29)

63.4 ii 7.6
66 (21)
29.8 ± 5.8
0/44
53 (17)
22 (7)
28 (9)

-

0 (0)
97 (31)
3 (1)

-

90
3
25
19
0.454

P-valu«

66.8 ± 8.1
62 (18)
28 5 ± 5.5
7/27

0.096
>0.2
>02

-

-

(32)
(1)
(8)
(6)
(± 0.126)

22 (7)
34 (11)
22 (7)
38 (12)
16(5)

0.141

0 502 (± 0.124)
31
31
28
28
3

>0.2
>0 2
>0.2
>02
0.198

(9)
(9)
(8)
(8)
(1)

Table 3.1: Baseline characteristics of study participants

Comparison of alpha diversity (microbiota diversity within each stool sample)
across the two cohorts, revealed no significant differences (Figure 3.1). There appears,
however, to be a wider distribution of diversities within Non-PPl users.

Shannon index

Chaol richness

Phylogenetic distance

6.0

350

55

300

5.0
45

250

40
3.5

200
150

3.0
P-Vaiue. 0.56
Non-PPl (29)

PPI (32)

Value 0.11
Non-PPl (29)

PPI (32)

P-Value 0.45
Non-PPl (29)

PPI (32)

Figure 3.1: Alpha diversity box-plots comparing the PPI and Non-PPl subject groups for Shannon
Index, Phylogenetic Distance and Chaol Richness.
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A number of stool-associated bacterial taxa were found to be differentially
abundant between PPl and non-PPI users even after adjusting for medication status,
gender, age and HFD (Table 3.2). At a phylum level, the abundance of Bacteroidetes
was lower in PPl users relative to the non-PPI control group (P < 0.007), while the
abundance of Firmicutes was higher (P < 0.008). Within Finnicutes these changes
were largely attributed to a relative increase in the Lachnospiraceae family, (P <
0.001 1), and the Holdemauia (P < 0.0003), Streptococcus (P < 0.036) and Blautia (P
< 0.077) genera. At a species-level, Holdemania fdifonnis (P < 0.0047) and
PseudofJavonifractor capillosiis (Clostridiales family; P < 0.016) increased and
decreased in PPl respectively. Clostridium cluster XlVa (P < 0.099) was also elevated
at the 10% significance level.

Relative abundance

Phylum
Bacteroidetes
Firmicutes
Family
Firmicutes, Lachnospiraceae
Genus
Firmicutes; Erysipelotrichaceae, Holdemania
Firmicutes: Streptococcaceae; Streptococcus
Firmicutes; Lachnospiraceae, Blautia
Species
Firmicutes; Erysipelotrichaceae; Holdemania
Firmicutes; Clostridium; Pseudoflavonifractor capillosus
Clostridium clusters
XlVa

PPl users

PPl non-users

Adjusted P-value

37.8
56,9

49.9
44.3

0.0068
0.0077

28.4

18.4

0.0011

00066
0.089
2 53

0.0002

4.1 X 10"*

6.7 X 10“^
5.7 X 10~*

0,0047
0.0158

0.16

0.11

0.0987

0.0151
149
5.92

1.1 X 10-''

0.0359
0.0773

Table 3.2: Relative abundance of specific taxa; adjusted in quantile analysis for age, gender, dietary
factors and use of other medications.

When metadata are not adjusted for using the quantile regression model a number
of additional taxa are significantly increased in PPl users; The genera Gramdicatella
(P < 0.005), Rothia (P < 0.005) and Dorea (P < 0.028), as well as the Clostridium
cluster XlVb (P < 0.042) and the species Clostridium glycyrrhizinilyticum (within
Clostridium cluster XlVa; P < 0.007), Rothia mucilaginosa (P < 0.016) were all
significantly increased in PPl users at the 5% level, while Streptococcusparasanguinis
(P < 0.064) and Streptococcus salivariiis (P < 0.064) were increased at the 10%
significance level. However, without adjustment for metadata, the genus Holdemania
and species Holdemania filiformis (P < 0.0047) and Pseudoflavonifractor capillosiis
were no longer significantly different between the groups.
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To investigate if it was possible to differentiate between PPI and Non-PPI users
based on eompositional profiles we applied both hierarchical clustering and Principal
Coordinate Analysis. Hierarchical Ward-linkage clustering based on Speannan
correlations of genera prevalent in at least 20% of samples is displayed in Figure 3.2.
While there were no obvious and distinct clusters related to PPI usage, 70% of the 20
samples in the smaller Cluster 1 were from PPI users. The significantly enriched
genera Holdemania, Streptococcus and Blautia were all highly abundant in the left
most sub-cluster within Cluster 1, which had a higher proportion of Finnicutes (bluecoloured families in the bar-chart of relative abundances in Figure 3.3). Cluster 2, on
the other hand, had a more even distribution where Non-PPI users were in a slight
majority. The differences in bacterial families between the two cohorts were evident
when ordering the samples according to their Firmicutes to Bacteroidetes ratio (Figure
3.3). The majority of the PPI samples were located to the left of the figure due to their
higher relative abundance of Firmicutes and lower Bacteroidetes, as both phyla were
statistically significant between the groups.
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Figure 3.2: Fleat-plot representing the taxonomic composition of samples at genus level. Spearman
correlations were performed followed by Ward clustering. Only genera in a minimum of 20% of
samples were retained. Bar-charts beneath the heat-plot represent taxonomic composition at family
level. Families are first organised by phylum abundance (highest to lowest) followed by family
abundance (highest to lowest) in each of the phyla.
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Figure 3.3: Bar charts representing taxonomic composition at family level ordered by Firmicutes to
Bacteroidetes ratio. Families are first organised by phylum abundance (highest to lowest) followed by
family abundance (highest to lowest) in each of the phyla.

Principal Co-ordinate Analysis based on weighted UniFrac distances (Figure 3.4),
in accordance with BrayCurtis and unweighted UniFrac distances (not shown), shows
a moderate shift in microbiota composition associated with PPI usage. Here, a majority
of Non-PPI samples, and some PPI samples, are grouped closer together, whereas a
majority of the PPI samples display a greater ‘spread’ along the two main principal
components, together explaining 48% of the total compositional variance. Kendall Tau
coiTelations of the significantly different genera with the principal components
{Holdemania PCI: -0.094, PC2: 0.085; Streptococcus PCI: -0.222, PC2: 0.229;
Blautia PCI: -0.374, PC2: 0.239 and Dorea PCI: -0.305, PC2: 0.184) indicate the
direction with which their abundances are correlated with the observed compositional
shift.
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Figure 3.4; Principal Coordinates Analysis (PCoA) based on weighted UniFrac distance. Ellipses were
set to a confidence interval of 80%. Arrows represent Kendall Tau correlations of the significantly
different taxa between PPI and Non-PPI u.sers. Length of the arrows indicate the degree of correlation
with the axes.

To investigate whether the diet of the two cohorts was responsible for shift
observed in Figure 3.4, we earned out Principle Component Analysis (PCA) of the
dietary data (Figure 3.5). Although there is a larger dispersion among the PPI users,
the two groups overlap due to the similarities in the dietary habits. To explore this
further, we perfonned Procrustes analysis on the microbiota using PCA of the
weighted UniFrac and PCA of the dietary data based on Euclidean distance (Figure
3.6). Through the use of the Monte Carlo method, a P-value of 0.789 was found,
therefore indicating that the shift in microbiota of the PPI subject was not as a result
of the diet.
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Principal Component Analaysis of Dietary Data

f>k3r-PPI
PPI

PCI 2580%

Figure 3.5: Principal components analysis of the dietary data based on Euclidean distance.

Procrustes PCA: Weighted Proportions and FFQ Data

Figure 3.6: Procrustes plot of the microbiota using PCA of the weighed UniFrac and PCA of dietary
data based on Euclidean distance. P-value (0.789) was calculated using the Monte Carlo method.

We did not detect any significant differences in the alpha diversity, beta diversity
or taxa abundances between users using rabeprazole and those using omeprazole,
which were the two most commonly used PPIs in this setting, though overall sample
size was small.
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4. Discussion
In this study which evaluated the largest number of long-term PPI users reported to
date, we were able to detect significant differences in the beta-diversity as well as the
relative abundance of bacterial taxa between PPI users and non-users. Most notably,
there was an increased ratio of Fimiicutes to Bacteroidetes among PPI users, as well
as significant differences in the abundance of other genera and species between long
term PPI users and PPI non-users.
Characterising the changes in the gut microbiome among PPI users is integral to
gaining a better understanding of the reported association between PPI use and enteric
infections, most notably CDI. The initial concern about PPI use pre-disposing users to
CDI emerged in a study by Dial et al. (Dial et al. 2005) demonstrating that PPI use
was associated with nearly a tripling in the odds of developing CDI. This finding has
been reproduced in several observational studies in a variety of clinical settings
(Freedberg et al. 2013; Freedberg et al. 2015a; Linsky et al. 2010; McDonald et al.
2015). A dose-response relationship has also been observed in several studies, with
the strength of association increasing among persons using higher doses of PPls, and
being reduced in users of H2-receptor antagonists (Dial et al. 2005; Kwok et al. 2012),
a much less potent forni of acid inhibition. PPI use has also been shown to increase
the rate of recun'ent CDI (Linsky et al. 2010; MeDonald et al. 2015), suggesting that
ongoing PPI use may interfere with sueeessful eradieation of Clostridial carriage with
antibiotic therapy. However, epidemiologic evidence can only suggest the presence of
an association between an exposure and an outcome. Fuilhenuore, the results obtained
from obseiwational studies may be biased by the presence of unmeasured confounders
which are associated with PPI use and CDI risk (Tleyjeh et al. 2012). As an example,
PPI users and the development of CDI are both associated with frailty, which is
difficult to precisely operationalise within the perfoiTnance of a retrospective study.
Currently, established guidelines on the prevention of CDI do not provide specific
direction on the use of PPIs (Surawiez et al. 2013). Given the limitations of
observational analyses, other lines of evidence of causality, specifically and
demonstration of a mechanism of action must be sought out.
As C. difficile is resistant to gastric acid mediated destruction, it is unlikely that the
association of CDI with PPI use is simply due to inereased transgastric survival of
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ingested spores (Nerandzie et al. 2009; Wilson et al. 1985). However, PPIs could
enhance colonic proliferation of C. difficile if reduction in gastric acid differentially
affected the survival of other microbiological organisms, causing changes in the faecal
microbiota that are more conducive to the development of CDI. This hypothesis could
be supported through the demonstration of: (i) PPIs inducing general changes to the
faecal microbiota that are known to pre-dispose the development of CDI, or, (ii) PPIs
causing effects on the microbiome analogous to other established risk factors for CDI
or, (hi) detecting a relative abundance of specific organisms among PPI users, which
have been demonstrated to elaborate metabolic outputs that promote the colonisation
and/or proliferation of C. difficile, or a relative reduction in the abundance of
organisms which would nomially compete with C. difficile for essential resource
substrates.
Persons who develop CDI are known to have a decrease in the alpha diversity of
the faecal microbiome compared to healthy controls, and are more likely to have a
relative increase in the abundance of certain Finnicutes, specifically Enterococcus,
Lactohacilliis species, as well as a reduction in Bacteroidetes, as well as a decrease in
Clostridiales Incertae Sedis XI, a nontoxigenic clostridiiim which may competitively
inhibit the proliferation of C. difficile (Antharam et al. 2013; Chang et al. 2008;
Goldberg et al. 2014). Clindamycin and beta-lactams, the antibiotics most strongly
associated with the development of CDI, also causes severe depletion in colonic
Bacteroidetes, and an increase in Gram positive cocci, mostly Finnicutes (Young and
Schmidt 2004). In animal studies, infusion of PPIs led to a marked reduetion in
Actinobacteria, which resulted in an inereased susceptibility to NSAID-induced
intestinal injury, suggesting that PPI induced shifts in the intestinal microbiota could
facilitate susceptibility to infection as well (Wallace et al. 2011). In this study,
longterm PPI use was not associated with a decrease in the richness and/or evenness
of organisms, although we did see depletion in Baeteroidetes and an increase in
organisms in the Firmicutes phylum. There have been a number of small studies which
have prospectively evaluated the composition of organisms found in stool in short term
PPI users. Tsuda et al. (Tsuda et al. 2015) evaluated both the alpha and beta diversity
among 12 persons in whom stool samples were obtained prior to PPI therapy, and then
1 week and 1 month following PPI initiation. A significant reduction in the OTU count
was seen in PPI therapy, with the magnitude of reduction approaching that found in
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persons with known CDI. However, a specifie change in the relative abundance of
specific bacterial taxa was not seen. Conversely, a study by Freedberg et al. (Freedberg
et al. 2015b) did not detect a decrease in overall bacterial diversity, but did see
reductions in specific taxa, most notably increases in enterococci and streptococci and
a reduction in non-CDI Clostridia] changes that are commonly seen among persons
with incipient CDI.
There may also be specific roles that specific species may have in encouraging or
preventing the development of CDI. As an example, many bacterial species synthesise
butyrate, a short-chain fatty acid which is an essential energy source for colonocytes
(Hamer et al. 2008; Rolfe 1984). The growth of C. difficile is inhibited in the presence
of colonic butyi'ate, and colonisation with C. difficile has been associated with a
decrease in butyrate-generating organisms, most notably organisms of the
Lachnospiraceae family {Clostridial cluster XIV) and Clostridial cluster IV (Louis
and Flint 2009). Non-toxigenic Clostridial species may also compete for essential
substrates such as sialic acid, inhibiting the growth of C difficile (Ng et al. 2013). In
our analysis, there were only a few species which were found to be more abundant
among PPI users after adjustment for pertinent metadata. PPI users were more likely
to have a greater abundance of organisms from the genus Holdemania, Streptococcus,
Blaiitia and Clostridial cluster XlVa. In our analysis, we found an increase in the
relative abundance of Lachnospiraceae, in particular those of the genus Blaiitia,
instead of the anticipated decrease. Overall, we did not detect any changes in the
relative abundance of any specific organisms which have been reported associations
with CDI. In previous analysis, Freedberg et al. (Freedberg et al. 2015b) reported
decreases in non-difficile Clostridial organisms, whereas in our analysis, there was a
decrease in the relative abundance of Clostridium cluster XlVa which did not reach
statistical significance (P = 0.099). Other studies evaluating the effects of PPIs on the
microbiome did not detect differences in the relative abundance of specific species or
genera among PPI users. While these findings do not indicate the presence of a
'‘smoking gun” that directly links PPI use to specific microbial changes pre-disposing
to CDI, it remains possible that more global effects of PPIs on the faecal microbiome
may be of concern.
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This study does have some notable limitations. First, the original intent of this study
was to evaluate the effects of long-term PPI use on bones, and thus we did not survey
this population on the totality of risk factors that may confound the relationship
between PPI use and its effects of gut microbes, such as a history of recent antibiotic
use or hospitalisation. Second, we did not assess for specific metabolic processes
associated with the microbiome of PPI users and non-PPI users to determine the
presence of products which may either inhibit or promote the proliferation of C.
difficile. Moreover, as this was a cross-sectional study, we cannot determine if the
microbiome characterisation varies over time, nor whether the microbiome among PPI
users had been altered compared to those same persons’ microbiome prior to the
initiation of PPI therapy. Also, we cannot be certain whether the changes we obseiwed
among long-tenn users differ from shifts which may occur immediately following
initiation of PPI therapy. Fuithennore, our study does not address whether short-temi
PPI use has any impact on the gut microbiome, as the lack of notable changes in the
microbiome may be due to a healthy-suiwivor effect. In spite of these limitations, this
study is the largest population-based assessment of the contents of the gut microbiome
among PPI users, with a large enough sample size to be able to adjust for pertinent
metadata.
Overall, this study demonstrates that long-term PPI users do not manifest changes
in their gut microbiome that would obviously pre-dispose to the development of GDI
or other enteric infections. However, long-term PPI users do have some gut
microbiome alterations but it remains to be proven if these changes have adverse
effects on health. Further work is required to characterise the bacterial metabolites
among PPI users, although at this point, a mechanism behind a causal association
between PPI use and the development of GDI remains elusive.
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A longitudinal microbiota study of Inflammatory Bowel Disease
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Abstract
Stool microbiota of patients with Inflammatory Bowel Disease (IBD) has
consistently been associated with decreased microbiota diversity, along with
differences in microbiota composition, albeit with inconsistency with regard to
specific taxa. However, comparisons between states of disease activity through
longitudinal studies are limited. Here, we present the largest longitudinal IBD
microbiota study to date, encompassing multiple stool samples from more than 700
subjects from two geographical locations (Cork, Ireland and Manitoba, Canada).
This is also the first longitudinal study to combine microbiota, medication, diet and
calprotectin. We found decreased diversity and stability in patients with CD and UC
compared to controls along with alterations in microbiota composition. Although
there were slight shifts and alterations in the microbiota composition and stability
between active and inactive disease, there was no difference in diversity or any
particular taxa. Age, diet and geographical location had a significant impact on
microbiota composition and diversity, as did medications and resection. We found
sub-groups of subjects dominated by particular taxa where Escherichia/Shigella and
Akkennansia muciniphila were more abundant in clusters over-represented by
patients with IBD. This study adds further evidence of an alteration in the gut
microbiota between subjects with IBD and controls in the largest, most
comprehensive longitudinal IBD microbiota study to date. However, in contrast to
existing studies, we show, through longitudinal sampling, that there is no difference
in the microbiota composition of patients in active and inactive disease.
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1. Introduction
Inflammatory Bowel Disease (IBD), largely Crohn’s Disease (CD) and Ulcerative
Colitis (UC), are chi'onic autoimmune conditions of the gastrointestinal (GI) tract.
They lead to an inappropriate inflammatory response resulting in abdominal pain,
rectal bleeding and diarrhoea. Differing rates of IBD between geographical locations,
and increasing incidence in the Western world and second generation immigrants,
provide evidence of environment factors influencing IBD aetiology. Furthermore, IBD
onset is not solely caused by genetics as familial studies have shown that between 6
and 32% of patients with IBD have a first or second degree relative with the same
disease (Ahmad et al. 2001).
Medications and antibiotics can profoundly impact the gut microbiota (Ferrer et al.
2017), and have been investigated as an environmental influence in IBD. Several
studies have shown associations between the contraceptive pill and IBD (Boyko et al.
1994; Cornish et al. 2008), while antibiotics in the first year of life increases the
likelihood of developing paediatric IBD (Shaw et al. 2010). Additionally, anti-TNF
therapy prescribed to patients with IBD caused alterations at genus level (Kolho et al.
2015) and corticosteroids decreased microbial stability (Halfvarson et al. 2017). Diet,
albeit with contradictory findings (Amre et al. 2007; Geerling et al. 2000; Sakamoto
et al. 2005) have also been linked to IBD pathogenesis along with Vitamin D
deficiency commonly noted in the diagnosis of IBD (Leslie et al. 2008). There has
been a paradoxical relationship between IBD and smoking with active smokers having
an increased risk of developing CD, while there is a protective effect with UC (Lakatos
et al. 2007).
Decreases in microbial diversity have been found in patients with CD and UC
compared to heathy controls (Halfvarson et al. 2017; Michail et al. 2012; Noor et al.
2010; Tong et al. 2013). The Finnicutes to Bacteroidetes ratio is decreased in patients
with IBD (Kabeerdoss et al. 2015; Walker et al. 2011), however this is not specific to
IBD and is observed in many sub-optimal health states (Mariat et al. 2009; Tilg and
Kaser 2011).

Increases in the families Enterobacteriaceae,

Pasteurellaceae,

Veillonellaceae and Fusobacteriaceae with a decrease in the abundance of the orders
Eiysipelotrichales, Bacteroidales and Clostridiales was noted in patients not exposed
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to treatment (Gevers et al. 2014). Several genus and species including Ruminococcus
hromii, Euhacterium rectale, Roishiiha, Akkermansia were decreased in UC
compared to healthy controls in a study by Rajilic-Stojanovic and colleagues (RajilicStojanovic et al. 2013). In contrast, Lactobacillus and Faecalihacterium have been
considered protective against IBD (Llopis et al. 2009; Sokol et al. 2008). Microbial
alterations in IBD have been extensively reviewed (Ohkusa and Koido 2015; Wright
et al. 2015). To date, there have been limited longitudinal microbiota studies
investigating IBD and in particular the transition from active to inactive disease states.
Cross-sectional studies have found a gut microbiota dysbiosis in IBD and differences
between active and inactive disease states. Although these studies are important in
providing evidence of microbial impact, they are prone to biases and confounding
factors such as patient diet and medication status, and in addition very little is known
about the microbiota shifts and dynamics within patients with IBD.

A study by

Halfvarson and colleagues of 137 individuals, 109 of which had IBD, found that the
IBD gut microbiota composition fluctuates more than that of a healthy individual
(Halfvarson et al. 2017). Although this study had the largest cohort at that time, the
authors concede that the sample size made statistical analysis difficult and essential
metadata such as diet was excluded from analysis.
Here we present the largest IBD cohort longitudinal study to date. Our study
involving 536 subjects with IBD, in both active and inactive disease, along with 166
healthy controls is the first IBD longitudinal study to combine microbiota, diet,
medication and calprotectin. We found that the microbial diversity was significantly
decreased in patients with IBD compared to controls but there were no differences
between activity states. The overall gut microbiota composition of patients with IBD
differs from controls with CD in active disease being the most dysbiotic. Although
there are differentially abundant species between patients with IBD diseases versus
controls, there are no species significantly different between active and inactive
disease. Age and various food groups are associated with both alpha and beta diversity,
while geographical location impacts microbial composition at a taxonomic level.
Medication and resection status also influenced the diversity and composition of the
gut microbiota.
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2. Materials and Methods
2.1 Cohort and Data Collection
This study was approved by the Cork hospital ethics committee and the University of
Manitoba (UM) Healthy Research Board (HREB). Study subjects in this analysis were
volunteers willing to provide faecal samples and complete questionnaires. The study
cohort consisted of two populations, Cork, Ireland (n = 291) and Manitoba Canada (n
= 411). In addition to patient demographics, all subjects were required to fill out a
Food Frequency Questionnaire (FFQ) to capture long-tenn dietary habits through
frequencies of medium food servings of 157 items. These frequencies were normalised
to per month counts and the food items were grouped into 28 broader food categories
for analysis. An active state of IBD was defined as a faecal calprotectin measurement
of > 250ug/g (Nancey et al. 2013). The clinical demographic data on the study subjects
is shown in Table 4.1.
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A)

Subjects
Number of Subjects
Gender (% male)
Age (mean ± SD)
Age of disease onset (mean ± SD)

Samples
Number of Samples (with metadata)
Resection undertaken (%)
Smoking Status
Non
Ex
Current
Alcohol Comsumption
>2 beverages per day
<2 beverages per day
Non
Biologies (%)
5ASA(%)
Mercaptopurine (%)
Corticosteroids (%)
PPIs (%)

B)

Manitoba
UC
141

CD
188
29
55±13
31 ± 12

Healthy Control
80
65
66 + 8
NA

38
57 ± 12
36+ 13

CD Active CD Inactive UC Active UC Inactive Healthy Control
397
171
416
88
96
NA
41
0
51
8
(%)
(%)
(%)

59
38
3

(%)
(%)
(%)

23
64
20
27
16
12
18

9
24
19
7
13

6
35
12
15
5

Subjects

13
0
2
0
0
51

3
34
15
6
6

Cork

UC
84
56
47 + 12
30 + 12

CD

Number of Subjects
Gender {% male)
Age (mean + SD)
Age of disease onset (mean + SD]

Samples
Number of Samples (with metadata)
Resection undertaken (%)
Smoking Status
Non
Ex
Current
Alcohol Comsumption
>2 beverages per day

122
50
44 + 12
28 + 11

CD Active CD Inactive UC Active UC. Inactive Healthy Control
157
62
185
59
185
47
NA
26
C
0
(%)
(%]
(%]

44

(%]

<2 beverages per day (%]
Non (%]
Biologies (%]
5 ASA (S'i)
Mercaptopurine (%)
Corticosteroids (%)
PPIs {%]

Healthy Control
86
40
36 ± 11
NA

46
46
7

5S
35
7

38

23

25
38
2S
27

46
30
20
21
7

50
7

6
16
13

8
5

49
47
5

73
14
12

61

19

73

35
7
2
48
8
30
8

43
38
13
37
6
19
5

15
12
0
0
0
0
1

Table 4.1: Demographics and sample sizes for a) the Manitoba and b) the Cork cohorts

2.2 Sample Processing and Sequencing
Canadian subjects performed stool collection at home, and subsequently posted the
samples to the study centre in Manitoba where they were stored at -80°C. Once all
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stool samples were collected, they were shipped on dry ice to Cork, Ireland for
microbiome analysis. Irish subjects brought samples to the gastroenterology clinic
which were subsequently delivered to the microbiology laboratory and frozen at 80°C. An aliquot of approximately 0.2 g was transferred into a tube with one 3.5 mm
glass bead, 0.1 mL of 1.0 mm zirconia/silica beads and 0.1 mL of 0.1 mm glass
beads (Biospec, Bartlesville, OK, USA). QIAamp Fast DNA stool kit (Qiagen
GmbH, Hilden, Germany) was used for DNA extraction. First, 1 mL of InhibitEX
buffer was added to the faecal samples, which were disrupted by bead-beating in a
Mini-Beadbeater-24 (Biospec) for 30 s three times at maximum speed (3450
strokes/min). Samples were then heated at 95°C for 5 mins and following this were
processed according to the kit manufacturer’s instructions resulting in genomic DNA
eluted in 200 IL of ATE buffer. DNA concentrations were measured using a
NanoDrop 2000 Spectrophotometer (Thenno Scientific, Wilmington, DE, USA) and
stored at 80°C until 16S rRNA gene amplicon sequencing library preparation.
Library preparation was performed following the Illumina (San Diego, CA, USA)
recommendations with some modifications. An aliquot of 15 ng of extracted DNA
was subjected to polymerase chain reaction (PCR) amplification of the V3-V4
hypervariable region of the 16S rRNA gene in a total volume of 30 IL. The primers
(Forward: 5'-CCTACGGGNGGCWGCAG-3’. Reverse: 5’GACTACHVGGGTATCTAATCC-3’) were selected from Klindworth et al. and
Illumina adapters, containing overhang nucleotide sequences, were added to the
gene-specific sequences (Klindworth et al. 2013). The PCR primers (Eurofms
Genomics, Ebersberg, Germany) at a concentration of 0.2 IM were used with the
Phusion High-Fidelity DNA polymerase (Thermo Scientific, Waltham, MA, USA).
PCR amplification was perfomied on a 2720 Thermal Cycler (Applied Biosystems,
Foster City, CA, USA) under the following conditions: 98°C for 30 s, followed by
25 cycles of 98°C for 10 s, 55°C for 15 s, 72°C for 20 s and a final cycle of 72°C for
5 min. The presence of the amplified 16S rRNA gene band was verified in an
agarose gel. Post-PCR products were purified using Agencourt AMPure XP
magnetic beads (Beckman-Coulter, Brea, CA, USA) and eluted in 50 IL of EB
Buffer (Qiagen). After purification, 5 IL of DNA was amplified in a second PCR
employing Nextera XT Index primer (Illumina). This PCR was run at 98°C for 30 s,
followed by eight cycles of 98°C for 10 s, 55°C for 15 s, 72°C for 20 s and a final
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cycle of 72°C for 5 min. A second purification step with Agencourt AMPure XP
magnetic beads was earned out after the Nextera PCR. The 16S V3-V4 rRNA gene
amplicon containing the Nextera indexes was finally eluted in 25 IL of EB Buffer
and DNA concentration was measured using Qubit high sensitivity dsDNA assay kit.
A pooled library was created by adding 40 ng of each sample. Finally, a diluted
sample of this library with a 30 nM concentration was sent for MiSeq sequencing
(Illumina) to Eurofms Genomics.
For the Irish cohort, a -80°C frozen aliquot containing approximately 0.5 g of
faecal material was used to measure calprotectin concentration in an ImmunoCap
250 autoanalyser employing EliA*^'' Calprotectin Immunoassay v2, following
manufacturer’s instructions. Results were expressed as pg/g faeces. The
BUllLMANN fCAL ELISA kit was carried out as per manufacturer's guidelines for
faecal calprotectin measurement in the Canadian cohort.

2.3 Bioinformatic analysis and statistics
First, '"cutadapr (Martin 2011) was used to remove the adapter sequences from the
V3-V4 region of the 16S rRNA gene amplicon reads allowing for an error rate of 0.2.
USEARCH (v. 8.1.1861) script ^\fastq_merge' was employed to merge forward and
reverse reads. The script '\split_lihranes" in QIIME was used to perform
demultiplexing with retention of reads under the following conditions: 1) minimum
average PHRED quality of Q25 and above, 2) a length of between 390bp and 465bp.
De novo clustering of Operational Taxonomic Units (OTUs) was earned out using
""cluster_otus'‘' in USEARCH. while chimeras were removed using ''iichime_rer with
the ChimeraSlayer GOLD database (Edgar et al. 2011). The Mothur implementation
of the Ribosomal Database Project (RDP) classifier (v. 11.4) was used to classify OTU
taxonomy (phylum and genus) with only classifications above the bootstrap cut-off of
80% being retained and all others assigned as unclassified at that particular rank
(Schloss et al. 2009). For classification of species and Clostridium clusters we
perfoiTned SPfNGO (v. 1.3) against the RDP database (v. 11.4) with default
parameters (similarity score of 0.05 and a bootstrap cut-off of 0.8) (Allard et al. 2015).
All downstream analysis was perfonned in R version 3.3.0. Alpha and Beta
diversity was calculated using the R package '^phyloseq'" while plots were constructed
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in "‘ggplot2'\

Differential abundance of the taxa was earned out using

'''MetagenomeSeq" (v.

1.14.2), differences in diet consumption between the

geographical locations and alpha diversities was calculated using Wilcoxon tests.
Heatplots were constructed using the made4 library with Spearman correlations
combined with hierarchical Ward clustering. Hierarchical clusters were cut using
''dynamic!reeCut” and tested with Fisher’s tests for the categorical data and the
wilcoxon tests for quantitative data. Spearman correlations were carried out to assess
con'elations between food groups/taxay'metadata and PCoA/PCA axes. Adonis from
the '"vegan' library was performed to investigate the effect of medications on overall
microbial compositional differences.

P-values were adjusted for multiple testing

where appropriate, using the Benjamini and Hochberg method (Benjamini et al. 2001).

3. Results
In the Manitoba cohort, controls were on average 10 years older than the IBD groups,
whereas Cork cohort subjects with CD and UC were 8 and 11 years older than controls
respectively. Patients with IBD from Cork were on average 10 years younger and
consisted of 20 percentage points more males compared to their Manitoba
counteiparts, while the Manitoba healthy population had 25% fewer females and were
30 years older on average. Full demographics are outlined in Table 4.1. Quality
filtering and processing of raw sequencing reads resulted in a mean of 21,647, (95%
Cl; 21,298-21,996) reads per sample and there were 3043 OTUs post chimera filtering.
As Manitoba samples were posted to the lab before being frozen there was a delay
of up to 5 days at room temperature due to transit. To ensure this did not impact results,
we conducted a pilot study with 4 fresh samples in duplicate stored for up to 7 days at
room temperature. There was no significant difference between time points in alpha
diversity, and samples clustered by subject as opposed to room temperature duration
by PCoA (Figure 4.1).
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Figure 4.1: Comparing samples stored for various periods of time at room temperature, a) Chaol
diversity, b) samples clustered by time at RT, c) samples clustered by control subject

3.1 Microbial composition, diversity and stability differs between
patients with IBD and controls
Beta diversity for the complete cohort (Plot of Bray-Curtis distance; Figure 4.2)
shows a significant shift along PCI and 2, with CD samples located furthest from
healthy controls, followed by UC. For each disease, the active state showed a
moderate shift further from controls than the inactive state, although this was only
significant for CD along PC2. Food groups and associated subject metadata was
correlated to the PC axes to find associations (Figure 4.2b, Table 4.2). Chaol
diversity was significantly correlated to the PC axes, followed by age and
calprotectin levels. With regard to overall microbiota composition, patients with CD
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or UC had significantly larger within-subject differences in beta diversity (Principle
Components 1 and 2) compared to controls and therefore the least stability (Figure
4.3a). The highest within-subject differences were between active and inactive
samples therefore indicating a shift or change in beta diversity (Figure 4.3b). The
smallest distance between time points from the same subject was amongst the
patients with CD or UC with two consecutive active samples. This distance was not
significantly different from healthy controls indicating similar stability.

CD Active

0 CD Inactive
|V] Healthy
UC Active
*

UC Inactive

•

Manitoba

A

Cork

Figure 4.2: a) Principle Coordinate Analysis based on Bray-Curtis distances with proportional
normalisation on all OTUs present in more than 5% of samples, with samples grouped by disease and
activity state. Violin plots show projections of PCoA points into PCI and PC2. B) Spearman
correlations between PC axes and food groups/metadata and alpha diversity. Only categories with
significant correlations are represented. The direction and length of the arrows indicate the direction
and strength of the correlation.
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PCI
P-value
0.1002

PC2
rho
P-value
-0.0710851
0.02075

rho
-0.0998708

Chaol

0.0009778
< 2.2e-16

-0.1314586
0.05557
0.7199818 < 2.2e-16

-0.0765565
-0.2335392

Dietary Information

PCI
P-value

Beta Diversity
Calprotectin
Age

Alcohol
Brown pasta
Brown/Wholemeal bread
High sugar foods

2.04E-05

0.000509831

1.51E-1S
2.26E-21
0.000211545

4.08E-18
6.34E-20
0.004865537

2.08E-09
8.97E-05

0.002152682

Poultry
Red Meats

PC2
adjusted P-value rho
P-value
1 0.026767532
0,169124852 0.503128119
0.05652993 -0.12297908
-0.350107199 0.002018926
1 0.005198523
0.366267052 0.896553804
1 0.019606946
-0.14732429 0.623838925

adjusted P-value rho

5.41E-08 -0.236161275
0.155657746

0.055669932

1 -0.076401948

0.182442729

1

0,053271673

Table 4.2: Correlations of metadata and dietary groups to Bray-Curtis PCoA.
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Healthy (84)

Figure 4.3: Distances between points from the same subject along PCI and PC2. a) Distances plotted
for distance type and b) distances plotted grouped by changes in statues between time-points.

A comparison of alpha diversity (Chaol) revealed that patients with CD and UC
from Cork and Manitoba had signifieantly lower microbial diversity than controls
(Figure 4.4a), irrespective of geographical location (Table 4.3). Microbial diversity
was also lower in UC inactive samples compared to those of CD (active and inactive),
but not for UC active. Although there were differences in median values (CD: 207 vs
210, UC; 248 vs 271), more so with UC than CD, there were no significant differences
between active and inactive states of CD or UC. When diversity was assessed for intra158

individual variation, comparing only patients with a sample in the aetive and inactive
disease state and the median value (CD: 187 vs 178, UC 229 vs 230), the differences
were largely removed (Figure 4.4b). Tracking individual subjects, only up to 60% of
samples eollected during active disease were lower in alpha diversity than the
corresponding inactive sample from the same subject (Figure 4.5).
a)

o

CO Active
(n-74)

CD Inactive
(n=237)

Healthy
(n=166)

UC Active
(n-50)

UC Inactive
(n-175)

b)

CO Active
(n-6'>)

CO Inactive

(n:^65)

He.tIthy
(nr 166)

UC Active
(n 60)

UC Inactive
(n=60)

Figure 4.4: Chaol diversity comparing disease type and status of patients with IBD versus healthy
controls, a) 1 sampled selected randomly per patient, b) only containing patients with both an active
and an inactive disease state sample to conduct paired tests.

159

Alpha Diversity: Chaol
Disease
CD vs Healthy
CD Active Vs Inactive
CD active vs Healthy
CD Inactive vs Healthy
UC vs Healthy
UC Active Vs Inactive
UC Active Vs Healthy
UC Inactive vs Healthy
CD vs UC
CD Active vs UC Active
CD Active vs UC Inactive
CD Inactive vs UC Active
CD Inactive vs UC Inactive
CD Active vs inactive (paired)
UC Active vs inactive (paired)

Canadian
Cohorts Combined
< 2.2e-16
5.52E-16
0.9575
0.2473
< 2.2e-16
5.77E-11
< 2.2e-16
1.25E-13
< 2.2e-16
2.95E-08
0.127
0.4526
1.27E-10
1.74E-05
6.78E-14
5.21E-07
1.84E-07 0.0001865
0.04844
0.1185
0.0002421
0.000351
0.06921
0.3125
4.20E-07
0.001685
0.1974
0.1639
0.3367
0.3761

Irish
< 2.2e-16
0.1619
2.20E-07
< 2.2e-16
1.34E-09
0.09162
1.94E-06
2.89E-07
0.0001089
0.9342
0.1041
0.1186
7.05E-06
0.6257
0.8469

Table 4.3: Statistical comparison of alpha diversity (Chaol) between groups for the complete, Cork
(Ireland) and Manitoba (Canada) cohorts.

Manitoba
S44b

in active

decreased in active

^ 40C

2
CO Active
CD Indctive
Hertithy
UC Active

Cork
'>4% decreased in active

□

UC Inactive

60^ decreased in active

Increased
for active
disease
Increased
for inactive
disease

Figure 4.5: Alpha diversity (Chaol) connecting points from the same patient. Red lines represent an
increased active state compared to inactive while black is an increased inactive state.

3.2 There are no species significantly altered between disease states.
The abundance of 67 and 30 species were significantly increased and decreased
respectively between CD and controls, while 61 and 27 were increased and
decreased between UC and controls (Figure 4.6, Tables 4.4-4.6). The most
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significantly increased species in CD compared to controls were Ruminococcus
gnaviis and Clostridium hylemonae (both absent from controls) along with
Eggerthella lenta. In contrast, a number of other Lachnospiraceae {Euhacterium
eligens, Euhacterium rectale and Faecalihacterium prausnitzii) and Ruminococcus
alhus were decreased in CD when compared to controls. Eggerthella lenta was also
increased in UC versus controls along with Holdemania filiformis and Turicihacter
sanguinis. Euhacterium eligens, Butyricimonas virosa and Clostridium
aminohutyricum were decreased in the UC group compared to controls. However,
there were no significant differences between CD active and inactive, and only one
species (Bacteroides dorei) significantly increased in UC active compared to
inactive. However, when paired tests were conducted between the same patient’s
active and inactive disease state samples, there was no significance for either IBD
condition. For a breakdown of the number of significant taxa between each group at
each rank see Table 4.4.
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Figure 4.6; Volcano plots of differential abundance at species level between groups. Points above the
line are significant while the position of each point indicates the direction of fold change. The size of
each point refers to the abundance of the species across the cohort while the colour indicates the
family rank.
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(sig/not)
Phylum
Family
Genus
Species
OTU

Phylum
Family
Genus
Species
OTU

CDvsh
(4/8)

CD vs UC
(0/12)
(4/41)
(13/87)

(98/106)
(269/516)

UC vs h
(4/8)
(30/14)
(54/45)
(89/107)
(2287/495

CD a vs CD i
(0/12)
(0/45)
(0/100)
(0/196)
(0/743)

CD a vs h
(3/9)
(19/26)
(47/53)
(68/129)
(133/611)

CD 1 vs h
(4/8)
(24/21)
(53/47)

CD a vs CD i
(0/12)
(0/45)
(0/99)
(0/196)
(0/737)

UC a vs UC i
(0/10)
(0/43)
(0/96)
(0/185)
(0/752)

(23/22)
(56/44)

(24/176)
(41/744)
UC a vs UC i
(0/11)
(0/42)
(0/98)
(95/105) (1/190)
(241/543) (2/687)

UC a vs h
(6/5)
(21/22)
(39/60)
(58/132)
(110/578)

UC 1 vs h
(4/8)
(26/18)
(49/50)
(87/110)
(242/540)

Paired Data
Phylum
Family
Genus
Species
OTU

Table 4.4: The number of taxa at each rank differentially abundant between each group (disease and
disease status).
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Table 4.5: Statistical comparison of patients with CD samples versus healthy controls using
MetagenomeSeq
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Table 4.6: Statistical comparison of patients with UC samples versus healthy controls using
MetagenomeSeq

3.3 Hierarchical clustering reveals groups dominated by prevalent
species
Samples were subjected to hierarchical clustering and divided into 10 clusters
based on their proportional species composition (using dynamicTreeCut on BrayCurtis distances), with several dominated by particular species (Figure 4.7, Tables
4.7 and 4.8). Clusters ranged in size between 79 and 378 samples and were often
distinguished by varying relative family abundances. Clusters 7-10 were driven by
Escherichia/Shigella, Akkermansia rnuciniphila and have significantly more subjects
with IBD than the other clusters. Cluster 1 {Bacteroides vulgatiis) 7, 8
{Escherichia/Shigella) and 10 {Akkermansia rnuciniphila) contain significantly more
subjects post resection, while clusters 4 {Eubacteriiim rectale) and 6 {Dialister
invisus) have more subjects taking Biologies and 5 AS A respectively (Figure 4.8).
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Cluster

IBD vs Healthy
CD vs Healthy
UC vs Healthy
CD vs UC
Gender
5ASA
Mercaptopurines
Corticosteroids
Biologies
PPIs
Resection

3

4

5

0.359 0,001: 5.72E-17
0.262 5E-04i 3.89E-13
0.04 1.50E-12
0.751
0.447 0.447
0.766
0.234 0.234 0.71909
0.883
1 0.88343
0.991 0.991 0.98636
0.551 0.935 0.55061
0,445
0.2
1
0.489 0.489
1
0.013 0.517 0.00282

0.214
0.115
0.598
0.447
0.234
1
0.991
0.551
0.014
1
0.395

0.311
0.506
0.251
0.587
0.234
0.883
0.991
0.566
0.2
1
0.032

1

2

7

8

0.351 0.00017
0.506 4.66E-05
0.014
0.0106
4E-04 0.41356
1 0.24234
0.029 0.01407
1 0,99102
0.95 0.55061
0.28 0.93336
1
1
0.003 0.01293

0.013
0.001
0.251
0.101
0.719
0.883
0.991
1
0.933
0.075
0.023

6

9

Increase
Decreased

Table 4.7; Comparison of patient metadata (Disease, gender, resection status and resection
medication) in each cluster compared to each of the other clusters combined.
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10

1.52E-05 1.71E-05
1.78E-05 4.05E-07
0.00019 0.03986
0.766 0.00224
0.79424 0.71909
0.88343 0.88343
0.98636
1
0.55061 0.94965
0.93336 0.44486
0.79757 0.79757
0.77898 0.00315

Clustered samples from
the same patient

I

i'

r

•

,*•',<•

• •

I

' ..

^ Unctassffied
aher
H verrucoinicrobiaceae
H Coriobactenaceae
I BifidoPactenaceae
H EnteroUacteriaceae
Prevotellaceae
^ Porphyromonadaceae
I Rtkenellaceae
I Bacteroidaceae
Laclobaciilaceae
H Erysipelotrichaceae
H Acidanijnococcaceae
I Peptosireplococcaceae
H Streptococcaceae
I '■^illonellaceae
m RumIrKxnecaceae
III Lachnospiraceae

Figure 4.7; Healplot of OTUs classified at species level with spearman correlations and ward.D2
clustering. The vertical colour bar represents the family of each species. The samples were divided
into 10 clusters (secondary horizontal colour bar) using dynamicTreeCut. The first horizontal colour
bar indicates the disease and status of each sample. The species names on the right of the plot, along
with the cluster number, are the drivers of the clustering. The barchart is the taxonomic composition
at family level of each sample ordered by phylum (highest to lowest abundance) followed by family
(highest to lowest), across the complete cohort. The PCoA at the bottom is the same as Figure 4.2 but
labelled by the 10 clusters.
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Sauces
Ready-made Meals
Nuts

f
'

Brown rice
Pasta/Rtce/
White pasta
Potato^ ® White rice
B Brown pasta
B Potatoes
Oily hsh
B other fish
Poultry
Processed Meats
B Red Meats
Cereals,'
Breads

Low fibre cereak
cereals
n Brown/Wholemeal bread
B Whfte bread

?iASA

B

Healthy

■ vcs
Mercdptopurlr>es

□ No

Corticosteroids

Figure 4.8; Gender, medication status, resection status, dietary categories and Chaol diversity with
samples in the same order as Figure 4.7.
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Cluster
Alcohol
Beans
Brown pasta
Brown rice
Brown/Wholemeal bread
Butter and oils
Coffee
Dairy
Dressing
Eggs
Fruit
High fibre cereals
High sugar foods
Low fibre cereals
Nuts
Oily fish
Other fish
Potatoes
Poultry
Processed Meats
Ready-made Meals
Red Meats
Sauces
Tea
Vegetables
White bread
White pasta
White rice

1
0.702
0.702
0.021
0,817
0.889
0.702
0.817
0,702
0.702
0.89
0,927
0.431
0.702
0.702
0.928
0.889
0.983
0,702
0.068
0.702
0.817
0.561
0.425
0.702
0.702
0.431
0.702
0.702

2
3
0.784 0.34301
0.934 0.34301
0.008 5.61E-06
0.813 0.45616
0.01 4.26E-06
0.737 0.34301
0.8 0.80921
0.348 0.80921
0,995 0.34301
0,417
0.8044
0,348 0.19996
0.348 0.27176
0.065 0.45616
0.348 0.27176
0.11 0.80921
0.348 0.78795
0,348 0.45616
0.025 0.76569
0.009 0.34301
0.813 0.73586
0.532 0.78795
0.348 0.27176
0,348 0.80921
0.348 0.11531
0.569 0.73586
0,683 0.45616
0.065 0.52353
0.009
0.8044

4
0.428
0.952
0.006
0.825
0.005
0.952
0.952
0.856
0.952
0.856
0.952
0.619
0.847
0.619
0.856
0.409
0.952
0.098
0.01
0.619
0.14
0,584
0.619
0.825
0.619
0.619
0.856
0.952

5
0.9922
0.7250
0.7883
0.9089
0.9089
0.7250
0.7250
0.9922
0.9922
0.7250
0.9922
0.9349
0.9089
0.9349
0.7250
0.9089
0.7250
0.7883
0,9922
0.7250
0.9089
0.9089
0.7250
0.7250
0.7250
0.7250
0.9089
0.7250

6
0.702
0.686
0.078
0.686
0.221
0.997
0.078
0.659
0.891
0.527
0.671
0.989
0.874
0.184
0.659
0.659
0.412
0.098
0.869
0.671
0.686
0,659
0.997
0.414
0.414
0.098
0.997
0.659

7
0,614
0.614
0.133
0.614
0.082
0.899
0.133
0.278
0.709
0.2
0,709
0.614
0.498
0,614
0.675
0.614
0,884
0.614
0.023
0.863
0.581
0.709
0.709
0.709
0.697
0,709
0,614
0.167

8
0.111
0.82
0.158
0.815
0.158
0.82
0.497
0.928
0.82
0.988
0.995
0.995
0.82
0.16
0.995
0.82
0,158
0.934
0.043
0.815
0.82
0.478
0.82
0.82
0.995
0.995
0.815
0.82

9
0.7377
0.7377
0.0000
0.9625
0.0172
0,7377
0.7377
0.9051
0.7377
0.8379
0.7676
0.6800
0.0661
0.7676
0.6800
0.2407
0.7992
0.0695
0.0001
0.9625
0.7377
0.0017
0.1433
0.9051
0.9625
0.9051
0.7377
0.7992

10
0.103
0.084
0.055
0.029
0.006
0.524
0.552
0.542
0.893
0.062
0.297
0.524
0.939
0.738
0,285
0.524
0.738
0.832
0.616
0.285
0.126
0,616
0.893
0.297
0.738
0.023
0,832
0.959

Increase
Decreased

Table 4.8; Comparison of patient FFQ items in each cluster compared to each of the other clusters
combined.

After clustering by species abundance and examining any resulting pairs of
samples, 36% of the paired samples were closest to samples from the same subject.
We compared the number of pairs per disease and state against the number of all
possible pairs per category using a Fishers test (Table 4.9). Patients with CD and UC
samples from the same disease state were not over-represented compared to controls.
However, fewer samples from the same patient in active and inactive disease were
closest to each other and this was significantly under-represented compared to
controls, CD (Active pairs and Inactive pairs) and UC (Active pairs and Inactive
pairs).
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Pairs
CD Active
CD Inactive
CD Inactive Active
UC Active
UC Inactive
UC Inactive Active
Controls

21
68
14
11
79
21
31

CD
CD
CD
CD
CD
CD
CD

Active vs CD Inactive
Active vs Control
Inactive vs Control
Altering vs Control
Altering vs CD Active
Altering vs CD Inactive

P-values
0.55
0.61
1
2.23E-11
4.61E-09
4.18E-16

UC
UC
UC
UC
UC
UC
UC

Active vs UC Inactive
Active vs Control
Inactive vs Control
Altering vs Control
Altering vs UC Active
Altering vs UC Inactive

0.054
0.32
0.29
6.70E-08
0.0036
1.63E-15

Non Pairs
46
120
243
31
103
210
55

Table 4.9; The number of pairs and non-pairs per group after hierarchical clustering and testing each
group for over-representation (Fishers test).

3.4 Age, diet and geographical location affect the microbiota.
Examining the alpha diversity between the two geographical locations uncovered
that CD active, control and UC inactive were significantly increased in the Cork
subjects compared to the Manitoba cohort (Figure 4.9). However, after adjusting for
age using a linear model, this observation was no longer seen for CD active and
controls. Age was also significantly con'elated to alpha diversity (Chaol), which was
significantly decreased in the older patients with CD (Figure 4.10). A number of
species were differentially abundant between the two locations with 68 for CD (23
active, 117 inactive), 97 for UC (16 active, 68 inactive) and 66 significantly different
between the control groups (Figure 4.11, Table 4.10).
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Figure 4.9: Alpha diversity comparing the subjects from Cork and Manitoba across disease and status
groups. P-values in black represent differences before adjustment for age, while the red values show
P-values after adjustment.
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Figure 4.10: Spearman correlations between alpha diversity (chaol) and age.
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Figure 4.11: Volcano plots showing differential abundance in species between the Cork and Manitoba
cohorts across disease and disease status. Points above the line are significant while the position of
each point indicates the direction of fold change. The size of each point refers to the abundance of the
species across the cohort while the colour indicates the family rank.

(Sig/not)
Phylum
Family
Genus
Species
OTU

CD
(3/9)
(16/27)
(38/61)
(68/127)
(159/568)

CD A
(1/10)
(6/32)
(12/76)
(23/149)
(41/488)

CD 1
(1/11)
(15/28)
(31/68)
(48/146)
(117/627)

UC
(0/11)
(13/29)
(19/78)
(39/156)
(97/660)

UC A
(0/10)
(2/35)
(4/70)
(3/141)
(16/425)

UCI
(0/11)
(12/30)
(17/80)
(36/159)
(68/687)

Healthy
(2/10)
(3/38)
(9/82)
(17/169)
(66/680)

Table 4.10: The number of taxa at each rank differentially abundant between the Cork and Manitoba
cohorts (disease and disease status).

A number of food groups (high sugar foods, brown pasta, poultry, red meats,
alcohol and brown bread) were significantly correlated to the two PC axes containing
the highest variation of beta diversity (Figure 4.2b, Table 4.2). Consumption of
brown pasta, chicken and high sugar foods were increased in patients with IBD,
while red meat, brown bread and alcohol were more associated with control subjects.
Additionally, 19 food groups were consumed differently between the population
170

cohorts (Figure 4.12) with alcohol, tea, potatoes and brown bread increased in the
Cork cohort, while vegetables, nuts and brown pasta increased for the Manitoba
group. The Cork participants consumed more non-oily fish and red meat while oily
fish and poultry were higher for those in Manitoba.
Brown/Whokme»l bread

Processed Meats

Manitoba

[±

Cork

Figure 4.12: Boxplots representing differential consumption of food groups between the Cork and
Manitoba cohorts. Only food groups with a significant difference were plotted (19). Outliers were
removed for plots as these were not a representation of the cohort.

Microbial diversity was significantly higher with increasing Healthy Food
Diversity (HFD), but only for all cohorts combined, and for UC inactive (Figure
4.13). Assessing Cork, Manitoba and combined cohorts, there were a number of food
groups were correlated with alpha diversity (Combined: 6, Cork: 2, Manitoba: 8).
The overall dietary composition of patients with IBD was moderately different from
controls with a significant shift away from controls in the dietary Principle
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Component Analysis (PCA) along PC2 (Figure 4.14a). When FFQ data was
correlated to PC 1 and PC2, the main drivers of the shift were identified with
vegetables and fruit which correlated with healthy controls and high sugar foods
towards subjects with IBD (Table 4.11). White bread, butter/oil, potatoes and red
meats were associated with a separate subset of patients with IBD (Figure 4.14b).
After removal of the main drivers, high sugar foods and vegetables, from the dataset,
the moderate shift was removed (Figure 4.15).
b)
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Figure 4.13: Spearman correlations between alpha diversity (chaol) and Healthy Food Diversity
(HFD) index.

Dietary PCA
Alcohol
Brown rice
Brown/Wholemeal bread
Butter and oils
Coffee
Dressing
Eggs
Fruit
High fibre cereals
High sugar foods
Nuts
Oily fish
Other fish
Potatoes
Poultry
Processed Meats
Red Meats
Vegetables
White bread

PCI
P-value
Adjusted P-Value rho
0.000101353
0.001824348 -0.154496867
0.738860063
1 0.013328607
3.28E-05
0.000622783 -0.164925237
3.66E-07
8 41E-06 -0.201276804
6.80E-06
0.000136087 -0.178470352
0.002977511
0.050617693 0.118336979
0.079475491
0.874230406 -0.070035327
2.87E-07
6.88E-06 0.203060687
0.004264355
0.063965321 -0.113898788
1.52E-19
4.10E-18 0.350091069
0.577796795
1 -0.022252572
0.254014685
1 0.045584131
0.007184767
0.100586741 -0.107173542
1.54E-06
3.39E-05 -0.190388455
0.184574925
1 0.053013457
l,89E-07 -0.228246584
7.25E-09
2.81E-06
5.90E-05 -0.185662488
4.31E-44
1.21E-42 0.516363074
1.12E-07
2.80E-06 -0.209790854

PC2
P-value
Adjusted P-Value
0.005767421
0.063441632
1.41E-11
3.38E-10
0.000152999
0.002447982
5.87E-11
1.35E-09
0.41390347
1
2.73E-09
6.01E-08
0.000114072
0,001939229
l.OlE-46
2.61E-45
0.00027453
0 004117947
1.50E-141
4.20E-140
9.55E-05
0.001718375
5.90E-05
0,001120212
0.020953671
0.001611821
9.08E-06
0000183855
8.75E-06
0 000183855
0.000489876
0,006858266
0.004355279
0.052263349
1.64E-131
4.43E-130
2.19E-20
5.47E-19

Table 4.11: Correlations of metadata and dietary groups to Dietary PCA.
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rho
0.110049167
0.265317995
0.150522132
-0.257358342
0.032659961
0.234455977
0.153365743
0.529751374
0.144704247
-0.800900769
0.155066446
0.159582958
0.125600219
-0.176056404
0.176367115
-0.138719028
-0.113633446
0.783573374
-0.357655862

|Vj
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[TT] CD Inactive
□ Healthy

UC Inactive

O

Overlapping
Unking data from
the same subject

Figure 4.14; Principle Component Analysis (PCA) of the food groups coloured by disease and disease
status. Violin plots represent the points in the PCA to assess shifts in the groups. Patients with greater
than 1 identical questionnaire are indicated by black circles. Spearman correlations between PC axis
of PCA and food groups/metadata (bottom left). Only categories with significant correlations are
repre.sented. The direction and length of the arrows indicate the direction and strength of the
correlation.
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Figure 4.15; Dietary PCA when Vegetables and High Sugar foods were removed from the Food
Frequency Questionnaire.
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3.5 Medications and resection alter the microbiota diversity and
composition.
Both microbiota diversity and composition were significantly impacted by resection
and the use of medications. Beta diversity showed a significant shift of resected
patients away from those who were not and from healthy controls (Figure 4.16).
Additionally, non-resected patients had a higher alpha diversity than resected and
there were 45 species differentially abundant (Table 4.12). Faecalibacterium
praiisnitzii and Methanobrevihacter smithii were increased in non-resected patients,
while Blautia prodiicta, Bacteroides fragilis and Riiminococcus gnaviis were
increased in resected patients. Patients on biologies (although not significant) and
PPls showed the same trend, being located further away from controls. One species,
Bacteroides stercoris, was significantly increased in patients on biologies (Table
4.12). Interestingly, the only medication to cause the microbial composition to be
more similar to controls was 5ASAs (Figure 4.15). Similarly, alpha diversity (Figure
4.17) was significantly higher for patients on 5 AS As compared to those who were
not. However, there were no species differentially abundant between patients on
5ASAs and those not.
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The affect of metadata on beta diversity
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Figure 4.16: Beta diversity using the Bray-Curtis metric with proportional normalisation on all OTUs
in greater than 5% of samples with samples grouped metadata (age, calprotectin levels, medication
information and resection status).
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The affect of metadata on alpha diversity (Chaol)
Resection

Mercaptopurine

<2.2e-16

<2.20-16

<2.2e-l6

n=166

n=138

n=387

n=166

Biologies

n=390

Corticosteroids

<22e-\6

<22e-16

/ * ''
/1\
,

\
n=166

N

J

n=166

n=50

n=402

1-H

PPI

n=166

Healthy

n=133

n=329

No

Yes

n=33

Healthy No

n=408

n=44

■ Healthy yes

Figure 4.17: Alpha diversity plots (Chaol) assessing differences in species richness when categorised
by medication information and resection status.
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Biologks
Bocteroides stercons

Resection

pvalues

adjPvalues

| In relation to Biologies

0.000234426
pvalues

adjPvalues

In relation to Resection

FaecaHbocterium prausnitzii
Blautio produaa

2.59E-10

2.59E-08

Cfostridium otdenense

4 06E-09

2.71E-07

Clostridium hylcmorux

5.99E-07
3.49E-06

Veilk)r)ello dispar

1.20E-08
8.72E-08
1.45E-07

4.84E-06

ParabQcterotdes distasonis

1.02E-06

2.56E-05

Clostridium leptum
Bocteroides fragilis

9.59E-07
4.21E-06

2.56E-05
9.35E-05

Rumiriococcus ofbus

5.36E-06 0 000104189

Huminococcus gnovus

Anoerostipes coccoe

5.73E-06 0.000104189

Eubacterium coprostanoligenes

6.52E-06 0000108621

Atistipes putredinis

1.47E-05 0.000226004
3 lOE-05 0000412867

Copfococcus catus
Eubacterium rectale

3.76E-05 0.000469757

Blautio glucerasea

9 08E-05 0001068428

Bocteroides dorei

0.000109695 0.001218837
0.000267189 0.002812516

Actinomyces odontoiyticus

0 000322435 0.003224348

Coprobocter fastidiosus

0.000400768 0.003751053

Clostridium methylpentosum

Clostridium ramosum

Morganella morganii

0.000412616 0.003751053
0000432683 0.003762459
0 000579685 0.004650757

Clostridium populeti

0000581345 0 004650757 Decreased

Coprococcus eutoctus

0000867766
0.00094634
0001055849
0.001152879
0.001325924

Bocteroides ovotus

Huminococcus bromii
Veillonella otypico
Clostridium innocuum
Hydrogenoanoerobocrerium socchorovorons

0.006675121 Decreased
0.007009927 Decreased
0.007541775 Increased
0 007950889
0.008839497

Euboctenum hollii

0.001789077 0.011542434
0 00208848 0.013052997

Clostridium sporosphoeroides

0002317551 0.014045763 Decreased

Clostridium ominobutyncum

0.002461865 0.014481556 Decreased

AnoerofUum pentosovorons
Eubacterium biforme

0002957293 0.016898815 Decreased
0.003173144 0.017628578 Decreased

Blautio schinkii

0.003825559 0.020678696

Oscillospira guilliermondii

0.004428298 0.023306832

Barnesiella intestinihominis
Clostridium symbiosum

0.004829992 0.024351655
0.004870331 0.024351655

Eubacterium suki

0.006707672 0.032720349

Catenibacterium mitsuokai

0.006998343 0.033325443 Decreased

Odonboaer lane us

0.007700828 0.035003761 Decreased

Methanobrevibacter smithii
Acetanoerobacterium elongatum

0.007626029 0 035003761 Decreased
0.009884072 0.043929211 Decreased

Eubacterium desmolans

0010399813 0.045216577 Decreased

Bilophila wodsworthia

Table 4.12: Differentially abundant taxa between patients with IBD on Biologies medication and
those not, and reseeted patients and non-resected.

177

4. Discussion
There are limited studies published assessing patients with IBD longitudinally.
Sampling subjects over time may uncover possible causes of transitions from active
to inactive disease states. Our study aimed to fill this void by analysing longitudinal
samples from the largest time series IBD cohort to date along with a large cohort of
healthy controls.
We observed a noticeable shift in the overall microbial composition with active
disease located further from controls than inactive for both IBD diseases. Although
differences between subjects with IBD and controls have been previously reported
(Gevers et al. 2014; Pascal et al. 2017), this activity-related trend, albeit modest, has
not. It was possible to identify significant associations between compositional shifts,
demographics and dietary habits. Faecal calprotectin, age, poultry, brown pasta and
high sugar foods were positively correlated with subjects with IBD, while red meats,
alcohol and brown bread were positively correlated with healthy control subjects.
Soda drinks and chocolate, both of which were grouped into high sugar foods, and
protein (high content in poultry) have previously been identified as an IBD risk
factor for the development of IBD (Jantchou et al. 2010; Russel et al. 1998).
However, high red meat consumption (high in protein) is also associated with IBD
(Hou et al. 2011) and we found this more common in the healthy control group. A
study investigating diet recommendations for patients with IBD found that avoidance
of alcohol, red meat and raw and cruciferous vegetables was advised. In addition, the
consumption of poultry was promoted (Hou et al. 2014), all of which agree with the
correlations we found between diet and the microbiota. Diet between patients with
IBD and controls differed significantly when plotted by PC A, where the strongest
correlated food groups were vegetables and high sugar foods, positively correlated
with controls and patients with IBD respectively. A study of French populations
identified a low incidence of IBD in the South compared to the North while the
South ate more fruit, vegetables, and oily fish, all of which are correlated towards the
healthy controls in our study cohort (Nerich et al. 2006). The greatest distance
between consecutive samples from the same patient on PCoA was between active
and inactive states and therefore the least stable. The microbiota of patients with IBD
were less stable than controls in agreement with previous findings for CD (Scanlan
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et al. 2006). Consecutive active samples from the same patient were the most stable
(IBD subjects) in composition (not significantly different from controls on PC2),
providing evidence that there is less change in the microbiota once an active state of
disease has been reached. Individual patient stability is high as previously reported
(Caporaso et al. 2011; Costello et al. 2009). When examining the stability of
mJcrobiota communities by disease and state, no category was significantly over
represented indicating that patients in continual remission or relapse have similar
stability to controls. However, samples clustered together from patients in altering
disease states of both CD and UC were significantly under-represented compared to
controls and IBD patients without disease state change. This provides further
evidence of a change or alteration in the microbial community between disease
activity states in the same patient. Microbiota diversity was decreased for both forms
of IBD and activity states compared to healthy controls, as has been reported in
previous studies (see reviews (Gong et al. 2016; Matsuoka and Kanai 2015)).
However, we did not find significance when comparing active versus inactive
disease. This finding was previously reported albeit with a small sample size (Wills
et al. 2014), while numerous other studies reported compositional alterations in the
gut microbiota composition (see systematic review (Prosberg et al. 2016)).
Additionally we found that any moderate but non-significant differences in diversity
were further removed when conducting paired tests between patient’s activity states.
Therefore we conclude that faecal microbiota diversity of a patient with IBD differs
from the healthy population but remains stable irrespective of disease status. To
confirm this further, individual patients were assessed longitudinally and only up to
60% of patient’s samples in the active state had decreased diversity compared to
their corresponding inactive state sample, thus far from discriminatory.
While abundances of taxa do not change within patients between activity states,
there are much larger compositional differences between subjects with IBD and
controls. Among the species we found significantly increased in CD compared to
controls, there is agreement with previous studies for Ruminococcus gnaviis
(Joossens et al. 2011; Willing et al. 2010) and Fiisohacterium micleatiim (Gevers et
al. 2014), even though the opposite effect has been observed for the former (Gevers
et al. 2014). We found decreased abundance in CD for Ruminococcus alhiis,
Euhacterium rectale and Faecalihactehum prausnitzii compared to controls, also in
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agreement with previous studies (Gevers et al. 2014; Kang et al. 2010) and meta
analysis (Cao et al. 2014). However, limited research has been undertaken between
patients with IBD longitudinally to capture transitions between active and inactive
disease. After using paired samples and tests, there was no significant differences for
either IBD condition.
We found sub-groups based on species clustering and associated these with a
number of factors. Clusters associated with B. viilgatus, A. muciuiphila and
Escherichia/Shigella contained significantly more resected patients, the latter of
which has previously been reported (Neut et al. 2002). There were also associations
with E. rectale and a sub-group over-represented by patients on Biologies, while the
same was true forD. invisiis and 5ASA medications. Kabeerdoss et al (2015),
reported similar results for E. rectale, which were more abundant in patients
receiving medications compared to treatment naVve (Kabeerdoss et al. 2015). Patients
on 5ASA medications had significantly higher diversity and located significantly
closer to controls in PCoA analysis when compared to non 5ASA users. Xue et al.
(2012) stated that the decrease in pH caused as a result of mesalazine (5ASA is the
active component) would allow for beneficial Bifidobacteria and Lactohacilli to
nourish, therefore inhibiting mucosal inllammation and inducing a more healthy like
microbiota (Xue et al. 2012). However, we did not find any taxa differentially
abundant between patients on 5ASA medications and those not. Resected patients
clustered further from healthy controls than those who were not on PCoA. Resected
patients also had an altered microbiota in tenns of species abundance compared to
non-resected and had significantly lower species diversity. However it was not
possible to establish if this is due to the resection process or disease severity, while
the date of resection is also not taken into account. An assessment of microbiota
changed due to resection would require samples pre and post-surgery from the same
patients.
Furthermore, there were differences in microbial diversity and taxonomic
abundance between the two geographical locations. A number of potential
contributors to this including variations in diet of which 19 food groups were also
identified. Although the Canadian cohort consumed to a higher degree a healthy diet
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more rich in vegetables, brown pasta, and oily fish, this was not reflected in species
diversity, as the two geographical locations were not significant different.
This study has significantly solidified the ideology that there is an alteration in the
microbiota between subjects with IBD and control subjects. We show that the IBDrelated microbiota has minimal variation in both diversity and composition across
active and inactive disease states. Patients with IBD exhibit relatively stable
microbial communities, similar to healthy subjects, when in either active or inactive
disease. However, there is a significant alteration in stability when transitioning
between disease states, although this is not driven by any particular species as none
were identified as significantly differentially abundant. An alternative investigation,
which may prove fruitful, is the examination of the functional potential of the
microbiota between disease states. The healthy microbiota may be a collection of
optimal functions rather than taxonomic community, and if functions are fulfilled, a
healthy state is reached. It is possible that although similar communities are present
between the active and inactive state, the functionality may differ greatly.
The importance of metadata collection such as dietary habits and medication is
clearly evident, as these can be correlated to the shifts in microbiota across groups.
Interestingly, despite differences in diets, location and age, both geographical
cohorts showed similar trends when analysing patients with IBD versus healthy
controls.
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Chapter V

Discussion and Future Perspectives
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There has been a large and sustained increase in the number of human gut microbiota
studies over the past decade, and with decreasing costs in sequencing technologies
combined with promising and thought-provoking results, this field is set continue
expanding. The importance of the gut microbiota along with its influence on health
and disease has been explored in both independent small scale and large international
studies. For instance, the Human Microbiome Project (HMP) launched in 2008 with
budget of $115 million and over the course of its initial 5 year phase, was very
successful contributing tools, protocols and a repository of data to the research area.
Most importantly, phase 1 of HMP resulted in an understanding of the human
microbiota through the characterisation of the microbial communities from various
body sites: skin, mouth, vagina, gut and lung (Beck et al. 2012; Huang et al. 2014;
Perez et al. 2016; Shreiner et al. 2015; Warinner et al. 2014). Its successes resulted in
phase 2, temied the Integrative Human Microbiome Project (iHMP), which focuses
on three cohorts; Pregnancy and Preterm Birth, Onset of Inflammatory Bowel Disease
and Onset of Type 2 Diabetes. The potential impact of the microbiota field has been
further acknowledged with the US government launching the National Microbiome
Initiative with a budget of Sl2lm. In combination with technology improving for
microbiota research, it is also becoming more accessible allowing for research in areas
previously unattainable. The Minilon from Oxford Nanopore Technologies, being the
size of a USB device, has permitted microbiota research to be conducted in space
(McIntyre et al. 2016) and in developing countries like Guinea (E Check Hayden
2015). Similarly the Illumina MiniSeq, although not portable, provides a benchtop
sequencing platform at much lower costs. Although continual development of highthroughput technologies like the Illumina HiSeq are important for furthering
microbiota research and knowledge, accessibility improvements should not be
abandoned.
Increased interest in the microbiota and bioinfomiatics leads to a number of
challenges. Gordon Moore, Intel co-founder, observed that every 2 years the power of
computing doubles and the price halves which has largely held true for over 50 years.
This, termed “Moore’s Law”, was sustainable with the growth of DNA sequencing
until 2007 where the price of sequencing a human genome plummeted from SlOm to
a number of thousands (Figure 5.1) (Hayden 2014).
186

1

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

Figure 5.1: Moore's law compared to the cost of genome sequencing (Erika Check Hayden 2014).

In 2013, the European Bioinformatics Institute (EBI), one of the largest biological
data repositories, reported that 20 petabytes (10'*’ bytes) of data were stored at their
site. Genomic data was one tenth of this data and was more than doubling every year
(Marx 2013). The National Centre for Biotechnology Information (NCBI) provides an
invaluable resource, GenBank, a database where genomes and sequencing data are
stored making it available for use by researchers. Statistics from the NBCI provide
more evidence of the growth in sequencing and the requirement for a solution to big
data storage (NCBI 2017) (Figure 5.2). It is projects that a zettabase (I0“‘ bytes) of
data will be generated by 2025 (Stephens et al. 2015).
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Figure 5.2: The growth of sequencing data stored by the NCBI (NCBI 2017)

Cloud computing offers a potential solution but is not without disadvantages.
Although data is accessed through the internet without the requirement for onsite
storage infrastructure size, analysis and comparisons would require a high level of
onsite resources. Cloud commuting can also be a source of bottlenecks with the
retrieval of data being cumbersome and availability hampered by power outages and
technical disruptions along with concerns of highly confidential data stored in third
party sites.
Chapter II of this thesis addresses one aspect of this challenge in the microbiota
research field. We explored the use of more cost effective approaches for metagenomic
sequencing through the use of the Illumina MiSeq and Ion PGM. These technologies
also result in a smaller data output than the Illumina HiSeq traditionally used.
However, we showed that a true representation of the sample may be missed using
lower throughput technologies compared to the Illumina Hiseq. It is important not to
sacrifice the integrity of results at the expense of data storage concerns and cost. Data
storage challenges need to be faced or will be detrimental to the field leading to failure
in reaching its ultimate potential.
The field of microbiota research, and bioinformatics as a whole, is victim to issues
in reproducibility of results. A survey interviewing over 1,500 researchers found that
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70% experienced difficulty in reproducing experiments (Baker 2016), while it has
been estimated that annually, $28 billion is spent in the US on preclinical biomedical
research which is not reproducible (Freedman et al. 2015). A second aspect to Chapter
II was investigating reproducibility in sequencing analysis. We compared sequencing
results from two sequencing technologies targeting various variable regions of the 16S
rRNA gene for amplification. We also compared data from shotgun sequencing
performed on three sequencing technologies and found biases based on the variable
regions selected for amplification in the marker gene sequencing. However, for
shotgun data sample similarity was based on the taxonomic classifier used, which was
a more powerful discriminator than both the sequencing technology and the amplicon
used. We highlight the requirement for caution when comparing datasets and results
from various sources. The methods in both library preparation and dataset analysis
may impact the results more than originally expected. Furthennore, labs focusing on
particularly taxa should optimise their analysis approaches to ensure accurate results.
It would be advantageous for all sequencing studies to include a control sample(s) as
part of their sequencing run(s). This would allow for the detection of biases between
runs and studies within the lab. In an ideal situation, a standardised control would be
sequenced in all microbiota studies to allow for accurate comparisons between labs,
along with means to test new software. It would be best to use a real environmental
samples, however this leads to challenges due unknown tme starting material. Mock
communities provide a known community, however lack the complexity of an
environmental sample. Additionally when alterations in expected abundance of mock
species are observed it is difficult to rule out errors in mock community fonnulation.
To aid reproducibility in microbiota studies, providing data availability along with
methods utilised are a requirement for many journals. Although a good starting point,
suppling scripts and software is insufficient as there is a need for commenting and
explanations to be included when publishing. Figure 5.3 outlines some of the “hidden”
parameters which must be taken into account when attempting to reproduce results
and existing methods (Kim et al. 2017). Existing resources, such as R markdown for
statistical analysis, provide a means to document all code in a clear, template fonnat
and could be beneficial if implemented as standard. Standard Operating Procedures
(SOPs) are also a potential solution to ensure reprodueibility and enable eomparisons
between studies. The National Institute of Standards and Technology (NIST) created
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an initiative called the “Genome in a bottle”, which aims to provide reference material,
methods and data for assessing human genome sequencing and analysis. Similarly,
the International Microbiome Standards (IHMS) project was constructed to develop
SOPs for data quality and comparability optimisation for metagenomic analysis
including metadata description, DNA extraction and sequence analysis. The
Microbiome Quality Control project aims to measure bias and reproducibility in the
field and provide guidelines. Although this is an improvement, it will be difficult to
ensure that procedures are adhered to and there remains a demand for further SOPs.
Additionally it must be taken into account that this field advances rapidly in both
hardware and software, and SOPs quickly become redundant and contain suboptimal
methods. There is a requirement for a balance between standardised methods and
creativity and innovation in analysis. Sandve and colleagues published 10 mles for
reproducible computational research which includes version control, avoidance of
manual manipulation steps and recording intemiediate results (Sandve et al. 2013).
These rules can be used as a template or starter guide for recording microbiota
analysis. If the field of microbiota analysis fails to deliver on reproducibility, it will
lose credibility and advancement will be hampered.

Figure 5.3: The hidden aspects affecting reproducibility in bioinformatics (Kim et al. 2017)
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Proton Pump Inhibitors prevent gastrie and duodenal uleers and are in the top 10
most prescribed drugs. These medications increase the gastric pH by inhibition of acid
production through the hydrogen-potassium pumps. Low pH acts as defence
mechanism thereby preventing the growth of pathogens, and as a result, concerns of
the use of PPI medications have been expressed, particularly due to the association
with Clostridium difficile infection. Chapter III of this thesis examines the effect of
PPls on the gut microbiota after long-term use compared to unexposed controls. In
this study we found an altered gut microbiota in subjects taking PPI medications
compared to controls. Participants taking PPIs had increased abundances of the genus
Streptococcus and the species Holdemaina filformis along with a shift away from
controls in PCoA analysis. Similar to other studies, microbial alterations were not
associated to those seen in C. difficile infection. Infections with C. <i///‘have decreased
microbial diversity and a decrease in butyrate producers. Nevertheless, PPI
medications cause a change in the gut microbiota profiles which is of concern,
although tliere is a lack of agreement amongst studies regarding the specific changes.
There is a requirement for transition from small scale cross sectional studies to large
scale longitudinal studies to better understand the impact of PPI on the microbiota
(Walker and Flint 2016). It also cannot be ignored that PPI medications are associated
with a 65% increased risk of being infected by C. diff and it is possible that the
alterations which might lead to infection by C. diff are not contributed solely to the
microbial composition but the functionality. It would therefore be of interest to
conduct a follow-up study investigating the functional profiles of the microbiota with
shotgun metagenomics or transcriptome sequencing.
Chapter IV of this thesis examines the microbiota of patients with IBD and more
specifically, the alteration between activity states through longitudinal sampling. This
is the largest longitudinal sample size for the study of IBD microbiota to date
(September 2017), as it encompasses over 500 patients with IBD and 166 healthy
controls resulting in over 1,800 samples. The sample size combined with the collection
of metadata and dietary information opened up many avenues for exploration and
analysis. There is a wealth of research comparing the gut microbiota of patients with
IBD and controls through the use of both biopsies and faecal samples, however
longitudinal studies are still limited, particularly with large sample sizes. Studies
consistently found alterations in the gut microbiota of patients with IBD compared to
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controls, but the nature of those changes often differ. There is some consistency in
finding a decreased biodiversity, abundances of E. coli elevated and Faecalihacterium
prausnitzii decreased in patients with IBD. Our study found an altered faecal
microbiota communities in patients with IBD compared to healthy controls. Similar to
other studies, we observed a decreased microbial diversity in patients with IBD and a
shift in the microbial communities away from controls in PCoA. However, and
perhaps surprisingly, separate to other studies, we did not observe a difference in
taxonomic abundances or biodiversity between disease activity states. As these
subjects were sampled longitudinally, we were able to control for individual variation
such as living conditions, diet and age. This study exemplified the benefits of
longitudinal sampling and also provided evidence of environmental factors
influencing the microbiota such as diet, age and medication. It is of utmost importance
that data on environmental factors which may potentially alter the microbiota are taken
into account during study design.
Moving foiivard in IBD microbiota research, it would be advantageous to sample
patients more frequently in an attempt to pinpoint the moment of relapse/remission.
More importantly we need to move away from community profiling and progress
towards microbial functional studies. Our study shows that there is no difference in
any individual taxa between activity states in IBD, however there any be key functions
which are not fulfilled. Functional profiling would help to understand the hostmicrobiota interactions and perhaps provide evidence of alterations in the functionality
of the gut microbiota leading to relapse and remission. Additionally, although faecal
samples are beneficial for longitudinal samples, there are concerns as its microbiota is
a proxy to the intestinal microbial communities and may be influenced by transit time.
Where possible, we need to examine biopsy samples although this makes frequent
sampling and the collection large sample sizes more difficult.
Currently diagnosis of IBD begins with the presentation of symptoms which are the
result of disease or transitioning towards diseased state. Prior to the presentation of
symptoms it may be possible to measure the trend towards a disease state through the
use of biomarkers. Inflammatory Bowel Disease (IBD) is a prime example where
microbial biomarkers could be exploited. Although many results thus far have proved
to be inconclusive for the diagnosis of IBD, a promising avenue would be the
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measurement of response to treatment. Michail and co-authors have shown that
patients with UC responding well to steroids have a higher diversity than those who
do not (Michail et al. 2012). Although in its infancy, biomarkers could prove to be
advantageous for patient monitoring and diagnosis.
The work carried out in this thesis covered aspects of both technical and exploratory
analysis. Chapter II dealt with the reproducibility of microbiota studies based on
results from different sequencing strategies and the use of software programs. Chapter
III examined the alterations of the microbiota due to PPI medications and provided
evidence of an effect. Both of these chapters have been published and cited proving
they are of value to the scientific community. Chapter IV contains the largest IBD
longitudinal microbiota study to date and shows that there are no differences in the
microbiota profiles of patients in active and inactive disease. The work in this thesis
provides answers to existing questions whilst also asking many more and providing a
platform for future discussion and analysis in the field of microbiota research.
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